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Abstract 
Backgrond: Functional gastrointestinal disorders (FGID) are chronic conditions 
characterized by symptoms for which no overt organic cause can be found. They affect up to 
20% of western populations with evidence suggesting they are equally common in the Third 
World (Spiller 2005). Although symptoms are generally mild or moderate, a small subset of 
cases shows severe manifestations, i.e. nausea, vomiting, bloating, abdominal distension, 
intractable constipation and chronic pain, with such an intensity hampering normal feeding 
and compromising considerably patients‟ quality of life. In addition, this subset of patients 
may also have recurrent intestinal sub-occlusive episodes, which occur in the absence of 
demonstrable mechanical causes, leading to numerous hospitalizations as well as useless and 
potentially harmful surgical interventions. This condition is referred to as chronic intestinal 
pseudo-obstruction (CIPO), a rare and intractable chronic digestive disease with symptoms 
and signs of intestinal obstruction without demonstrable mechanical cause. CIPO can result 
from derangements affecting the integrity of a variety of regulatory cells/tissues, i.e. smooth 
muscle cells, the interstitial cells of Cajal (ICC) (pace-makers of gut motility), and neurons 
(either intrinsic – the enteric nervous system- or extrinsic nerve pathways).  
Aims and experimental studies: The present thesis was conceived to provide a thorough 
account of the molecular defects underlying CIPO and highlight new strategies of neuro-
epithelial protection to prevent enteric neurodegeneration. The experimental studies are based 
on genetic analysis of CIPO patients and characterization of RAD21 in the ENS of human and 
mouse intestine. Other studies are focus on 5-hydroxytryptamine-4 (5-HT4) receptor 
particularly studying whether the activation of colonic epithelial 5-HT4 protects against 
experimentally induced inflammation of the mouse colon. 
Conclusion: My thesis focuses on both mechanisms of neurodegeneration and 
neuro/epithelial protection as a paradigm to better understand both pathophysiology of severe 
conditions such as CIPO, and related targeted therapeutic options. 
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LIST OF ABBREVIATIONS 
5-HT serotonin 
ACTG actin G2 
AF activity front(s) 
AFUs Arbitrary fluorescence units 
APOB48 Apolipoprotein B48 
BUPA bursts of uncoordinated phasic activity 
BWA Burrows-Wheeler Aligner; v0.6.2 
CAID Chronic Atrial Intestinal Dysrhytmia  
CCT Cytosolic Chaperonin Containing TCP-1 
CdLS Cornelia de Lange syndrome 
ChAT choline acetyl transferase 
CIPO Chronic intestinal pseudo-obstruction 
DAI disease activity index 
DAPI 4,6-diamidino-phenylindole,dihydrochloride 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethyl sulfoxide 
dpf days post fertilization 
DSS dextran sodium sulfate 
EC enterochromaffin cells 
ECs endothelial cells  
EMSA electromobility shift assays 
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EN enteral nutrition 
ENS enteric nervous system  
FBS fetal bovine serum 
FGID Functional gastrointestinal disorders  
FITC fluorescein isothiocyanate 
FLNA filamin A 
FVM Familial Visceral Myopathy  
GATK Genome Analysis Toolkit 
GFAP glial fibrillary acid protein  
GI gastrointestinal 
HDS histological damage score 
hpf hours post fertilization 
hpi post bead injection 
IBD inflammatory bowel disease 
IBS Irritable Bowel Disease 
IBS-C constipation predominant IBS 
IBS-D diarrhea-predominant IBS 
ICC interstitial cells of Cajal 
IJP inhibitory junction potential 
IP intraperitoneal 
IR Immunoreactivity 
LCLs lymphoblastoid cell lines 
LES lower esophageal sphincter 
MGS Mungan syndrome 
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MNGIE Mitochondrial Neurogastrointestinal Encephalomyopathy  
MO morpholino 
MOI multiplicity of infection 
NCAM neuronal cell adhesion molecule  
nNOS neuronal nitric oxide synthase 
NPY Neuropeptide Y;  
NT non-targeting 
PBS phosphate buffered saline 
PDGFRα Platelet-derived growth factor receptor-α 
POLG1 polymerase gamma 
PPN partial parenteral nutrition 
qRT-PCR Real-time quantitative RT-PCR 
ROH Runs Of Homozygosity 
rtPCR reverse transcriptase polymerase chain reaction 
SNP single nucleotide polymorphism 
SPUPA sustained periods of uncoordinated phasic activity 
SRB sulforhodamine B 
TNBS trinitrobenzene sulfonic acid 
TPN total parenteral nutrition 
TYMP thymidine phosphorylase 
UES esophageal sphincter 
WES Whole exome sequencing 
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Chapter I 
5. MORPHO-FUNCTIONAL ORGANIZATION OF THE ENTERIC NERVOUS SYSTEM 
The enteric nervous system (ENS) shows the unique feature of being the largest and most 
complex division of the peripheral nervous system (PNS). The ENS is “brain-in-the-gut” 
since it is capable of controlling a vast array of digestive functions independently from the 
central nervous system (CNS). Within the ENS, nerve cells and glia are organized in plexuses, 
either non-ganglionic (boundles of nerve fibers) or ganglionic, i.e., myenteric (Auerbach‟s) 
and submucosal (Meissner‟s) ganglia, which are interconnected by nerve bundles (Figure 1). 
An intact ENS is essential for body homeostasis, while, in contrast, abnormalities of ENS 
cause digestive disorders. Thus, a properly functioning gastrointestinal (GI) tract requires a 
normally developed and operative ENS in order to control motility, secretion/absoprtion, 
blood flow, cross-talk with the immune system as well as plays a role in the maintenance of 
epithelial barrier. Another noteworthy aspect pertains to the interplay between the ENS and 
the gut microbiota, i.e. the trillion of germs dispersed throughout the lumen of the gut, mainly 
concentrated in the most distal segments. 
 
Figure 1. Organization of the ENS of human and medium–large mammals. 
The ENS has ganglionated plexuses, the myenteric plexus between the longitudinal and circular layers 
of the external musculature and the SMP that has outer and inner components. Nerve fiber bundles 
connect the ganglia and also form plexuses that innervate the longitudinal muscle, circular muscle, 
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muscularis mucosae, intrinsic arteries and the mucosa. Innervation of gastroenteropancreatic endocrine 
cells and gut-associated lymphoid tissue is also present, which is not illustrated here. Abbreviations: 
ENS, enteric nervous system; SMP, submucosal plexus. Modified from Furness, J.B. The Enteric 
Nervous System (Blackwell Oxford, 2006). 
 
The GI tract is a continuous tube that runs from the mouth to the anus. The alimentary canal 
includes the mouth, pharynx, esophagus, stomach, small intestine (consisting of duodenum, 
jejunum, and ileum) and large intestine. It is within this intricate organ that a number of 
coordinated processes are necessary for digestion and absorption. Muscular sphincters 
compartmentalize the bowel, dividing it into functionally distinct regions with different 
luminal environments. The upper esophageal sphincter (UES) maintains the highest resting 
pressure of all sphincters, preventing air from entering the esophagus. It consists of striated 
muscle, is under control of the swallowing center in the medulla, and relaxes during 
swallowing to permit food to enter the esophagus. The lower esophageal sphincter (LES) 
separates the esophagus and the stomach and consists of smooth muscle that relaxes during 
swallowing. It functions to coordinate the passage of food into the stomach after swallowing 
and prevent the reflux of gastric contents, including acid, into the esophagus. A defective LES 
can contribute generate symptoms such as heartburn. The pyloric sphincter separates the 
stomach from the duodenum, and its resting pressure contributes to regulate gastric emptying 
and prevent duodenal-gastric reflux. Reflux of bile acids and digestive enzymes can lead to 
gastritis, ulcer formation, and risk of perforation. The ileocecal sphincter is a valve-like 
structure that separates the ileum and cecum, preventing back flux of colonic contents into the 
ileum. A subgroup of patients with irritable bowel syndrome can experience bloating, bowel 
distension and pain partly due to bacterial overgrowth in the small intestine. Finally, the 
internal (smooth muscle) and external (skeletal muscle) anal sphincters control elimination of 
waste products. A constant detection of luminal contents allows for ingested material to be 
transported caudally at a physiological rate, allowing each region of the gut to perform their 
respective function. Smooth and skeletal (in the esophagus and anus) muscle contractions are 
thus coordinated into activity patterns, such as segmentation (small intestine) or haustration 
(colon) that grind, mix, and propel aborally the ingested food. Secretory mechanisms exert a 
pivotal role in order to maintain an appropriate pH and a regulated concentrations of 
electrolytes, enzymes, and mucous. The pH of the highly acidic chyme in the stomach reaches 
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1.5 to 3.5. At this pH, the hydrogen ion concentration is around 3 million times that of the 
arterial blood. Secretion of hydrogen carbonate ion into the lumen of the duodenum by the 
exocrine pancreas neutralizes the acidic chyme delivered from the stomach to duodenum. 
These changes are necessary to promote digestion, absorption, and detoxification of ingested 
materials. A continuously regenerated semipermeable epithelial barrier separates the lumen 
from the internal milieu of the body. This barrier promotes absorption, but also avoid the 
leakage of indispensable molecules into the intestinal lumen as well as the transit of digestive 
enzymes, toxins, and germs into the body from the lumen. Clearly, this highly organized 
structure of the GI tract and its related physiological functions require a sophisticate degree of 
regulation and coordination, provided by the ENS. Thus, since the ENS contributes 
significantly to body homeostasis and it is not surprising that any noxae perturbing ENS 
maintenance and integrity can result in a variety of disorders some of them so severe to be life 
threatening and / or hinder significantly the patients‟ quality of life. 
 
5.1 Developmental aspects  
During ENS development, precursors emigrate to the gut from the vagal and sacral neural 
crest. The population as a whole, if not each cell, is pluripotent and diverges to give rise to 
enteric neurons and glia. Notably, there is little cell death within the bowel and neurons are 
generated in the appropriate numbers. After development, maintenance of the mature ENS is a 
balanced phenomenon, in which the process of apoptotic cell death causes extensive neuronal 
loss that is complemented by an equally active process of neurogenesis. Gliogenesis also 
occurs. In contrast to the developmental period, neuronal precursor cells of the mature bowel 
do not express SOX10, although they continue to express nestin and p75NTR (Figure 2). 
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Figure 2. The dynamic life history of enteric neurons and glia.  
This scheme summarizes the dynamic life history of enteric neurons and glia. Modified from Rao M. 
et al 2017.  
 
The development of the ENS has been investigated in a wide array of animal models, 
including mice, chickens (Goldstein and Nagy, 2008), zebrafish (Shepherd and Eisen, 2011) 
and invertebrates (Copenhaver, 2007). Consistent evidence acquired over many years of 
research in this field indicates that all the neurons and glia of the ENS arise from neural crest-
derived cells that migrate into the developing GI tract during development. The majority of 
these arise from the vagal enteric neuronal crest cells (ENCCs), which originate in the caudal 
hindbrain region of the neural tube, opposite somites 1-7 (Yntema and Hammond, 1954; Le 
Douarin and Teillet, 1973). During development, these vagal ENCCs migrate into the foregut 
(developing esophagus and stomach), and colonize the developing GI tract in a rostral to 
caudal wave (Young and Newgreen, 2001). In the developing mouse, ENCCs reach the 
foregut at E9.5, enter the midgut (developing small intestine) at E10.5, and reach the anal end 
of the colon at E14.5 (Kapur et al. 1992) (Figure 3). 
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Figure 3. Migratory pathways of enteric neuronal cell crests (ENCCs) through the mouse gut 
during embryonic life. ENCCs enter the foregut around developmental stage E9 and migrate caudally 
within the gut mesenchyme. At E11.0–E11.5, there is a transient apposition of the midgut and 
postcaecal gut, and a subpopulation of vagal ENCCs (shown in purple) takes a short-cut across the 
mesentery to colonize the colon. The transmesenteric cells give rise to the ENS in a large part of the 
colon. Vagal ENCCs reach the anal end of the gut around E14.5. Cells derived from the sacral neural 
crest (shown in blue) emigrate to the vicinity of the hindgut around E11.5, but then undergo a waiting 
period and enter the distal hindgut around E13.5 along with nerve fibres arising from extrinsic 
neurons.7 As the gestation period for a mouse is ~19 days, colonization of the gut by ENCCs takes 
>25% of the gestation period. Abbreviations: ENCCs, enteric neural crest-derived cells; ENS, enteric 
nervous system. From Obermayr et al. 2013. 
This is the longest migration of cells during embryonic development, and takes place over 
approximately 3 weeks in human foetal development (Wallace and Burns, 2005). Sacral 
ENCCs also contribute to a small population of neurons and glia in the colon (Le Douarin and 
Teillet, 1973; Pomeranz and Gershon, 1990; Serbedzija et al. 1991a; Burns and Le Douarin, 
1998; Wang et al. 2011). Differentiation of neurons takes place before ENCCs have reached 
the anal end of the gut. In the developing mouse embryo, around 10-15% of ENCCs in the 
midgut express panneuronal markers at E10.5 (Baetge and Gershon, 1989; Young et al., 
1999). These neurons are located along the entire length of the colonized gut, including at the 
migratory wavefront (Young et al., 1999). 
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The early events of ENS development, such as migration and proliferation, have been 
extensively examined in several studies (Gershon, 1981; Young and Newgreen, 2001; 
Anderson et al., 2006; Heuckeroth and Pachnis, 2006; Heanue and Pachnis, 2007; Young, 
2008; Laranjeira and Pachnis, 2009; Gershon, 2010; McKeown et al., 2012; Sasselli et al., 
2012b). A failure of ENCCs to reach the anal end of the colon results in Hirschsprung disease 
(HSCR), a congenital disease characterized by the lack of enteric ganglia for a variable length 
throughout the gut. The aganglionic segment of the intestine causes a functional obstruction 
since the affected region cannot generate peristalsis and therefore propel its contents. 
Complete colonization of the GI tract requires complex coordination of ENCC proliferation, 
survival, migration, and differentiation. These events are regulated by a number of key factors 
including: 1) soluble factors released from the gut mesenchyme; 2) the expression of 
extracellular matrix molecules; 3) expression of cell surface receptors by ENCC; and 4) the 
expression of transcription factors by ENCCs that regulate downstream events. The two main 
signaling pathways involved are the glial cell line derived neurotrophic factor (GDNF) – Ret / 
GDNF family receptor α1 (GFRα1) and the endothelin 3 (ET-3) – endothelin receptor B 
(EDNRB) pathway. GDNF and ET-3 are produced by the gut mesenchyme and ENCCs 
express Ret, and its GFRα1 co-receptor, as well as EDNRB (Heanue and Pachnis, 2007). 
There are also genetic interactions between many of these factors (Wallace and Anderson, 
2011). Mice that lack GDNF, Ret, or GFRα1 have complete aganglionosis of the small and 
large intestines (Schuchardt et al., 1994; Pichel et al., 1996; Sanchez et al., 1996; Enomoto et 
al., 1998), whereas mice that lack ET-3 or EDNRB only have aganglionosis of the terminal 
colon (Baynash et al., 1994; Hosoda et al., 1994). The next sections will detail the critical step 
occurring during development of the ENS, namely cell migration of vagal and sacral 
component; proliferation and survival; development of the two main ganglionated (myenteric 
and submicosal) plexuses; and, finally, development of enteric neuron subtypes. 
 
5.1.1 Cell migration. Many factors are important for control of the migration of vagal 
ENCCs. The migratory behavior of these ENCCs have been examined in several time-lapse 
imaging studies using intact preparations of embryonic gut (Young et al., 2004; Druckenbrod 
and Epstein, 2005; Druckenbrod and Epstein, 2007; Wang et al., 2011). ENCCs migrate in 
chains and cell-cell interaction is important for regulating this behaviour (Young et al., 2004; 
Druckenbrod and Epstein, 2005). The typical paradigm how to study migration mechanisms 
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involved changes / modification of signaling systems (Anderson et al., 2006; Breau et al., 
2009; Druckenbrod and Epstein, 2009; Zhang et al., 2012b). In some cases delays into the 
timetable of ENCC migration can result in colonic aganglionosis. For example, the aneural 
hindgut of older embryos (E16.5) is less permissive to ENCC migration than that of younger 
embryos (E11.5, Hotta et al., 2010). This can be due to several factors, such as changes in the 
expression of certain attractive and repulsive factors (e.g. increased laminin expression in the 
colon between E13.5 and E14.5) (Druckenbrod and Epstein, 2009); and the same factors can 
exert different effects on ENCCs at different ages (e.g. GDNF has a proliferative effect on 
ENCCs from E12.5 gut, but this effect is reduced on ENCCs from older embryonic gut) 
(E14.5 - E16.5) (Chalazonitis et al. 1998). The increased laminin expression is thought to 
prevent ENCC migration through the colon at E14.5. Delays in ENCC migration would result 
in colonic aganglionosis at birth, as observed in Ednrb
-/-
, β1 integrins conditional knockout, 
and Ret 9/- hypomorphic mice (Breau et al. 2006; Uesaka et al. 2008; Druckenbrod and 
Epstein, 2009). However, more recent studies in L1
-/y
, Tcof1 +/1 and Gdnf +/1 mice have 
shown that although ENCC migration is delayed, the cells can still reach the anal end of the 
colon (Anderson et al. 2006; Flynn et al. 2007; Barlow et al. 2012) and therefore no 
aganglionosis occurs at birth. In the case of Tcof1 +/- mice, there is increased proliferation of 
ENCCs at the wavefront of migration at E11.5, and also decreased neuronal differentiation, 
thereby promoting the migration of ENCCs through the hindgut (Barlow et al. 2012). 
Therefore, finely tuned processes involving ENCC proliferation, survival, migration and 
differentiation, along with that of the microenvironment of the mesenchyme are required for 
complete colonization of the hindgut. 
In addition to the most prominent component (i.e. vagal), also another neural crest component 
conytibutes to form the ENS, i.e. the sacral NCCs. These precursor cells migrate out from the 
neural tube at later stages, E9-9.5, than the vagal component at least in the mouse (Serbedzija 
et al. 1991b). They then pause at the nerve of Remak (which is an extension of the pelvic 
plexus) in chick embryos (Burns and Le Douarin, 1998) and the pelvic ganglia in mouse 
embryos (Kapur, 2000) for several days, prior to migrating into the hindgut. In both chick and 
mouse embryos, the sacral NCCs enter the gut (hence ENCCs) after the entry of vagal NCCs 
into the hindgut (Burns and Le Douarin, 1998; Kapur, 2000). However, there is a small period 
of time when the two populations are distinct as the sacral NCCs enter the caudal hindgut 
prior to its colonization by vagal ENCCs (Druckenbrod and Epstein, 2005). The presence of 
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vagal NCCs is not necessary for the migration of sacral ENCC into the gut as sacral NCC 
derived neurons are found in the gut when vagal ENCCs are ablated (Burns et al. 2000; Burns 
and Le Douarin, 2001) and in transgenic animal models, where vagal-derived ENCCs are 
absent from the gut (Durbec et al. 1996; Cacalano et al. 1998; Anderson et al. 2006a; Erickson 
et al. 2012). Derivatives of the sacral ENCCs in the ENS account for up to 17% of neurons in 
the distal hindgut, and cannot completely colonize the colon to compensate the absence of 
vagal NCC derivatives (Burns and Le Douarin, 1998; Burns et al. 2000; Erickson et al. 2012). 
The developmental potential of sacral ENCCs is reduced in comparison to vagal ENCCs, as 
transplantation of vagal ENCCs to the level of pre-migratory sacral NCCs results in increased 
colonisation of the hindgut (Burns and Le Douarin, 2001; Burns et al., 2002). The increased 
potential of vagal ENCCs appears to be due to increased expression of Ret in comparison to 
sacral ENCCs (Delalande et al. 2008). The migratory behavior of sacral ENCCs has been 
observed in in vitro co-cultures where a piece of pelvic ganglion was apposed to a segment of 
aneural hindgut (Wang et al., 2011). The donor sacral ENCCS appear to migrate along nerve 
fibers that had extended into the gut from the pelvic ganglion donor tissue (Burns and Le 
Douarin, 1998; Wang et al., 2011). Sacral NCCs contribute to the ENS of the colon, more the 
myenteric, rather than submucosal, plexus  (Burns and Le Douarin, 2001). Overall, the 
physiological effect of ablation of sacral ENCCs remains unknown. 
 
5.1.2 Proliferation and survival. Proliferation of ENCCs is important for producing sufficient 
numbers for colonizing the gut. ENCCs proliferate as they migrate towards (Barlow et al. 
2008) and through the gut (Gianino et al. 2003; Young et al., 2005). Reducing the number of 
vagal NCCs results in incomplete colonization of the GI tract (Yntema and Hammond, 1954; 
Petersvandersanden et al., 1993; Burns et al. 2000), and a mininum number of NCCs is 
required for full colonisation (Barlow et al. 2008). The density of ENCCs impacts directly on 
their migratory behavior. For example, when the ENCC population at the wavefront is 
decreased, the distance that they migrate also decreases in direct proportion to the number of 
remaining cells (Young et al. 2004; Druckenbrod and Epstein, 2005). 
A model of “frontal expansion” has been proposed, where proliferation of ENCCs near the 
migratory wavefront drives the invasion of ENCCs into the uncolonized gut (Simpson et al. 
2007). In these experiments, increased proliferation of cells near the wavefront was detected 
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in gut organ cultures in vitro (Simpson et al. 2007); however, this increased proliferation has 
not yet been detected in vivo (Young et al. 2005; Barlow et al. 2012), except in the zebrafish 
gut, which like cultured explants of gut, do not grow while being colonised by ENCCs (Olden 
et al. 2008). In the mouse, the proportion of dividing ENCCs is not significantly different near 
the wavefront in comparison to the colonized regions of the gut (Young et al. 2005). 
Furthermore, there does not appear to be distinct proliferative zones within the GI tract, with 
dividing ENCCs and neurons located throughout the colonized gut (Young et al. 2005; 
Walters et al. 2010; Barlow et al. 2012). It seems likely that while high proliferation rates are 
required at the wavefront to drive migration into the uncolonized regions (Simpson et al. 
2007), high proliferation rates are also required behind the wavefront in vivo to maintain the 
density of cells while the gut is growing rapidly in length. 
Regulation of cell death is also important during ENS development (Enomoto, 2009; 
Chalazonitis et al. 2012). Prior to entering the foregut, there is apoptotic death of vagal 
ENCCs en route to the gut, which is important for regulating ENCC numbers (Wallace et al. 
2009). Once they enter the gut, very little ENCC or neuronal cell death has been detected 
(Gianino et al. 2003; Kruger et al. 2003; Wallace et al. 2010), which is, as indicated above, 
very different from many other parts of the developing nervous system. One study has found 
that conditional loss of GFRα1 signaling in mice at E12.5 – E15.5 in embryonic development 
results in neuronal cell death in the colon and subsequently, colonic aganglionosis at birth 
(Uesaka et al. 2007). However, cell death in these mice did not involve common cell death 
executors, i.e. caspase-3 or caspase-7, or the proapoptotic protein Bax, nor did dying cells 
exhibit the morphological features of apoptosis such as chromatin compaction and 
mitochondrial pathology (Uesaka et al. 2007), raising the possibility that this form of cell 
death has not been detected in previous experiments using traditional techniques of TUNEL 
or caspase staining. Instead, cell death was detected by abnormal nuclear shapes using 
electron microscopy (Uesaka et al., 2007). The death of Sox10-expressing ENCCs has been 
detected in mice without defects in signaling pathways, using live imaging of ENCCs that 
express the fluorescent protein Venus in their nucleus (Corpening et al. 2011). In these cells, 
death was observed as fragmentation of the nucleus, and was identified in a small percentage 
of Sox10-expressing ENCCs at all different regions along the colonised gut (Corpening et al. 
2011). A very recent study has also reported a decrease in the number of Hu-expressing 
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neurons per ganglion in the rat antrum between 4-12 weeks after birth suggesting significant 
postnatal neuronal cell death in the antrum (Baudry et al. 2012). 
 
5.1.3 Development of the myenteric and submucosal plexuses.  In the small intestine of both 
chickens and mice, ENCCs first congregate in the outer mesenchyme, forming the future 
myenteric plexus (MP), while the submucosal plexus (SMP) develops several days later, from 
a secondary migration of cells from the MP (Gershon et al. 1980; Pham et al. 1991; Kapur et 
al. 1992). In mice, neurons can be detected in the presumptive SMP of the small intestine at 
E15.5 (Jiang et al. 2003). The secondary migration of ENCCs into the SMP is dependent on 
netrin-deleted in colo-rectal cancer (DCC) signaling. Netrins are expressed in mucosa of the 
developing small intestine, while DCC, a netrin receptor, is expressed by ENCCs. Netrin
-/-
 
mice lack submucous ganglia, indicating that netrin acts as a chemoattractant to a sub-
population of myenteric ENCCs (Jiang et al. 2003). Recently, GDNF is also an important 
chemoattractant for the migration of ENCCs from the presumptive MP to the SMP (Uesaka 
and Enomoto, 2012). In the embryonic mouse, the circular muscle does not differentiate until 
after the colonisation of the hindgut at E14.5 (McKeown et al. 2001). As the ENCCs migrate 
down the hindgut, they are dispersed through the presumptive circular muscle layer. As the 
circular muscle differentiates, the ENCCs condense into a single layer on the serosal surface 
of the circular muscle, thus forming the MP (McKeown et al., 2001). Neurons are present in 
the location of the presumptive SMP of the colon at E18.5, but are sparsely distributed, and 
colonic submucosal ganglia are not evident until post-natal day (PD)3 (McKeown et al. 
2001). 
Vagal NCCs do not express any neuronal markers en route to the foregut (Anderson et al. 
2006a), and differentiation takes place as ENCCs migrate through the GI tract. In the 
developing mouse, ENCCs that express neuronal markers are present in the foregut at E9.5, 
and in the midgut at E10.5 (Baetge and Gershon, 1989). These cells express a variety of 
panneuronal markers such as Hu (Fairman et al. 1995), neuronal class III β-tubulin (TUJ; 
Fairman et al. 1995; Conner et al. 2003), neurofilament-M (NF-M; Payette et al. 1984), 
protein gene product 9.5 (PGP9.5; Young et al. 2002) and microtubule associated protein 2 
(MAP2; Baetge et al. 1990). Enteric neurons at E10.5 and E11.5 are also known as the 
“transiently catecholaminergic” population of ENCCs as all ENCCs that express pan-neuronal 
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markers also express tyrosine hydroxylase (TH) at these ages (Baetge and Gershon, 1989; 
Young et al. 2002). By E12.5, TH expression is downregulated and is only present in a 
subpopulation of enteric neurons. The embryonic transiently catecholaminergic neurons are 
different from the TH positive dopaminergic neurons of the adult ENS (Li et al. 2011). It does 
not appear to be any distinct neurogenic zones in the ENS as these early enteric neurons are 
dispersed amongst the undifferentiated ENCCs, including at the migratory wavefront of 
ENCCs (Young et al. 1999; Young et al. 2002). The differentiation of ENCCs into neurons 
impacts on the colonization of the GI tract by ENCCs, which is vital to ENS development. 
ENCCs migrate through the gut as chains and lay down a network of ENCCs. Time lapse 
imaging experiments have shown that the chains are maintained for many hours after their 
initial formation (Young et al. 2004). Through development, cells aggregate together to form 
distinct ganglionic clumps with interconnecting neurite fiber strands. The formation of 
ganglia proceeds in a rostral-to-caudal progression (Epstein et al., 1991). In the mouse, enteric 
ganglia start to become distinct at E13 as revealed by increased separation between groups of 
cells (Young et al. 1998b). An increase in the number of neurons per ganglion has been 
described through embryonic development (Tanano et al. 2005). Changes in the morphology 
of ganglia have been described in the early postnatal development of the rat (Schafer et al. 
1999). In the duodenum, MP at birth appeared more densely packed with cells than those of 
older postnatal ages, whilst in the colon, distinct ganglia were not present until P7 (Schafer et 
al., 1999). 
The neuronal cell adhesion molecule (NCAM) and its polysialylated form, PSA-NCAM, are 
important in ganglion formation. Immunohistochemical studies have shown that both NCAM 
and PSA-NCAM are present in developing enteric neurons, and PSA-NCAM is important for 
the clustering of enteric neurons in vitro (Faure et al. 2007). Regulation of NCAM expression 
and polysialylation involve bone morphogenic protein 4 (BMP4) and the transcription factor 
Hand2 (Faure et al. 2007; Lei and Howard, 2011). Inhibition of BMP4 signaling results in the 
formation of smaller ganglia in chick embryos, and also in a reduced neurite fasciculation in 
mouse embryos (Goldstein et al. 2005; Fu et al. 2006). The clustering of neurons in vitro is 
dependent on the presence of BMP4 signaling (Faure et al. 2007). The formation of enteric 
ganglia is disrupted in a conditional Hand2 mutant, and the organized network structure of the 
ganglia is absent in these mice (Lei and Howard, 2011). This is thought to be due to decreases 
in the regulation of NCAM expression in the ENS of these mice (Lei and Howard, 2011). In 
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β1 integrin mutant mice, there is also abnormal ganglia formation, however, this does not 
appear to be as severe as that of the Hand2 mutant, as distinct ganglia are still present (Breau 
et al. 2006). In the β1 integrin mutant, ENCCs aggregate together during migration, leaving 
large cell-free space, which lead to the formation of an abnormal ganglia network (Breau et al. 
2006). The expression of cell adhesion molecules, including that of NCAM, did not appear to 
be disrupted in the β1 integrin mutants (Breau et al. 2006). Mathematical modeling of ganglia 
formation has suggested that threshold criteria for ENCC proliferation, differentiation, and 
cell-cell adhesion are required for the normal formation of enteric ganglia (Hackett-Jones et 
al. 2011). 
Likewise enteric neurons, also glial cells originate from the same neural crest progenitors, 
which migrate and colonize the GI tract. Upon colonization of the embryonic gut, neural-crest 
derived progenitors mature into neurons and glia via Hedgehog/Notch pathway (Gershon and 
Rothman 1991; Ruhl 2005). In the mouse ENS, the development of enteric glia occurs later 
than that of enteric neurons (Young et al. 2003). Cells immunoreactive for S100b are present 
only in the duodenum at E14.5 (Young et al. 2003), and cells expressing GFAP are present at 
E16.5 (Rothman et al. 1986). Prior to this, the precursors of enteric glia maintain Sox10 
expression, which is downregulated in neurons (Young et al. 2003). Expression of B-FABP, 
which is restricted to glial precursors and not common precursors of both neurons and glia, is 
present in the foregut and midgut at E11.5 (Young et al. 2003). The molecular pathways 
influencing the development of enteric glia are not well understood. Sox10 is essential for the 
generation of enteric glia (Britsch et al. 2001; Paratore et al. 2001). Notch and Foxd3, which 
indirectly regulate the expression of Sox10, are therefore also important for gliogenesis in the 
ENS (Okamura and Saga, 2008; Mundell et al. 2012; Wahlbuhl et al. 2012). One pathway has 
been identified whereby signaling through the ErbB3 receptor has been found to promote glial 
differentiation (Chalazonitis et al. 2011a). The ErbB3 receptor is expressed by the developing 
enteric glia and regulated by Sox10 (Britsch et al. 2001). Glial growth factor 2 (GGF2) is a 
ligand of ErbB3 expressed by the enteric mesenchyme and promotes glial differentiation 
(Chalazonitis et al. 2011). BMPs, which promote neurogenesis, also promote gliogenesis via 
this pathway as they promote the expression of ErbB3 (Chalazonitis et al. 2011). In the adult 
ENS, enteric glia has been shown to play many different roles in regulating GI function 
(Furness, 2006; Neunlist et al. 2014). One recent study has shown that they act as adult neural 
22 
 
stem cells of the ENS and can differentiate to enteric neurons in response to injury (Laranjeira 
et al. 2011). 
 
5.1.4 Development of enteric neuron subtypes.  The age at which a neuronal precursor exits 
the cell cycle is defined as the birthdate of that neuron. In the developing CNS, it is thought 
that neuronal precursors exit the cell cycle prior to expressing neuronal markers, hence, 
neurons are “postmitotic”. In contrast to this, neurons in sympathetic ganglia (Rothman et al. 
1978) and the developing ENS continue to divide after initiating their expression of pan-
neuronal markers (Teitelman, 1981; Young et al. 2005). However, there does not appear to be 
division of enteric neurons that express subtype specific markers (Young et al. 2005), hence, 
enteric neurons appear to exit the cell cycle prior to their subtype differentiation. However, 
further investigation is required as there is currently no reliable immunohistochemical method 
for detecting cholinergic enteric neurons during embryonic development. 
5-hysroxytryptamine (5-HT) / serotoninergic and choline acetyltransferase (ChAT) / 
cholinergic neurons are “born” at E8, which is prior to the entry of vagal NCCs into the gut 
(Pham et al. 1991). Several other subtypes begin to be born at E10, including VIP, NYP, 
enkephalin and CGRP neurons (Pham et al. 1991). A subsequent study showed that NOS, 
CALB and GABAergic neurons were born from E12.5 to P1, however, E12.5 was the earliest 
birthdate examined (Chalazonitis et al. 2008). In both studies, the birthdates of neurons in the 
MP were found to be earlier than those of submucous plexus neurons (Pham et al. 1991; 
Chalazonitis et al. 2008). In the third study, the birth of VIP neurons was examined in chick 
embryos (Epstein et al. 1992). So far, no correlation between the time of cell cycle exit and 
the first immunohistochemical detection of its neurochemical phenotype has been determined. 
This length of time appears to vary for different neuronal subtypes. 
 
5.2 Structural features  
The ENS is a complex neuronal network, which runs along the length of the GI tract, from the 
esophagus to the anus. The entire structure of the ENS is arranged into ganglia, aggregates of 
neuronal cell bodies and glial cells, connected by interganglionic strands in order to form two 
plexuses: the myenteric (Auerbach‟s) and the submucosal (Meissner‟s) (Furness 2012; Costa 
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and Brookes 2008). The outer myenteric plexus is located between the longitudinal and 
circular smooth muscle layers and is (although not exclusively) involved in the control of gut 
motor patterns. The inner submucosal plexus resides within the submucosa and is involved 
with local fluid secretion and absorption (Furness et al. 1990; Brehmer et al. 1998). Taken 
together the network formed by the two ganglionated plxuses is constituted by about 100 
million neurons in the guinea pig (in humans likely 400-500 millions) and even more 
supporting cells (enteric glia) outnumbering from 3 to 5 times enteric neurons (Furness 2006). 
 
5.2.1 Myenteric plexus (MP). The MP forms a network around the gut, which extends from 
the upper esophagus to the internal anal sphincter. The MP is embedded within the two layers 
of the muscularis externa, i.e. the circular and longitudinal coats, and composed by a neuronal 
cell bodies and related nerve processes (Furness 2006). The MP shows numerous differences 
in its morphological organization, among GI segments of different species (Vittoria et al. 
2000; Domeneghini et al. 2004; Chiocchetti et al. 2009b). A subserosal ganglionated plexus 
has been identified in the cattle abomasum (Vittoria et al. 2000) and in the human sigmoid 
colon (Crowe and Burnstock 1990). However, in all other human colonic levels examined 
(ascending, transverse and descending colon) the subserosal plexus showed no ganglia but 
only nerve fibers (Ibba-Manneschi et al. 1995). Generally, in the MP, ganglia are bigger than 
the SMP in terms of number of neurons, and are linked by interconnecting strands (or primary 
strands), which constitute the so-called primary plexus (Furness 2006). The MP are located in 
parallel to the circular muscle layer, although this feature can vary among species (Irwin 
1931); primary interconnecting strands show longitudinal course, an organization that seems 
to be a distinctive feature of the MP in most small and large mammals (Scheuermann et al. 
1986; Gabella 1987; Santer and Baker 1988; Pearson 1994; Furness 2006; Freytag et al. 2008; 
Bodi et al. 2009). The other two components of MP are the secondary and tertiary plexuses 
(Furness 2006). The secondary plexus is constituted by fine bundles of nerve fibers running 
parallel to the circular muscle layer and primary plexus (Balemba et al. 1999; Furness 2006). 
The tertiary plexus is made by thin interconnecting strands (the smallest in size) supplying the 
longitudinal muscle layer (Scheuermann et al. 1986; Balemba et al. 1999; Furness 2006). 
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5.2.2 Submucosal plexus (SMP). The SMP is well developed in the small and large intestine, 
while only a few submucous ganglia can be found in the esophagus (third inferior part) and 
stomach particularly in large mammals, including humans (Lefebvre et al. 1995; van 
Ginneken et al. 1996; Teixeira et al. 2001; Izumi et al. 2002; Furness 2006). The 
interconnecting strands of the SMP are usually thin and SMP ganglia are small. The SMP is 
organized in a single layer in small mammals (Timmermans et al. 2001), whereas it shows a 
multilayered (two or three layers) organization in large mammals (Brehmer et al. 2010). In 
these species two different ganglionated plexuses can be identified, namely the internal 
submucous plexus and the external submucous plexus (Schabadasch 1930; Gunn 1968; 
Messenger and Furness 1990; Timmermans et al. 1992a; Timmermans et al. 1992b; Pearson 
1994; Timmermans et al. 1997). External and internal SMP are separated by a thin connective 
tissue layer (Gunn 1968; Christensen and Rick 1987; Hoyle and Burnstock 1989; Balemba et 
al. 1998) and by submucosal blood vessels (Balemba et al. 1998). The external and internal 
SMPs appear different among the investigated species. Generally, they can be distinguished 
on the basis of their location, architecture, meshwork density, size and form of the ganglia, 
and light microscopic appearance (Stach 1977b; Stach 1977c; Stach 1977a; Stach 1978; 
Scheuermann and Stach 1984). The external SMP shows the most irregularly organized nerve 
meshwork, while the internal meshwork is smaller and more regular compared to the external 
SMP (Gunn 1968; Scheuermann et al. 1987; Hoyle and Burnstock 1989; Timmermans et al. 
1990; Balemba et al. 1999). Additionally, the two compartments of SMP neurons also show 
differences in the content of neurochemical messengers / transmitters, being the external SMP 
more similar to that of myenteric neurons (Scheuermann W.D. 1998; Hens et al. 2000). In 
addition to the mucosa, some neurons of the external SMP also supply the muscular layer 
(Sanders and Smith 1986; Furness et al. 1990; Timmermans et al. 1994b; Timmermans et al. 
1997; Porter et al. 1999; Timmermans et al. 2001). The internal SMP neurons supply the 
mucosa and only a small number have projections to the muscle layers (Porter et al. 1999; 
Timmermans et al. 2001). Thus, in conclusion the external and internal SMP neurons overlap 
in terms of functional control of fluid movements, local blood flow and sensory functions, 
while the external SMP can also affect gut motility (Timmermans et al. 1990). 
 
5.2.3 Neurochemistry of enteric neurons. Enteric neurons are able to synthesize and release 
about 30 different mediators / bioactive substances that may act as messengers, i.e. 
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neurotransmitters, neuromodulators and neuropeptides (Table 1). Studies over the years have 
clearly shown that each subclass of enteric neurons can be characterized on the basis of the 
combination of messengers. This property is known as neurochemical coding and turned to be 
a feature of the ENS that is maintained through most animal species (Costa et al. 1996). 
Primary neurotrasmitters exert the same role in different species and along the GI tract. These 
substances include acetylcholine (ACh) and tachykinins in enteric excitatory motor neurons, 
and nitric oxide (NO), vasoactive intestinal polypeptide (VIP) and others messengers in 
inhibitory motor neurons. Inhibitory motor neurons may be immunohistochemically identified 
by the presence of the neuronal nitric oxide synthase (nNOS), the neuronal isoform of the 
enzyme synthesizing NO, the primary neurotransmitter released by inhibitory motor neurons, 
while excitatory motor neurons may be immunohistochemically identified by the presence of 
the synthesizing enzyme choline acetyltransferase (ChAT). Secondary neurotransmitters or 
modulators include substances which may vary among different groups of neurons depending 
on the GI tract and the species considered (Furness 2006) (Table 1). Research performed in 
the last thirty years has shown that classification of the several classes of enteric neurons is 
the result of a combination of various technical approaches and criteria. These features 
include: neuronal shape; histochemical and immunohistochemical staining; projections; and 
electrophysiological and functional properties. 
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Table 1. Multiple transmitters of functionally distinct enteric neurons that control digestive function. 
Abbreviations: 5-HT, 5-hydroxytryptamine; ACh, acetylcholine; CCK, cholecystokinin; ChAT, 
choline acetyltransferase; CGRP, calcitonin gene-related peptide; GRP, gastrin releasing peptide; ND, 
not determined; NPY, neuropeptide Y; NOS, nitric oxide synthase; PACAP, pituitary adenylyl-cyclase 
activating peptide; VIP vasoactive intestinal peptide. From Furness 2006. 
 
5.2.4 Neuronal shape. Enteric neurons were categorized by Dogiel according to their shape 
using the methylene blue staining technique (Dogiel 1899). Myenteric and submucosal 
neurons were morphologically classified in three types, referred to as Dogiel type I, II and III. 
After Dogiel, many other authors proposed additional classifications based on individual 
neuronal morphology revealed by silver impregnation technique, immunoreactivity for 
neurofilaments and / or other markers (Stach 1989; Brehmer et al. 1999; Stach 2000; Brehmer 
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et al. 2002; Brehmer et al. 2004b). Taken together, these studies confirmed and extended the 
Dogiel classification from three up to seven types of neurons in addition to „mini-neurons‟. 
The morphological classifications of enteric neurons has been underestimated (Brehmer 
2006), however, the possibility to correlate the morphological appearance of a given neuron to 
its neurochemical code, as well as bioelectrical / functional properties has also refueled the 
importance of studying the morphology of the enteric nerve cells. 
 
5.2.5 Functional aspects. From a functional standpoint, enteric neurons can be divided in 
motor neurons, interneurons, intrinsic primary afferent neurons (IPANs) (Costa and Brookes 
1996; Furness 2000), and intestinofugal afferent neurons (IFANs) (Furness 2003) (Figure 4). 
 
 
Figure 4. Types of neurons in the small intestine. The types of neurons in the small intestine, all of 
which have been defined by their functions, cell body morphologies, chemistries, key transmitters, and 
projections to targets. Neuron Types: Ascending interneurons (1); Myenteric intrinsic primary afferent 
neurons (IPANs) (2); Intestinofugal neurons (3); Excitatory longitudinal muscle motor neurons (4); 
Inhibitory longitudinal muscle motor neurons (5); Excitatory circular muscle motor neurons (6); 
Inhibitory circular muscle motor neurons (7); Descending interneurons (local reflex) (8); Descending 
interneurons (secretomotor and motility reflex) (9); Descending interneurons (migrating myoelectric 
complex) (10); Submucosal IPANs (11); Non-cholinergic secretomotor/ vasodilator neurons (12); 
Cholinergic secretomotor/vasodilator neuron (13); Cholinergic secretomotor (non-vasodilator) neurons 
(14); Uni-axonal neurons projecting to the myenteric plexus (15); motor neuron to the muscularis 
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mucosa (16); innervation of Peyer‟s patches (17). Abbreviations: LM longitudinal muscle, MP 
myenteric plexus, CM circular muscle, SM submucosal plexus, Muc mucosa. From Furness 2012. 
 
Motor neurons. The category of motor neurons includes excitatory and inhibitory neurons 
directed to the GI musculature; secretomotor / vasodilator neurons are able to regulate 
mucosal secreting cells and vasodilation / vasoconstriction of the intestinal vasculature. 
Furthermore, another subset is represented by secretomotor neurons and neurons innervating 
entero-endocrine cells (Furness et al. 2000). The motor neurons innervating the smooth 
muscle of digestive tract are located within the MP of rodents (Wilson et al. 1987; Song et al. 
1998) and within myenteric and external and internal submucous plexuses of large mammals 
[MP > external SMP > internal SMP] and humans [MP > external SMP > internal SMP] 
(Sanders and Smith 1986; Timmermans et al. 1990; Timmermans et al. 1994b; Porter et al. 
1999; Hens et al. 2001). These neurons could be distinguished in circular muscle motor 
neurons, longitudinal muscle motor neurons, and motor neurons innervating the muscularis 
mucosae. According to the peristaltic reflex, the excitatory motor neurons are especially 
localized aborally to the innervated circular and longitudinal muscle (Brookes et al. 1991; 
Michel et al. 2000), while the inhibitory motor neurons are generally localized orally to the 
innervated circular and longitudinal muscle (Brookes et al. 1992; Brookes et al. 1996; 
Brookes et al. 1997; Pfannkuche et al. 1998; Yuan and Brookes 1999; Michel et al. 2000).  
Interneurons. These are the enteric neurons with the longest projections. These cells, which 
have been identified with certainty only in the guinea-pig (Costa and Brookes 2008), mouse, 
rat, and human are mainly localized in the MP. Interneurons form long functional chains of 
ascending and descending elements through which information may travel for short or long 
distances (Pompolo and Furness 1993). Interneuron projections extend up to 14 mm anally 
and up to 136 mm orally in guinea pig small intestine (Song et al. 1997). It is worth noting 
that interneurons may also function also as mechanoceptors (Stebbing and Bornstein 1996; 
Spencer et al. 2006; Dickson et al. 2007; Smith et al. 2007). So far, four types of interneurons 
have been identified in the guinea-pig small intestine: one ascending and three types of 
descending interneurons. The ascending interneurons are MP Dogiel type I cholinergic 
neurons (Furness 2000; Brookes 2001) and may contain also calretinin, SP, neurofilament 
triplet protein (NFP), and enkephalin (Brookes et al. 1997). Descending MP interneurons (5% 
of all ENS cells in guinea-pig) are phenotypically cholinergic neurons further distinct into 
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three types based on their immunoreactivity for NOS/VIP, SOM and 5 hydroxytryptamine 
(5HT) (Portbury et al. 1995; Song et al. 1997; Brookes 2001). 
nNOS/VIP/ChAT/immunoreactive Dogiel type I interneurons can contain also neuropeptide 
Y (NPY) (Uemura et al. 1995), gastrin releasing peptide (GRP), bombesin (BN) (Brookes, 
2001) and the enzyme alkaline phosphatase (Song et al. 1994). SOM/ChAT immunoreactive 
Dogiel type III MP neurons (Portbury et al. 1995; Song et al. 1997) project to other MP 
ganglia and also to SMP ganglia (Brookes 2001). Also, 5HT/ChAT immunoreactive Dogiel 
type I MP neurons send their projections to MP and SMP and seem to have significant roles 
in excitatory pathways regulating both motility and secretion (Neal and Bornstein 2007). 
Intrinsic primary afferent neurons (IPANs). The IPANs are the first neurons of the reflex 
pathways in the intestine (Furness et al. 2004a). They are involved in the control of 
physiological functions as motility, blood flow and secretion, being responding to several 
stimuli, such as distention, luminal chemistry and mechanical stimulation of the mucosa 
(Furness 2006). IPANs have typical electrophysiological properties. In fact, they have broad 
action potentials that are related to both sodium and calcium currents and are followed by 
early and late (slow) after hyperpolarizing potentials (AHPs) (Furness et al. 2004a). Their 
targets are represented by mucosa and other MP and SMP neurons (Bornstein et al. 1989; 
Kirchgessner et al. 1992; Song et al. 1992; Evans et al. 1994). Cell bodies of multi-axonal 
IPANs are 10-30% of neurons in SMP and MP ganglia of the small and large intestine; no 
IPANs are detected in the esophagus and they are rare in the stomach, where motility is 
primary controlled by vagal efferents (Furness et al. 2014). All the IPANs of guinea-pig and 
other species intestine show Dogiel type II morphology (non-dendritic, multi-axonal type II 
neurons) (Kirchgessner et al. 1992; Kunze et al. 1995; Bertrand et al. 1997; Kunze et al. 1998; 
Kunze et al. 1999). A large percentage (82-84%) of myenteric IPANs of the guinea-pig ileum 
expresses IR for the calcium-binding protein calbindin (CALB) (Furness et al. 1988; Iyer et 
al. 1988; Costa et al. 1996) and almost all MP and SMP IPANs express cytoplasmic NeuN-IR 
(Chiocchetti et al. 2003; Van Nassauw et al. 2005). Furthermore, all of them show ChAT-IR 
(Steele et al. 1991; Li and Furness 1998). Notably, only 30% of submucosal IPANs of the 
guinea-pig ileum appear to be IR for CALB (Iyer et al. 1988; Song et al. 1991; Quinson et al. 
2001), and that CALB is not confined to the IPANs since it is also localized in 50% of 
submucosal calretinin-IR secretomotor / vasodilator neurons (Quinson et al. 2001). Many 
researchers studied CALB-IR also in other species, with the aim to establish whether CALB 
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could be considered an IPAN marker. In the pig small intestine, CALB cannot be considered 
markers of IPANs, being mainly localized in interneurones and intestinofugal neurons 
(Brehmer et al. 2004a; Brown and Timmermans 2004). Dénes and Gábriel (Denes and Gabriel 
2004) described CALB-IR myenteric neurons in rabbit small intestine. These cells showed 
Dogiel type I morphology, ChAT-IR, and were identified as interneurons. Also in the mouse 
colon, CALB cannot be considered a good marker of IPANs, while the anti-CGRP antibody is 
considered the most specific marker of these cells (Furness et al. 2004b). Non-dendritic 
multiaxonal type II neurons involved in mucosal innervations have been demonstrated also in 
porcine (Hens et al. 2000) and human (Hens et al. 2001) small intestine. Unlikely from 
guinea-pig, porcine and human (and mouse) IPANs express CGRP, which has been 
considered a specific marker of type II neurons in these species (Scheuermann et al. 1986) 
(Scheuermann et al. 1991; Timmermans et al. 1992a; Balemba et al. 1998; Hens et al. 2000; 
Wolf et al. 2007).  
Intestinofugal primary afferent neurons (IFANs). Intestinofugal neurons represent a unique 
subset of enteric neurons with their cell body located in the myenteric ganglia and projections 
giving off the intestinal wall (Szurszewski et al. 2002). Most of them show a Dogiel type I 
morphology, whereas a minority have Dogiel type II features (Lomax et al. 2000; Ermilov et 
al. 2003). IFANs act as mechanoceptors, being able to detect changes in volume and to 
respond to the stretching (but not to the tension) of the smooth muscle cells (Crowcroft et al. 
1971; Szurszewski and Weems 1976; Kreulen and Szurszewski 1979). Once activated, IFANs 
usually release Ach in the in the prevertebral ganglion (PVG) thereby evoking nicotinic fast 
post synaptic potentials (Szurszewski 1994). A subset of IFANs responds to colonic 
distention by releasing gamma-amino butyric acid (GABA), which facilitate Ach release from 
cholinergic IFANs in PVG. Because of IFANs activation, the response of the reflex entero-
PVG circuitry is the release of noradrenaline by sympathetic neurons in GI wall. This effect 
modulates smooth muscle contraction or myenteric neuron activity (Parkman et al. 1993; Ma 
and Szurszewski 1996; Walter et al. 2016). The functional significance of this reflex arc is to 
counteract large increases in tone and intraluminal pressure during filling (Szurszewski et al. 
2002). 
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5.2.6 Enteric glia.  The existence of accompanying non-neuronal cells (hence the term glia) 
dates back to the beginning of the 19th century with the first glial cells were described by 
Robert Remak who detailed very elegantly „special cellular elements‟ while reporting in his 
thesis (published in 1838) on nerve fibers and their surrounding sheats, later on called 
Schwann cells. However, the term “glia” (in the ancient Greek γλία language means “glue”) 
was introduced by Virchow (1856). Virchow used for the first time the word glia describing 
the neuroglia in the CNS. He thought neuroglia was a kind of connective tissue and found that 
this tissue also contained cellular elements. We owe the first drawings of a star-shaped glial 
cell to Otto Deiters (1865). 
Concerning the ENS, the first description of nucleated satellite cells around nerve cell bodies 
of the enteric ganglia was given by Dogiel (1899), and many other investigators have studied 
these cells in the ganglia and nerve strands of the gastrointestinal plexuses and referred to 
them as „Schwann cells‟ (Stöhr 1952). The term „enteric glial cell‟ was used for the first time 
by Giorgio Gabella in his original and extremely accurate research made along 10 years of 
work in (Gabella 1971 to 1981). Other studies, which have used immunohistochemical 
markers to locate enteric glia, revealed that these cells are common in the ganglia and nerve 
fiber bundles. Enteric glia express glial fibrillary acidic protein (Jessen and Mirsky 1980, 
1983) and the S-100 Ca
2+
-binding protein (Ferri et al. 1982b), both of which are typical of 
CNS astrocytes. Glial cells in other autonomic ganglia do not contain glial fibrillary acidic 
protein (Jessen and Mirsky 1983). Electron microscopy studies also showed that what it was 
intended as “enteric neuronal satellite cells” actually are glial cells closely reminiscent of 
astrocytes of the CNS and distinct from Schwann cells of other peripheral ganglia or nerve 
trunks (Gabella 1971, Gabella 1972, Cook & Burnstock 1976, Gabella 1981, Komuro et al. 
1982). Specifically, enteric glial cells partly surround nerve cell bodies and axons in the 
ganglia, leaving bare large areas of neuronal membrane at the surface of ganglia; also, their 
processes contain bundles of gliofilaments and are surrounded by a single basement 
membrane (none of these aspects are detectable in Schwann cells). There is a marked 
difference in the glial cell-to-axon relationship between small (guinea pig, rat) and large 
mammals (such as cat or human). In small mammals, glial cell processes fail to penetrate in 
the interstitium between nerve cell bodies as well as axons in the neuropil (Gabella 1972a, 
Komuro et al. 1982). In fact, many nerve processes show direct membrane-to-membrane 
contacts with each other; the glial cells only separate them into groups and rarely form a 
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sheath around an individual axon. In contrast, in enteric ganglia of human and monkey, axons 
are separated from one another by intervening glial cell processes (Baumgarten et al. 1970).  
Compared with other peripheral glial cells (e.g., Schwann cells), enteric glial cells do not 
form basal laminae and they ensheath nerve bundles and not individual axons (Bannerman et 
al. 1986). In addition to the previously mentioned glial fibrillary acidic protein (GFAP) and 
S100b, other available immunohistochemical markers for glial cell labeling in the adult gut 
include and Sox (SRY-box) 8/9/10, the first two being the most frequently used (Ruhl 2005; 
Hoff et al. 2008). Recently, marker expression analysis showed that the majority of glia in the 
myenteric plexus co-express GFAP, S100b, and Sox10 (De Giorgio et al. 2012). However, a 
considerable fraction (up to 80%) of glia outside the myenteric ganglia, did not show labeling 
for these markers. The alternative combinations of markers reflect dynamic gene regulation 
rather than lineage restrictions, revealing an extensive heterogeneity and phenotypic plasticity 
of enteric glial cells (Boesmans et al. 2015) (Figure 5). 
 
 
Figure 5. Differential expression of HuC/D and Sox10 in enteric glia of the myenteric plexus of 
the ileum. (a) Confocal photomicrograph showing double immunostaining for HuC/D (green 
fluorescence) a panneuronal marker and Sox10 (red) positive nuclei of glial cells. Note the presence of 
many Sox10-positive glial cells surrounding HuC/D labeled myenteric perikarya reflecting the 
structural and functional interplay of these two cell types in the ENS. Calibration bar= 25 µm. From 
De Giorgio et al. 2012. 
 
Enteric glial cells have long been thought to exert a mere mechanical property by supporting 
neurons. Many evidence, however, indicates that these cells exhibit a number of functions, 
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ranging from support to neurotransmission to enteric neuronal maintenance and survival 
(Gulbransen and Sharkey 2012; Neunlist et al. 2013; Neunlist et al. 2014; Boesmans et al. 
2015). In fact, glial cells are involved in many crucial tasks, such as synthesis of 
neurotransmitter precursors, uptake and degradation of neuroligands (i.e., detoxification of 
glutamate and g-aminobutyric acid), and expression of neurotransmitter receptors, thereby 
contributing to neuron-glia cross talk and neurotransmission (Neunlist et al. 2013). 
Furthermore, glial cells exhibit immunological properties (Ruhl 2005; Neunlist et al. 2008; Da 
Silveira et al. 2011), participate in epithelial barrier functions (Steinkamp et al. 2003; Neunlist 
et al. 2007; Savidge et al. 2007; Savidge et al. 2007; Bouchard et al. 2008; Van Landeghem et 
al. 2011) and evoke neuroprotection (Neunlist et al. 2014) (Figure 6). In addition, enteric glial 
cells have neurogenic potential being capable of generating enteric neurons in response to 
injury (Joseph et al. 2011; Laranjeira et al. 2011). Recent works also demonstrated that enteric 
glial cells can respond to neurotransmitters by changes in intracellular Ca2+, such as 
purinergic (ATP) (Gomes et al. 2009; Gulbransen and Sharkey 2009; Gulbransen et al. 2010) 
serotonergic and cholinergic signaling mechanisms (Boesmans et al. 2013). 
 
 
Figure 6. Enteric glial cells are central regulators of gut homeostasis and can play a role in gut 
diseases. (A) In normal conditions, glia control a number of neuronal aspects, i.e. neuroprotection, 
neuromediator expression, or neuronal renewal via liberation of different mediators. In addition, glia 
exhibit a key role in intestinal epithelial barrier integrity through the release of function-specific 
messengers (gliomediators). Taken together these features indicate that enteric glia possess protective 
and reparative properties in the gastrointestinal tract. (B) In pathological conditions, such as 
inflammation or bacterial stimulation, a phenomenon, known as reactive enteric gliosis (similar to 
astrogliosis in the brain) can occur. This contributes to the development of intestinal inflammation, but 
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also participate in protection/repair of intestinal epithelial barrier/neuronal lesions evoked by these 
mechanisms. (C) Enteric glia death (induced by specific viruses or pathogens) or abnormal enteric gliosis could 
contribute to neuronal degeneration or barrier dysfunctions observed in some chronic intestinal or extraintestinal 
diseases. From Neunlist et al. 2014. 
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Chapter II 
6. ENTERIC NEUROPATHIES 
 
6.1 General characteristics  
Several GI disorders can result from enteric neuropathies, including both primary and 
secondary forms. These neuropathies have been grouped as congenital or developmental 
neuropathies; sporadic and acquired neuropathies; neuropathies associated with other disease 
states and iatrogenic or drug-induced neuropathies (Furness, 2012). Any damage, noxae or 
dysfunction involving the main effectors or the control system of the gut physiology may be 
responsible for the onset of a wide array of pathological conditions involving some lethal or 
seriously disabling manifestations (Schemann and Grundy 1999; Knowles et al. 2013). 
Pathologies that involve the ENS include dysmotilities such as achalasia, CIPO and 
Hirschsprung‟s disease (De Giorgio and Camilleri 2004). A view of the major milestones in 
ENS neuropathology over the years has been reported in Figure 7. 
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Figure 7. Synopsis summarizing some of the major milestones in ENS neuropathology over the years, 
i.e. from Hirschsprung‟s seminal description of congenital aganglionosis of the colon up to the London 
classification. Colors shown here couple the author(s) (above the curvilinear arrow) with the 
corresponding neuropathological acquisition (reported in the horizontal arrow). From De Giorgio et al, 
2014) 
 
6.2 Primary neuropathies 
Enteric neuropathies are classified as primary in the case that the ENS is the major target of 
the disease process. Most are termed as „idiopathic‟ to denote the poor aetiological 
understanding of these conditions. Among primary neuropathies are: Hirschsprung‟s disease, 
idiopathic achalasia, idiopathic gastroparesis and CIPO.  
Hirschsprung‟s disease is characterized by an absence of enteric neurons (aganglionosis) in 
terminal regions of the gut, leading to tonic contraction of the affected segment, intestinal 
obstruction and massive distension of the proximal bowel (megacolon).Constipation is the 
dominant presenting symptom in Hirschsprung‟s disease. The cardinal feature of 
Hirschsprung‟s disease is an absence of enteric nerve cell bodies in the distal part of the colon 
and in the rectum. The extent of the defect varies from patient to patient. The absence of 
enteric nerves results in the inability of the distal gut to pass meconium and later, feces. 
Various genetic mutations, including in the receptor tyrosine kinase RET gene (Luo et al 
1993) and in the endothelin receptor-B gene (ENDR-B) are associated with the familial 
Hirschsprung‟s disease (Robertson et al 1997). Loss of interstitial cells of Cajal has also been 
reported in this disease but other studies report a normal complement of interstitial cells of 
Cajal (Rolle et al 2002). Recent study by Chakravarti et al. observed that for most multigenic 
disorders, clinical manifestation (penetrance) and presentation (expressivity) are likely to be 
an outcome of genetic interaction between multiple susceptibility genes. As compared with 
wild-type mice intestinal gene expression, loss of Ret in null homozygotes led to differential 
expression of ∼300 genes (Chakravarti et al. 2017). Corrent studies identified 28 de novo 
mutations in 21 different genes. Eight of the de novo mutations were identified occur in RET, 
the main HSCR gene, but the remaining 20 mutations reside in genes not reported in the ENS. 
These genes are also expressed in human and mouse gut and/or ENS progenitors. Importantly, 
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the encoded proteins are linked to neuronal processes shared by the central nervous system 
and the ENS (Gui et al. 2017).  
Idiopathic achalasia is an esophageal motility disorder characterized by a failure of the 
esophageal smooth muscle to generate effective peristalsis and by a failure of the lower 
esophageal sphincter to relax completely during swallowing (Goldblum et al. 1994). Several 
neuropathologic findings have been described including injury of inhibitory nitric oxide 
producing nerves, degenerative changes of the vagus nerve and an occasional presence of 
cytoplasm inclusions in the dorsal motor nucleus of the vagus nerve and myenteric plexus. 
Since the initiating factor(s) and mechanisms leading to these characteristic features are 
currently unknown (Kraichely et al 2006), further studies are currently ongoing on the 
identification of gene abnormalities highlights novel signaling pathways involved in the 
neuro-interstitial cell of Cajal changes underlying achalasia (Bonora et al 2017 under review). 
The pathophysiology of idiopathic gastroparesis is varied and includes smooth muscle 
fibrosis, loss of enteric nerves, extrinsic neuropathy and loss of ICC (Zarate et al 2003). 
Recent data suggest a significant role for loss of nNOS expression in enteric nerves and loss 
of organized ICC networks as dominant cellular defects in diabetic gastroparesis. It is 
unknown if these findings are applicable to other causes of gastroparesis.  
CIPO indicates a condition in which affected subjects show failure of the propulsive forces of 
intestinal peristalsis to overcome the natural resistances to flow. Myogenic and neurogenic 
altered mechanisms contribute to CIPO (De Giorgio et al. 2011). Concerning CIPO-related 
neuropathies, there are evidences of neuronal degeneration and loss, with or without 
ganglionitis due to lymphocytic and eosinophilic infiltrate (De Giorgio and Camilleri 
2004).Since this thesis is focused on this pathological condition a deep overview will be 
presented in next chapter. 
 
6.3 Secondary neuropathies  
Secondary neuropathies are defined as pathological conditions in which the ENS is not the 
primary target of the disease. The classification of this neurophaties can be as degenerative 
and inflammatory, based on the mechanisms underlying the enteric neuronal pathology. 
Degenerative neuropathies include diabetes mellitus (DM), while inflammatory neuropathies 
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include paraneoplastic enteric neuropathy and Chagas disease (Knowles et al. 2013). 
Symptoms depend on the type of nerves affected, more frequentely there are described 
abdominal pain, heartburn, dysphagia, post prandial fullness, nausea, diarrhoea and 
constipation. In diabetic gastroparesis several key cell types are affected by diabetes. Etiology 
or risk factors have not been clearly identified. Failure to sustain elevated heme oxygenase-1 
(HO1) expression is associated with delayed gastric emptying in diabetic mice and 
polymorphisms in the HO1 gene (HMOX1) are associated with worse outcomes in other 
diseases (Gibbons et al 2017). Recent study showed that longer poly-GT repeats in the 
HMOX1 gene are more common in African Americans with gastroparesis. Nausea symptoms 
are worse in subjects with longer alleles (Gibbons et al 2017). 
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Chapter III 
7. CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO) 
7.1 General features 
Chronic intestinal pseudo-obstruction (CIPO), a rare and potentially life-threatening disorder 
with unknown prevalence and incidence, (Amiot et al. 2009; Di Nardo et al. 2017) is viewed 
typically as an insufficiency of the intestinal peristalsis that mimicks a sub-occlusive disease 
in the absence of mechanical obstructions (De Giorgio et al. 2004; Stanghellini al. 2007). The 
severity of the clinical presentation and the limited understanding of the disorder contribute to 
poor quality of life and increased mortality (Mann et al. 1997). In addition, there are no 
specific biochemical or molecular biomarkers of CIPO, hindering further a correct diagnosis.  
CIPO can result from derangement affecting the integrity of a variety of regulatory 
cells/tissues, i.e. smooth muscle cells (effectors of contractility / relaxation), the interstitial 
cells of Cajal (ICC) (pace-makers of gut motility and regulators of neuronal input to smooth 
muscle cells), and neurons (either intrinsic – the enteric nervous system or extrinsic nerve 
pathways) (Di Nardo et al. 2017). In some cases, CIPO is associated with inflammation, 
predominantly of the enteric ganglia, which exhibit inflammatory neuropathy (De Giorgio et 
al. 2011). Based on the type of cellular pathology, CIPO has been classified into two major 
categories: visceral neuropathies and visceral myopathies. Neuromuscular and ICC 
abnormalities observed in CIPO may be “secondary” to a number of recognized diseases (e.g, 
metabolic, paraneoplastic, or neurologic disorders), or “idiopathic” in nature (De Giorgio et 
al. 2007). Enteric neurodegenerative abnormalities and immune-mediated changes may occur 
in gut specimens of patients with neuropathic CIPO. Inflammatory neuropathies are 
characterized by a dense inflammatory infiltrate characterized by CD3 positive (composed of 
both CD4 and CD8) lymphocytes almost invariably confined to the myenteric plexus (hence 
the term of lymphocytic myenteric ganglionitis). The close apposition of CD3 lymphocytes to 
myenteric neurons provides the basis to neuro-immune interactions targeting and affecting 
ganglion cell structure and survival (Antonucci et al. 2008). Indeed, experimental evidence 
indicates that inflammation/immune activation in the gastrointestinal tract can profoundly 
affect both morphology and function of the ENS.  
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7.2 Genetic aspects  
From a genetic perspective, X-linked, autosomal dominant and recessive forms have been 
identified with mutations in filamin A (FLNA) (Clayton-Smith et al. 2009; Gargiulo et al. 
2007), actin G2 (ACTG2) (Lehtonen et al. 2012), thymidine phosphorylase (TYMP) (Nishino 
et al. 1999) / polymerase gamma (POLG1) (Giordano et al. 2009) and more recently in 
SGOL1 (Chetaille et al. 2014). However, the underlying genetic alterations and molecular 
mechanisms remain unknown in most CIPO cases. Deglincerti et al mapped a locus in a large 
consanguineous family segregating an autosomal recessive form of CIPO (Deglincerti et al. 
2007; Mungan et al. 2003). In the affected family members, the major clinical feature was 
represented by CIPO, in addition to megaduodenum, long-segment Barrett esophagus, and 
cardiac abnormalities of variable severity (OMIM 611376; Mungan syndrome, MGS).  
Specifically, the main mutations known involve several genes:  
 
 FLNA (Xq28 chromosome) 
The FLNA gene is involved in a form of X-linked POIC; encoding for filamin A, a protein 
that binds actin-binding protein. Actin filaments are connected by filamina A to allow the 
orthogonal branching within the cell. The protein is involved in cytoskeletal remodeling 
allowing variations in cell shape and migratory processes. Studies of an Italian family have 
identified a hemizigosis mutation in in the FLNA gene in affected males. The deletion of two 
bases in exon 2 identified a premature stop codon in position 103. In the presence of this 
mutation there is an excess in the formation of "constriction rings", structures important for 
the contractility of the cells. The shorter FLNA form may be responsible for cytoskeletal 
abnormalities by highlighting its role in the structure and function of enteric neurons 
(Gargiulo et al, 2007). 
• ACTG2A (chromosome 2p13.1) 
The actins are highly conserved proteins involved in various types of cell motility and 
cytoskeletal maintenance. Three types of actins have been identified: actin α, β and γ. Actin γ-
2 is the protein encoded by the ACTG2A gene and represents an isoform expressed in the 
smooth muscle at the enteric level producing the SMA protein. The R148S mutation of 
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ACTG2 was observed in Familial Visceral Myopathy (FVM), a form of myopathic pseudo-
obstruction with autosomal dominant transmission (Lehtonen et al, 2012; Matera et al, 2016) 
and appears to be associated with de novo sporadic POIC cases. ACTG2
R148S
 variant is 
abnormally incorporated into actin filaments, with less actin-myosin II interaction and less 
stress fiber formation. This variant also appears to reduce the ability to interact with the 
actinic chaperonin CCT (Cytosolic Chaperonin Containing TCP-1), imposing correct actinic 
folding. In conclusion, R148S mutation interferes with the assembly and acto-myosin 
function of the intestinal musculature of FVM patients and the alteration in intestinal 
propulsion observed in FVM appears to be closely correlated with the decrease in the actin 
function at the enteric level. Through immunohistochemistry, accumulation of ACTG2 in the 
intestinal circular muscles, not found in the muscularis mucosae, can be observed in patients 
with FVM. 
 
• TYMP (chromosome 22q13.32) 
The gene encodes Thymidine Phosphorylase (TP), a protein with enzymatic activity capable 
of converting thymidine nucleosides and deoxyuridine into thymine and uracil. Mutations in 
TYMP lead to a reduction of TP activity with consequent toxic accumulation of nucleosides 
in the plasma of patients with Mitochondrial Neurogastrointestinal Encephalomyopathy 
(MNGIE). At mitochondrial level there are alterations such as multiple deletions and 
mitochondrial DNA depletion. MNGIE is characterized by peripheral neuropathy, chronic 
progressive external ophthalmoplegia, leukoencephalopathy and multiple mtDNA deletions in 
skeletal muscle. Thymidine phosphorylase also appears to play a role in the inhibition of glial 
cell proliferation (Hirano et al, 1999). Recent studies, conducted by our research group, have 
shown that in the liver there is a high expression of TP, suggesting that the transplant of this 
organ can be a valid therapeutic strategy (De Giorgio et al, 2016; Boschetti et al. , 2014). 
 
• POLG1 (15q26.1) 
The gene encodes the catalytic subunit of the mitochondrial genome polymerase. 
The mitochondrial DNA polymerase is heterodimeric consisting of a homodimer of regulatory 
subunits plus a catalytic subunit. Mutations in this gene lead to multiple deletions in mtDNA 
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with clinical features such as skeletal myopathy and visceral dysmotility which are described 
in hypoperistalsis and CIPO. mtDNA depletion seems to be the likely cause of a visceral 
myopathy causing hypoperistalsis and intestinal pseudo-obstruction. Based on these findings, 
the external layer of muscularis propria is confirmed as the most susceptible point of the 
gastrointestinal tract to develop mtDNA depletion, possibly because of the constitutive low 
abundance of mtDNA within smooth muscle cells at this site. (Giordano et al, 2009). 
 
• SGOL1 (chromosome 3p24.3) 
The protein encoded by this gene is a component of the cohesin complex involved in the 
regulation of the cohesion of the sister chromatids which acts by protecting the centromeric 
from the cleavage during the mitotic phase. Mutations in homozygosity of the SGOL1 gene 
cause the Chronic Atrial Intestinal Dysrhytmia (CAID), which is chronic intestinal atrial 
dysrhythmia. Dysrhythmias are part of disorders involving pacemaker activity, both at cardiac 
and intestinal levels. In 17 patients with CAID was observed the coexistence of a pathological 
phenotype both at intestinal and cardiac levels. Specifically, the heart level disorder 
manifested as Sick Sinus Syndrome syndrome; instead the intestinal level it manifested as 
CIPO for the involvement of Cajal and SNE cells (Chetaille et al, 2014). 
Whole Exome Sequencing (WES) analysis identified new genes mutated in CIPO. In order to 
identify the genetic defects in CIPO patients negative for RAD21 mutations, we selected a 
subset of CIPO cases associated with an enteric hypoganglionosis. We identified novel de 
novo missense variants in the genes B3GAT2 and SMC3 in two cases, and a missense variant 
in SCN11A in a patient with CIPO and small fibers neuropathy with severe abdominal pain. 
B3GAT2 encodes for the beta-1, 3-glucuronyltransferase 2 enzyme, involved in the synthesis 
of a complex sugar moiety present in neuronal cell adhesion molecules implicated in 
migration and adhesion (Gouveia et al, 2012). The protein encoded by SMC3 is a RAD21-
binding protein and part of the cohesin complex. Mutations in SMC3 have been also 
described in the Cornelia de Lange syndrome (Deardoff et al, 2007), but the missense change 
in the CIPO patient maps to a different region. SCN11A encodes for the Nav1.9 sodium 
channel subunit. Since null scn11a mice show perturbed gut motility, SCN11A mutations may 
cause an intestinal gut dysmotility also in humans (Copel et al, 2013). We designed a targeted 
resequencing panel and identified several variants including a premature stop codon in 
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B3GAT2, and various rare/novel missense changes in SCN5A, SCN9A, SCN10A, SCN11A 
and TRPA1 (10.7% of patients) in additional CIPO patients (89 Italian and 29 Swedish 
patients, the latter recruited in collaboration with G. Lindberg and M. D‟Amato). (Table 2). 
PATIENT ID DIAGNOSIS VARIANTS POLYPHEN-2 MAF ExAc 
ITAtarget_1 CIPO(M) ACTG2, 
p.Arg257Cys 
 Novel 
SWEtarget_2 CIPO (F) B3GAT2, p.Lys95X 
(rs7535544542) 
 MAF:0.00000825 
Allele frequency: 1/121180 
ITAtarget_4 CIPO (F) SCN5A, 
p.Val2016Met 
Probably damaging Novel 
ITAtarget_5 CIPO, SFN (F) SCN9A, 
p.Gly616Arg 
(rs201338643) 
Benign  
(SIFT: Tolerated) 
MAF: 6.627e-05 
Allele frequency: 8/120722 
SCN9A, 
p.Pro610Thr 
(rs41268673) 
Benign 
 (SIFT: Tolerated) 
MAF:0.005261 
Allele frequency: 496/94286 
ITAtarget_8 CIPO (F) SCN9A, 
p.Asn1245Ser 
(rs141268327) 
Probably damaging MAF:0.005262 
Allele frequency: 496/94286 
ITAtarget_11 CIPO (M) SCN10A, 
p.Arg351Cys 
Probably damaging Novel 
SWEtarget_1 CIPO (F) SCN10A, 
p.Asp1769Ala 
(rs377121469) 
Probably damaging MAF: 7,415e-05 
Allele frequency: 9/121382 
ITAtarget_7  SCN10A, 
c.1867+8C>T 
(rs370354229) 
/ 
(Splice region) 
MAF:0.0001422 
Allele frequency: 17/119532 
ITAtarget_3 CIPO (M) SCN10A, 
p.Pro991Leu 
(rs138413438) 
Probably damaging MAF: 0.000892 
Allele frequency: 108/121082 
SWEtarget_3 Nav1.5 (LoF) SCN11A, 
p.Lys419Asn 
(rs150269814) 
Probably damaging MAF: 0.000725 
Allele frequency:88/121382 
ITAtarget_12 CIPO (M) SCN11A, 
p.Arg889Lys 
/ Novel 
ITAtarget_9 CIPO (F) SCN11A, 
p.Gly481Glu 
(rs13059805) 
 
Benign (SIFT: Tolerated) MAF:0.03075 
Allele frequency: 3704/120442 
SCN11A, 
p.Cys625Tyr 
Possibly damaging MAF:1.67e-05  
Allele frequency: 2/119790 
ITAtarget_10 CIPO (M) TRPA1, Probably damaging Novel 
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p.Arg458Cys 
(rs374228201)) 
ITAtarget_2 CIPO/SFN (F) TRPA1, 
p.Asp477Asn 
(rs61753711) 
/ Novel  
ITAtarget_6 CIPO (M) TRPA1, p.Try840Ser / Novel 
Table 2 
Table 2: Analysis of variants identified in n= 118 CIPO patients (89 Italian cases (69 F, 20 M, age 
range=7-70 yrs, mean=35.2); 29 Swedish cases (24 F, 5 M, age range=20-68 yrs, mean=46.0.)  
 
7.3 Cohesin complex molecules: The RAD21 
RAD21 (8q24.11 cromosome) is a transcription factor and a key central component of the 
multi-protein cohesin complex (Xu et al. 2011) (Figure 8), which functions to protect 
chromosome separation during the metaphase–anaphase transition of mitosis (Guacci et al. 
2007). RAD21 is ubiquitously expressed in many tissues (Faure et al. 2012) and its critical 
role emerged from mouse knock-out, which showed a lethal early embryonic phenotype 
(Biswas et al. 2016). Studying a familial cluster of CIPO patients, we have recently 
demonstrated a novel loss-of-function mutation in RAD21, which was associated with enteric 
neuropathy and severe gut dysmotility in the affected family members. The CIPO-causing 
RAD21 mutation was found to alter the expression of related genes, including RUNX1 and 
APOB. Moreover, the RAD21 loss-of-function mutation was associated with a markedly 
reduced number of enteric neurons, thus implying a neurogenic origin of the gut dysmotility 
reported in the affected family (Deglincerti et al 2007, Bonora et al. 2015). 
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Figure 8. Cohesin complex Stucture: the structure include SMC1 and SMC3 subunits that linked proteins with 
ATP domain at one end. Togheter with RAD21 and STAG formed a large ring structure that can surround the 
sister chromatids. ATPase domains are needed to load cohesin to DNA. RAD21 is also able to link different sites 
within the genome, regulating the transcription of some genes; due to this characteristic it is involved in various 
processes linked to tumorigenesis (modified from Deardorff et al, 2012). 
 
The distribution of RAD21 in the enteric nervous system, the intrinsic neural network 
controlling gastrointestinal (GI) physiology and homeostasis (De Giorgio et al. 2007, Rao et 
al. 2017), remains unknown. The mutation of RAD21 p.622 Ala> Thr is associated with a 
clinical phenotype that includes insufficient intestinal peristalsis and severe subocclusive 
episodes. Delay in intestinal motility and decrease in enteric neurons has also been 
demonstrated in vivo using a Danio rerio (zebrafish) model. In this model was observed the 
consequences produced by the silencing of RAD21 orthologues, Rad21, using splice blocking 
morpholino (MO), which allows block the splice sites of the pre-mRNA of interest.  
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Chapter IV 
 
8. THE SEROTONERGIC SYSTEM IN THE GUT  
8.1 5-hydroxytryptamine (5-HT) receptors 
Serotonin receptors are classified into seven types, 5-HT1 through 5-HT7. Each type can have 
subtypes (A, B, etc.). These receptors are localized in the brain and in peripheral organs but 
their distribution is not homogeneous. The majority of 5-HT receptors are postsynaptic, with 
some exceptions, most notably 5-HT1A and 5-HT1B that are mainly presynaptic and 
modulate serotonin release. The signaling pathways to which these receptors are coupled are 
known, but it is has not been possible to link direct clinical effects systematically to their 
stimulation. Serotonin receptors are coupled to G proteins except 5-HT3 receptors which are 
receptor-channels, also called ionotropic receptors, which, in the activated state, are open and 
permeable to sodium and potassium cations. SERT 5-HT transporter, represents established 
targets for many pharmacological agents that affect brain function, including 
psychostimulants, antidepressants and neurotoxins (Figure 9).  
      
 
Figure 9. Schematic representation 5-HT synaptic terminals. Monoamine transporters are localized 
to perisynaptic sites, where they are crucial for the termination of monoamine transmission and the 
maintenance of presynaptic monoamine storage. Several selective pharmacological agents acting at 
each monoamine transporter are shown. Amph., amphetamine; 5-HT, 5-hydroxytryptamine; MDMA, 
3,4-methylenedioxymethamphetamine; SERT, 5-HT transporter (modified from Torres et al. 2003). 
 
47 
 
The sensitivity of monoamine transporters, for substrates and inhibitors, has been examined in 
brain preparations and in heterologous systems with recombinant transporters. Actually, in the 
scenario of GI disorders, some the most interesting targets for pharmacological intervention 
are the 5-HT receptors that are known to affect gut motor function, in particular the ones 
belonging to the 5-HT1, 5-HT2, 5-HT3, 5-HT4, and 5-HT7 subtypes (De Ponti 2004).  
The current knowledge on the serotonin system in the GI leads to conclude that the 
modulation of gut-derived serotonin and the serotonin pathways represents a significant and 
promising way of treating patients with GI dysmotility conditions. 
The focus in gastroenterology has been on 5-HT3 and 5-HT4 receptors (Table 3), although in 
I present two studies on 5HT4. 5-HT4 receptors are also highly expressed in the colonic 
epithelium, where they appear to be expressed by all epithelial cells (Hoffman et al. 2012). 
Epithelial 5-HT4 receptors mediate a variety of responses, including 5-HT release, chloride 
secretion and goblet cell degranulation, as well as enhanced propulsive motility and reduced 
visceral hypersensitivity by intraluminal administration of a 5-HT4 agonist (Hoffman et al. 
2012). 5-HT4 receptor agonists have prokinetic and anti-nociceptive actions and have been 
used to treat constipation-predominant irritable bowel syndrome (Mawe et al. 2013), but the 
functions of these receptors are still being elucidated, and they likely include protective 
actions. Furthermore, 5-HT4 receptors also appear to play a role in the development and (Li et 
al. 2011) survival of enteric neurons, since neuronal density is reduced in the intestines of 5-
HT4 knockout mice.  
 
Table 3. 5-HT receptor subtypes in the gut:5-HT1P receptors are the only 5-HT receptors that have 
not yet been cloned. They are not included in the IUPHAR nomenclature of 5-HT receptors. B fEPSP, 
fast excitatory postsynaptic potential; upward arrow, increase; downward arrow, decrease. 
 
 
 
 5HT1A 5HT1B-D 5HT2A 5HT2B 5HT3 5HT4 5HT7 5HT1P
a 
Recetptor 
distribution 
Enteric neurons Enteric neurons; 
smooth 
muscle(?) 
Enteric neurons; 
smooth muscle; 
enterocytes 
Enteric neurons; 
smooth muscle 
Enteric neurons Enteric neurons; 
smooth muscle; 
enterocytes 
Enteric neurons; 
smooth muscle 
Enteric neurons; 
smooth muscle 
Funtional  
effectsb 
<Trasmitter 
release 
(presynaptic 
action) 
>Trasmitter 
release; relaxes 
gastric fundus 
>Trasmitter 
release; contracts 
muscle; 
>secretion 
>Trasmitter 
release (?); 
contracts muscle 
Causes fEPSPs in 
some neurons 
>Trasmitter 
release 
>secretion; 
Activates IPANs 
>Trasmitter release 
(presynaptic 
action);relaxes 
muscle; >secretion 
Activates IPANs; 
Inhibits 5HT release 
from EC cells 
Mediates slow 
EPSPs; 
>Trasmitter 
release; 
Relaxes muscle 
Mediates slow 
EPSPs; 
>Trasmitter 
release; 
Relaxes muscle; 
Activates IPANs 
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8.2 Serotonin synthesis and secretion  
5-HT belongs to the monoamine neurotransmitter family. Transepithelial signaling, involving 
pressure- or nutrient-induced secretion of paracrine messengers, such as serotonin 5-HT, 
initiates secreto-motor reflexes (Bertrand, 2004; Gershon and Tack, 2007). Most of 5-HT 
(~95%) is located in enterochromaffin (EC) cells, while a minimal component is contained in 
interneurons (~2%) of the ENS. Serotonin biosynthesis is dependent on two enzymes: 
tryptophan hydroxylase 1 (TPH1) present in EC cells; and TPH2 expressed in neurons. 
Interestingly, TPH2, but not TPH1, knock-out mice, showed a decreased myenteric neuronal 
density and proportions of dopaminergic and GABAergic neurons, thus implying that 5-HT, 
further to its functional properties, may exert an important role on neuronal survival in at least 
a subset of enteric neurons (Wood, 2011). Uptake, mediated primarily by the serotonin 
transporter (SERT) in enterocytes and neurons, terminates the action of released 5-HT, while 
an array of receptors widely expressed in the ENS triggers its biologic actions (Tonini, 2005; 
Galligan and Parkman, 2007; Beattie and Smith, 2008). In the gut, SERT mediate the 
reuptake into epithelial cells, platelets and other cells. SERT is able to binds 5-HT and 
internalizes the molecule through the cellular membrane; it is present both in the mucosa and 
enteric nerves. As consequence, SERT represents a critical inactivating mechanism for the 
serotonin signal and in maintaining the 5-HT homeostasis (Figure. 10) (Wade et al. 1996). 
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Figure 10. 5-HT signaling in the gut. a) The sequence of events involved in 5-HT signaling in the 
gut. At rest, 5-HT is synthesized by enterochromaffin cells. Upon mechanical or chemical stimulation, 
5-HT is released into the interstitial space of the lamina propria and binds to receptors on nearby nerve 
fibers. 5-HT signaling is terminated during the recovery phase: 5-HT is transported by serotonin 
transporter into epithelial cells where it is enzymatically degraded, or it enters the blood stream where 
it is transported into platelets and stored for future use. b;c) Immunostaining for 5HT and SERT in a 
human rectal biopsy specimen demonstrating that essentially all cells in the colonic glands are SERT-
immunoreactive. (Modified from Mawe and Hoffman 2013). 
 
8.3 Serotonin influences gut physiology  
For decades, it has been widely believed that serotonin has a major role in regulating GI 
function (Gershon and Tack 2007). This belief is based on a huge number of different 
findings. These include the well known observation that most of the body's serotonin is 
synthesized and stored in the intestine, the presence of many different serotonin receptors 
within the intestinal wall and very large amount of observations of altered intestinal behavior 
following treatment with exogenous agonists and antagonists. However, despite a mountain of 
evidence, the actual roles of serotonin in the GI tract have been maddeningly difficult to 
identify. Reasons for this failure include that there are both neural and mucosal sources of 
serotonin within the gut and the widespread and overlapping distribution of specific serotonin 
receptor subtypes. Various 5-HT4 agonists have been developed to treat gastrointestinal 
disorders characterized by altered motility (Waeber C et al. 1994), including the 5-HT4 full 
agonist, prucalopride, which significantly improves symptoms and quality of life of patients 
with severe chronic constipation with excellent safety and tolerance profile (Tack J et al. 
2012). Interestingly, 5-HT4 receptors have also been shown to modulate neuronal survival 
and neurogenesis (Gershon MD et al. 2007). Indeed, in the central nervous system, 5-HT4 has 
been shown to be involved in synaptic plasticity crucial to cognitive processes and memory 
consolidation (EWaeber C et al. 1994). Recent findings also provide evidence for a role of 5-
HT4 in mediating neurogenesis and synaptic plasticity in the ENS (Takaki M et al. 2014). 
Furthermore, 5- HT4-/- mice showed loss of enteric neurons and reduced size of the surviving 
neurons at 1 month in addition to delayed gastrointestinal transit (Liu MT et al. 2009). 
Finally, in vitro treatment with 5-HT4 agonists increased the number of enteric neurons 
developing from precursor cells and/or surviving in culture, supporting neurogenetic 
properties mediated by this receptor subtype (Liu MT et al. 2009). In this study, we tested the 
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hypothesis that the 5-HT4 full agonist, prucalopride, exerted a protective effect against 
neuronal injury using an established model of oxidative stress and different types of human 
neuronal cell lines, primary human enteric neurospheres (Bondurand N et al. 2003) and 
human submucosal neuron whole mount preparations obtained from colonic biopsies 
(Lebouvier T et al. 2010). We demonstrated that 5-HT4 activation stimulated a specific 
protective response in the different neuronal cells analyzed, including human enteric neurons. 
Our findings open new avenues in the treatment of gastrointestinal disorders and homeostasis, 
especially in relation to neurodegeneration often underlying severe gut dysmotility.
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Chapter VI 
 
10. Mutations in RAD21 Disrupt Regulation of APOB in Patients with Chronic 
Intestinal Pseudo-obstruction 
 
Modified from 
 
―Mutations in RAD21 Disrupt Regulation of APOB in Patients with Chronic Intestinal 
Pseudo-obstruction‖ 
Elena Bonora, Francesca Bianco, Lina Cordeddu, Michael Bamshad, Ludmila Francescatto, 
Dustin Dowless, Vincenzo Stanghellini, Rosanna. Cogliandro, Greger Lindberg, Zeynel 
Mungan, Kivanc Cefle, Tayfun Ozcelik, Sukru Palanduz, Sukru Ozturk, Asuman Gedikbasi, 
Alessandra Gori, Tommaso Pippucci, Claudio Graziano, Umberto Volta, Giacomo Caio, 
Giovanni Barbara, Mauro D'Amato, Marco Seri, Nicholas Katsanis, Giovanni Romeo and 
Roberto De Giorgio. 
Gastroenterology. 2015 April ; 148(4): 771–782.e11. 
 
Abstract 
 
Background & Aims—Chronic intestinal pseudo-obstruction (CIPO) is characterized by 
severe intestinal dysmotility that mimicks a mechanical sub-occlusion with no evidence of gut 
obstruction. We searched for genetic variants associated with CIPO to increase our 
understanding of its pathogenesis and indentify potential biomarkers. 
 
Methods—We performed whole-exome sequencing of genomic DNA from patients with 
familial CIPO syndrome. Blood and lymphoblastoid cells were collected from patients and 
controls (individuals without CIPO); levels of mRNA and proteins were analyzed by 
quantitative reverse transcription PCR, immunoblot, and mobility shift assays. cDNAs were 
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transfected into HEK293 cells. Expression of rad21 was suppressed in zebrafish embryos 
using a splice-blocking morpholino (rad21a MO). Gut tissues were collected and analyzed. 
 
Results—We identified a homozygous mutation (p.622, encodes Ala>Thr) in RAD21 in 
patients from a consanguineous family with CIPO. Expression of RUNX1, a target of RAD21, 
was reduced in cells from patients with CIPO compared with controls. In zebrafish, 
suppression of rad21a reduced expression of runx1; this phenotype was corrected by injection 
of human RAD21 mRNA, but not with the mRNA from the mutated p.622 allele. rad21a MO 
zebrafish had delayed intestinal transit and greatly reduced numbers of enteric neurons, 
similar to patients with CIPO. This defect was greater in zebrafish with suppressed expression 
of ret and rad21, indicating their interaction in regulation of gut neurogenesis. The promoter 
region of APOB bound RAD21 but not RAD21 p.622 Ala>Thr; expression of wild-type 
RAD21 in HEK293 cells repressed expression of APOB, compared with control vector. The 
gut-specific isoform of APOB (APOB48) is overexpressed in sera from patients with CIPO 
who carry the RAD21 mutation. APOB48 is also overexpressed in sporadic CIPO in sera and 
gut biopsies. 
 
Conclusions—Some patients with CIPO carry mutations in RAD21 that disrupt the ability of 
its product to regulate genes such as RUNX1 and APOB. Reduced expression of rad21 in 
zebrafish, and dysregulation of these target genes, disrupts intestinal transit and development 
of enteric neurons. 
Keywords 
sporadic and familial chronic intestinal pseudo-obstruction; intestinal motility; animal model; 
genetic analysis 
 
Methods 
Patients and controls 
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An additional 21 Italian and 12 Swedish sporadic patients with idiopathic CIPO were 
included in the study (eight males and 25 females; mean age: 38.6+/−16.6 years). In Table 1 
the major clinical characteristics of these patients are described. 500 Turkish controls were 
recruited at the Universities of Ankara and Istanbul; 240 controls of European ancestry were 
recruited at the University of Bologna. All data from patients and controls, including the 
informed consents, were handled in accordance with local ethical committee‟s approved 
protocols and in compliance with the Helsinki declaration. 
 
High-Throughput SNP genotyping and Whole Exome Sequencing Analysis 
400 ng of genomic DNA from peripheral blood was used for high-throughput SNP 
genotyping on Illumina Infinium HD Assay Gemini platform (Illumina, San Diego, CA, 
USA), according to manufacturer‟s protocol. Genotypes were converted into PLINK format 
with custom scripts. PLINK v1.07 (http://ngu.mgh.harvard.edu/~purcell/plink/) was used to 
isolate individual Runs Of Homozygosity (ROH) that showed > 1 Mb overlap Mb overlap 
between the three affected siblings.  
RAD21 mutation screening in idiopathic CIPO cases 
PCR primers for human RAD21 (NM_006265.2) were designed with Primer3 v4.0 
(http://primer3.ut.ee) and are available on request. Genomic DNA extracted from peripheral 
blood was amplified according to the following PCR conditions: 30 ng of DNA, 2.5 mM 
MgCl2, 0.5 mM dNTPs, 0.5 μM primers, 5% DMSO in a final volume of 20 ml using the 2X 
KAPA Fast Taq Polymerase Master mix (KAPA Biosystems, MA, US). Forty cycles were 
carried out as follows: 95°C 1‟, 95°C 15‟‟, 58°C 1‟, 72°C 1‟, with a final extension of 30‟‟ at 
72°C. PCR products were purified onto Millipore PCR clean-up plates and directly sequenced 
on both strands using the BigDye v1.1 kit (Life Technologies, Carlsbad, CA, USA). 
Electropherograms were visualized with Chromas version 2.0 and Sequencer version 4.7. 
 
RAD21 cDNA transfection into HEK293 cells 
Human RAD21 cDNA inserted in pCMV6 vector in frame with DDK epitope was purchased 
from OriGene (OriGene, Rockville, MD, USA). The mutation corresponding to p.622 
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Ala>Thr was inserted by site-directed mutagenesis using the QuickChange XL mutagenesis 
kit (Agilent Technologies, Santa Clara, CA, USA) according to manufacturer‟s instructions. 
The insertion of the changes was verified by direct sequencing. 3x105 HEK293 human renal 
cells (ATCC, UK) were plated for transfection of the different plasmids using liposomes 
according to manufacturer‟ 
instructions (Lipofectamine, Life Technologies). Protein and RNA extraction was performed 
after 48 hrs from transfection.  
 
Gene expression analysis 
Total RNA from 1.5 ml fresh blood was extracted with the QIAGEN Blood Total RNA kit 
(QIAGEN, Venlo, Limburg, Netherlands). Total RNA from lymphoblastoid or transfected 
cells was extracted with RNeasy kit (QIAGEN). Total RNA from 1.5 ml fresh blood was 
extracted with the QIAGEN Blood Total RNA kit (QIAGEN, Venlo, Limburg, Netherlands). 
Total RNA from 5x106  LCLs or HEK293 cells, cultured according to standard protocols, 
was extracted with the RNeasy kit (QIAGEN). 1µg of DNase I-treated RNA was used for 
reverse transcription with random hexamers using the Multiscribe RT system (Life 
Technologies) at 48°C for 40′ in a final volume of 50 µl. qRT-PCR was performed with 
SYBRGreen, 0.5 µM primers, in an ABI 7500 Real-Time PCR System (Life Technologies). 
All target genes were normalized with the corresponding endogenous 
control (beta-actin) using the ∆∆Ct comparative method. PCR primers are available on 
request. 
 
Zebrafish functional assays 
A published ret MO was used.18 To measure rad21a MO efficiency, total mRNA was 
extracted from control and MO injected embryos, reverse-transcribed and the site targeted by 
the MO was PCR amplified (Figure S1).  
 
Microgavage 
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Control and rad21 MO injected embryos were developed to 5dpf. Zebrafish larvae were 
anesthetized in Tricaine (Sigma), mounted in 3% methylcellulose and injected with 
fluorescent beads into the mouth as described Cocchiaro JL et al. 2013). 
 
Electromobility shift assay (EMSA) 
2x10
6
 LCLs were rinsed in cold PBS-Na3VO4 0.2 mM, pelleted by centrifugation at 1600xg 
and lysed in 400 µl of Buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1mM EDTA, 1 mM 
DTT, 1 mM Na3VO4 and a protease inhibitors cocktail) for 15 min in ice. 25 µl of 10% NP-40 
were added and the samples were centrifuged at 16000xg 30 sec. The nuclear pellets were 
resuspended in 50 µl Buffer C (20 mM HEPES pH 7.9, 0.4 mM KCl, 0.1mM EDTA, 0.1 mM 
EGTA, 1 mM DTT, 1 mM Na3VO4 and a protease inhibitors cocktail), incubated on ice for 45 
min, and centrifuged at 16000xg 10 min at 4°C.10 µg of nuclear extracts, 20 fmol of biotin-
labelled probes, 2 µg of sheared salmon sperm DNA, 2.5% glycerol, 5 mM KCl and 5 
mMgCl2 were incubated at room temperature for 30 min in 20 µl. Cold probes were added at 
a concentration 200X. The nuclear complexes were resolved by non-denaturing 
electrophoresis on 4% polyacrilammide gel, transferred onto nitrocellulose membrane at 380 
mA 30 min at 4°C, crosslinked via UV binding 15 min at room temperature. For supershift 
assay, nuclear extracts were incubated at the same conditions as reported above, but the 
complexes were immunoprecipitated 40 min at 4°C with 1.5 µg of rabbit anti-RAD21 
antibody (Abcam) before the EMSA assays. Complexes were resolved under non-denaturing 
conditions using a 3.5% polyacrylamide gel. EMSA shift was revealed with the LightShift 
Chemiluminescent EMSA Kit (Thermo Scientific Inc., IL, US). The used biotin-labelled 
probes are the following: 
hAPO_AC2 5′-
CGGAGTTGTCAAGGCGGGGGCTGCAGGCAGAGGGCGCTAAAGAGCCCA 
GGATGGCCGGG-3′ (chr11:116,662,104-116,662,163, hg19);  
hAPOB_c1 5′-
CAGAGCACTGAAGACGCTTGGGGAAGGGAACCCACCTGGGACCCAGCCC 
CTGGTGGCTGCGGCTGCAT-3′ (chr2:21,267,106-21,267,173, hg19) ; 
hAPOB_c2 5′- CATTCCCACCGGGACCTGCGGGGCTGAGTGCCCTTCT-3′ 
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(chr2:21,266,910-21,266,946, hg19). 
 
Immunoprecipitation and western blotting 
2×10
6
 LCLs were used for immunoprecipitation assays. Crude sera of patients were diluted in 
PBS. Serial dilutions for cases and controls were performed (1:5, 1:10, 1:100, Figure S2A). 
2x106  LCLs were lysed in 50 mM HEPES, 1 mM EDTA, 10% glycerol, 1% Triton X- 100, 
150 mM NaCl in presence of protease inhibitors (Roche Diagnostics, Basel, Switzerland) and 
phosphatase inhibitors (Inhibition Cocktails 2 and 3, Sigma, St. Louis, MO, US). Pre-clearing 
was performed with rabbit IgG (Millipore, Billerica, MA, US) 1 hr at 4°C. 
Immunoprecipitation assays were performed at 4°C using 0.8 µg rabbit anti-SMC1 or anti-
RAD21 antibody/reaction (Sigma Prestige) on Protein GSepharose (Sigma). Proteins were 
separated by SDS gel electrophoresis, transferred onto nitrocellulose membrane (GE 
Healthcare, Little Chalfont, UK) and subjected to western blotting with the Western Breeze 
kit (Life Technologies). Proteins extracted from sera of patients were diluted 1:5 in PBS, 
quantified with Lowry method and Coomassie Blue gel staining, separated by SDS gel 
electrophoresis, and transferred onto nitrocellulose membrane (GE Healthcare). Primary 
antibodies used were the following: goat anti-APOB48 1:250 (Santa Cruz, Texas; USA) and 
goat anti-APOB 1:1000 (Dako, Santa Clara, CA, US); rabbit anti-APOB100 (Abcam, 
Cambridge, UK) 1:200; mouse anti-GAPDH (Abcam) diluted at 1:5000. Bands were 
visualized by the ECL method (GE Healthcare).  
 
Immunohistochemistry 
Immunohistochemistry was performed on paraffin-embedded adult human colon tissues 
(patients routinely operated for uncomplicated colon cancers commonly used as controls for 
immunohistochemical experiments) according to protocols validated in our laboratory. 
Briefly, tissue sections were treated to remove paraffin embedding by three sequential washes 
in xylene and graded ethanol. Antigen unmasking was performed by heating sections at 95°C 
in 10 mM Sodium citrate buffer, pH 6.0, for 10 min and subsequent cooling at room 
temperature for 30 min. To reduce endogenous peroxidases, tissue sections were treated with 
an ad hoc blocking kit (GeneTex Inc., Irvine, CA; USA) and incubation for 16 h at 4°C with 
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primary antibodies. The following primary antibodies were used: anti-human APOB48 (Santa 
Cruz) and antihuman APOB diluted 1:100 (Abcam); anti-human RAD21 diluted 1:250 
(Sigma Prestige), anti-human APOBEC1 diluted 1:100 (Creative Diagnostics, Bristol, UK). 
Incubations with the corresponding blocking peptides or with the secondary antibodies only 
were performed as negative controls (Figures S2a, b). Fluorescent secondary antibodies were 
diluted 1:300 in Triton-X and incubated 60 min at room temperature, before subsequent 
dehydration and visualization under a LEICA DMLB fluorescent microscope. DAB staining 
was performed according to standard protocols. 
 
Quantitative evaluation of ganglion cells 
We counted the number of neurons after immunostaining with a rabbit polyclonal anti human 
neuronal specific enolase (NSE) antibody 1:400 (Millipore, Germany). For each section, 25-
28 high power (40x) microscopic fields, along the neuromuscular ridge of the myenteric 
ganglia, were captured to assess NSE immunoreactive neuronal cell bodies / ganglion.22 The 
same procedure was performed for the counts of neurons in the submucosal ganglia. Sections 
were examined using a Leica microscope equipped with a digital camera. Quantitative 
evaluation of neuron number in myenteric and submucosal ganglia was performed according 
to Ganns D et al. 2006.  
 
Statistical analysis 
Case-control association study for SNP rs72105712 was performed using Haploview 4.0 
(http://www.broadinstitute.org/scientific-community/science/programs/medical-and-
population-genetics/haploview/). Statistical analysis of quantitative differences was 
performed using the Student‟s t-test from the GraphPad package 
(http://graphpad.com/quickcalcs/). Fluorescent cell count was performed with ImageJ 
(http://rsbweb.nih.gov/ij); χ2 tests were calculated using the dedicated option from GraphPad. 
 
Results 
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Identification of a novel RAD21 mutation in CIPO 
We performed a combined single nucleotide polymorphism (SNP)-genotyping/next 
generation-sequencing approach in a consanguineous CIPO pedigree of Turkish origin 
(Figure 1A), where we previously mapped a linkage locus with a multipoint LOD 
score=5.019. 14 High-throughput SNP-genotyping in the family and detection of Runs of 
Homozygosity (ROH) by PLINK (http://ngu.mgh.harvard.edu/~purcell/plink/) confirmed the 
locus,14 by identifying two regions of extended homozygosity: 91,878,147-113,307,176; 
116,713,296-124,956,205. We then performed WES on genomic DNA from two affected 
individuals (IV-9 and IV-11, Figure 1A). We filtered data for variants that were a) 
homozygous in our patients; b) rare (MAF <1%) in public databases (EVS, dbSNP); and c) 
predicted computationally to be pathogenic. We found a single variant fulfilling all these 
conditions inside our linkage interval on chromosome 8 (Figure 1; Figure S3A). This 
homozygous allele affects the coding change c. 1864 G>A in RAD21 (NM_006265.2), and is 
predicted to generate a missense substitution p.622 Ala>Thr (Figure 1B). Mutation Taster 
(http://www.mutationtaster.org/) and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/)21 
analysis predicted this change to be "disease causing" and "damaging", respectively (Mutation 
Taster p= 0.9999; PolyPhen-2 HumDiv score: 0.999, sensitivity: 0.14; specificity: 0.99; 
HumVar score: 0.993; sensitivity: 0.47; specificity: 0.96), and the variant was absent from 
public databases (dbSN: www.ncbi.nlm.nih.gov/SNP/, 1000 Genomes: 
www.1000genomes.org/, ESP: http://evs.gs.washington.edu/EVS/) and from 1000 control 
chromosomes of Turkish origin analyzed by our group. To test the candidacy of this allele, we 
performed segregation analysis on all available family members: all three affected sibs carried 
the change in a homozygous state and all carriers of the risk haplotype (including the parents) 
were heterozygous (Figure 1A). 
To evaluate whether RAD21 mutations were also prevalent in other idiopathic CIPO cases, we 
screened 21 Italian and 12 Swedish individuals with pseudo-obstruction, defined by clinical, 
manometric and radiological examination (Table 1). We did not identify any mutation in 
RAD21 coding region, although a 1bp-indel was detected with high frequency in the upstream 
region (m.a.f= 0.364; g.11788122-11788123 ins(C)); rs72105712 (dbSNP137)). Since no 
allele frequencies were known for this SNP, we investigated the frequency in a control group 
of European ancestry (N= 240); we found no differences between cases and controls (m.a.f.= 
0.36 in cases; 0.34 in controls; χ2= 0.08, p-value= 0.77). To test the candidacy of RAD21 
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further, we evaluated its expression in blood and lymphoblastoid cell lines (LCLs) obtained 
from one homozygous patient and several controls, including one unaffected wild-type 
brother. Real-time quantitative RT-PCR (qRT-PCR) showed that RAD21 expression in the 
affected individual was comparable to that in controls, either in blood (Figure S3B) or in LCL 
cDNA (Figure S3C). The mutant protein was also expressed in LCLs in amounts comparable 
to wild-type cells (Figure S3D; upper panel). Likewise, testing the interaction of RAD21 with 
SMC1, one of its known partners, (Panigrahi AK et al. 2012) co-immunoprecipitation 
experiments showed that the mutant protein still retains SMC1-binding activity (Figure S3D, 
middle panel). 
Since one of the main target genes activated by RAD21 is RUNX1 (Horsfield et al. 2007, 
Marsman et al. 2014); we investigated whether mutated RAD21 could hamper its 
transcription activity: indeed, the affected individual‟s LCLs showed significantly reduced 
RUNX1 expression compared to controls (Figure 1C). Similarly, transfection of mutant 
RAD21 cDNA in HEK293 cells and  
subsequent RT-qPCR revealed a significant decrease in RUNX1 expression (p=0.0028, 
Student‟s t-test) compared to cells transfected with wild-type RAD21 cDNA (Figure S3E). 
 
Rad21a suppression causes downregulation of runx1 expression and loss of enteric 
neurons in vivo 
To test the hypothesis that RAD21 is necessary for enteric development and to assay the 
pathogenic potential of the newly discovered allele in a physiologically relevant in vivo 
system, we investigated RAD21 in zebrafish development. 
Given our in vitro observations on the role of RAD21 on RUNX1 expression and its 
downregulation in patient's cells, we asked whether RAD21 can replicate this defect in vivo 
and whether the patient‟s mutation has the expected effect. We identified (by reciprocal 
BLAST) the sole ortholog of RAD21 and we injected zebrafish embryos with a rad21a splice 
blocking morpholino (MO) (at 1–2 cell stage, Figure S2A,B). Embryos were fixed at 14hpf 
(hours post fertilization) and stained with a runx1 probe. During zebrafish development, 
runx1 is expressed in the posterior lateral plate mesoderm (PLM). We observed defects in 
runx1 expression patterns recapitulating prior studies, Horsfield et al. 2007, and Marsman et 
61 
 
al. 2014 with runx1 expression either partially or completely absent in rad21a morphants 
(Figures 2A–C). Runx1 expression was rescued by co-injection of MO with human WT 
RAD21 mRNA. In contrast, co-injection of MO and mRNA encoding the p.622 Thr allele was 
not able to rescue runx1 expression, indicating that the RAD21 mutation has a loss-of-
function effect in vivo (Figure 2D). 
To test whether we could recapitulate the CIPO phenotype seen in RAD21 mutant patients, 
including a severe impairment of gut motility and marked hypoganglionosis (Deglincerti et al. 
2007) we characterized the zebrafish gut. Subsequent to MO injection, embryos were allowed 
to develop to 5dpf, at which time the digestive system has developed (Ng et al. 2005). 
Notably, we saw no appreciable runx1 expression in the gut at this stage of development (data 
not shown), suggesting an earlier onset of the enteric phenotype. Control and MO embryos 
were fed fluorescent beads through microgavage, a technique that allows to determine the rate 
of intestinal motility as a function of time (Cocchiaro et al. 2013). After eight hours post bead 
injection (hpi), embryos were divided into 1–4 zones based on anatomical landmarks (Figure 
3A) and the presence of fluorescence in each segment was scored. Consistent with the CIPO 
phenotype, rad21a morphants showed delayed food transit along the gut (Figure 3B). 
Moreover, staining of enteric neurons along the gut with antibodies against HuC/D showed a 
significant depletion of enteric neurons (Figure 3C). Quantitative analysis of the zebrafish gut 
(Figure 3D) at 4 (upper panel) and 5 (lower panel) dpf stages revealed that rad21 morphants 
had a marked reduction of HuC/D-immunolabeled enteric neurons compared to controls, 
suggesting a neurogenic cause of the observed motility defects. 
Notably, previous reports on rad21a morphants and rad21nz171 mutants have shown 
significantly reduced expression of ascl1a, a neuronal marker. Ascl1 is also a transcription 
factor required for the development of serotonergic neurons (Pattyn et al. 2004). An ASCL1 
mutation has been reported previously in Haddad syndrome, a condition encompassing 
congenital central hypoventilation syndrome and Hirschsprung‟s disease (MIM 209880).  
These data, the similarity of rad21a morphants to the hypoganglionic phenotype observed in a 
mouse model for the ret mutation C620R (Carniti  et al. 2006; Yin et al. 2007) raised the 
possibility that RAD21 and RET might act synergistically during gut neurogenesis. We 
therefore performed epistasis analysis by co-injecting rad21a and ret MOs at subeffective 
doses, at which each MO alone was indistinguishable from control embryos. We observed 
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strong epistasis on the innervation of the gut; co-injection of the two genes phenocopied the 
phenotype of high dose rad21 MOs (Figures 3E, F). At the same time, overexpression of RET 
did not rescue rad21 morphants, or vice versa, suggesting that the two genes act on the same 
process but not directly in the same pathway. This observation is consistent with previous 
studies that showed RET to be induced by NGF in a runx1-independent manner (Luo et al. 
2007). 
 
The mutant RAD21 p.622 Ala>Thr does not bind to RAD21-binding elements in 
Apolipoprotein B promoter 
Recent data have shown that RAD21/CTCF binding sites are present in the apolipoprotein 
A1/C3/A4/A5 gene cluster on chromosome 11 and that altered binding of these factors to 
these sites dysregulates apolipoprotein expression (Mishiro et al. 2009). We therefore 
performed electromobility shift assay (EMSA) experiments to test whether the mutant 
RAD21 protein could retain its binding affinity for the above-mentioned sites, in particular for 
the AC2 site (Mishiro et al. 2009). We observed no differences between the nuclear extracts 
from wild-type and mutant LCLs in binding to this site (Figure S3F). Next, we investigated if 
the nuclear extracts from wild-type and mutant LCLs could show differences in binding to 
human APOB promoter (Carlsson et al 1989). In silico analysis with MatInspector identified 
two binding sites for RAD21/CTCF (hAPOB_c1, chr2:21,267,137-21,267,173, matrix score: 
0.862; hAPOB_c2, chr2:21,266,910-21,266,945, matrix score: 0.807) which maps to the two 
regulatory regions of the proximal APOB promoter (Carlsson et al 1989). EMSA assays 
performed with probes corresponding to the two sites showed a specific shift only in the 
presence of wild-type nuclear extracts (Figure 4A). Moreover, specific supershifts with an 
anti-RAD21 antibody were detectable only in wild-type, but not in mutant, nuclear extracts 
(Figure S4A). Transfection of the plasmids carrying either wild-type or mutant RAD21 
cDNAs in frame with the DDK-epitope, in HEK293 cells, and subsequent RT-qPCR analysis 
of APOB expression revealed that wild-type RAD21 overexpression reduced APOB levels 
compared to the empty vector (p=0.0098; Student‟s t-test). In contrast, overexpression of the 
mutant protein had no effect, similarly to the empty-vector transfections (Figures 4B, C). 
These data suggest that RAD21 might act as a repressor of APOB. 
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Apolipoprotein B (APOB) is overexpressed in CIPO patients 
APOB transcript generates two different proteins, APOB48 and APOB100 isoforms, both 
present in serum (Black et al. 2007). Since our data suggested a RAD21-regulated expression 
of APOB, we analyzed sera from the CIPO patient homozygous for RAD21 mutation (IV-9), 
and from wild-type controls. We detected an elevated expression of APOB48 in the patient, 
whereas no significant differences could be appreciated for APOB100 (Figure 5A and  Figure 
S5A). To understand whether APOB overexpression was unique to this patient or whether it 
might represent a more generalized phenomenon, we evaluated sera from RAD21 mutation-
negative idiopathic CIPO patients and from control subjects. APOB48 showed an increase in 
CIPO patients (Figure 5B and Figure S5B). Moreover, compared to CIPO, sera derived from 
12 patients with functional bowel disease, namely seven diarrhea-predominant IBS (IBS-D), 
four constipation predominant IBS (IBS-C) and one with alternating bowel IBS (IBS-C/D), 
did not show APOB48 overexpression (Figure 5C and Figura 11 Figure S5C). Furthermore, 
western blot analysis on the sera of patients with other gastrointestinal disorders, i.e. anorexia 
nervosa and mechanical intestinal obstruction, did not identify any APOB48 increase.  
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Figure 11: APOB relative expression (A.U.) of sera’s patients. Chonic intestinal Pseudo-Ostruction 
(CIPO), Achalasia (ACHA), Hirschsprung disease (HSCR), Celiac Desease (CD), Non Celiac Gluten 
Sensitivity (NCGS), Irritable Bowel Syndrome with Diarrhea (IBS-D), Irritable Bowel Syndrome with 
Constipation (IBS-C), Irritable Bowel Syndrome - Alternating (IBS-A) and Healthy Controls (HC). 
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Data are expressed as single values. Horizontal lines represent mean values. * P<0 .0001 vs. CIPO 
(simple contrast analysis of variance, ANOVA).  #P<0.001 vs. HC (simple contrast ANOVA). 
 
Immunohistochemical analysis of gut biopsies (mainly ileum) of sporadic CIPO patients 
revealed APOB48 expression in myenteric neurons and in cells of the lamina propria, 
reminiscent of immunocytes (Figure 5). Consistent with the results obtained in the sera, the 
APOB48 signal was increased markedly in the biopsies of CIPO cases compared to controls 
and IBS cases (Figures 5D i-iv-vii). The quantitative analysis of immunolabeled cells in the 
lamina propria of eight CIPO patients (five Italian and three Swedish) indicated a significant 
increase in the number of APOB48-positive cells compared to the other individuals (controls 
n=3;IBS patients n=3) (32.9±9.2% vs 7.2±2.5% cases vs controls; p=0.0012, Student‟ t test; 
32.9±9.2% vs 5.6±1.5% CIPO cases vs IBS cases; p=0.0008; CIPO cases (8) vs all (6), 
p=0.0001; Figures 5Dv-vi-vii). In addition, quantitative analysis performed in the gut biopsies 
of sporadic CIPO patients with a marked increased in APOB48 revealed a significant 
reduction in the number of neuron specific enolase (NSE)-labeled myenteric ganglion cell 
bodies / gaglion compared to control specimens (CIPO cases 22.71± 8.10 vs controls 
48.65±13.80; p-value=0.0039, Student‟s t-test; Figure 5E). No significant differences were 
observed for neurons in the submucosal plexus between CIPO cases and controls (CIPO cases 
5.61 ± 0.39 vs controls 8.36 ±2.96; p-value=0.1079, Student‟s t-test). We observed RAD21 
staining in multiple tissues and throughout different components of the gut, as shown 
previously (www.proteinatlas.org), although no differences were appreciated between CIPO 
and controls (Figure S6A i-iv). Expression of APOBEC1, the gut-specific RNA editing 
enzyme responsible of the formation of APOB48 isoform, was also investigated; we observed 
similar immunostaining in control and CIPO tissue biopsies (Figure S6B i-ii). 
 
Discussion 
This study provides in vitro and in vivo evidence that a novel homozygous mutation in 
RAD21 is associated with a syndromic form of CIPO (Deardorff MA et al. 2012). RAD21 is 
also a transcriptional regulator that binds to many sites in the genome (Parelho V et al. 2008). 
In concordance with the key role(s) of RAD21 in regulating cell division, altered expression 
and somatic loss-of-function mutations have been reported in different cancers (Cuadrado A 
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et al. 2012; Kon A et al. 2013). Furthermore, heterozygous germline mutations in cohesin 
subunits, i.e. RAD21, SMC1, STAG, or in regulators of cohesin, e.g. NIPBL, cause a broad 
spectrum of disorders referred to as cohesinopathies (namely Cornelia de Lange syndrome, 
CdLS, OMIM 122470), characterized by facial dysmorphisms, growth retardation, 
developmental delay and/or intellectual disability, and multiorgan involvement, including 
musculoskeletal malformations ranging from brachyclinodactyly to severe reduction defects 
(de Lange C et al. 1933, Ireland M et al. 1993, Jackson L et al. 1993, Opitz JM et al. 1985).  
We observed a similar loss-of-function phenotype for two missense CdL mutations 
(p.376Pro>Arg, p.585Cys>Arg) and for our CIPO variant in RAD21 (p.622Ala>Thr). 
However, in the consanguineous family studied herein the heterozygous carriers of the 
RAD21 mutation did not show sign of CdLS (Deglincerti A et al. 2007). Previously described 
patients with CdLS and different RAD21 heterozygous mutations did not show 
gastrointestinal abnormalities such as CIPO (Minor A et al. 2014). It is worth noting that the 
mutations observed in CdLS and in our CIPO patients map to different RAD21 domains, 
potentially suggesting that specific mutational mechanisms in RAD21 can lead to different 
clinical entities in humans. Consistent with this notion, the CIPO-causing mutations do not 
appear to abolish the ability of RAD21 to bind to SMC1, whereas it does attenuate its 
transcriptional repressive role of other targets, such as APOB. Recently, however, a mutation 
in SGOL1, another cohesin protein, has been associated to severe gut and cardiac dysrhythmia 
in the absence of other congenital abnormalities or cohesinopathies (Chetaille P et al.2014). 
RAD21 plays an important role in the development, survival and maintenance of epithelial 
cells and neurons of the gastrointestinal tract and mice heterozygous for a Rad21 null 
mutation exhibit gastrointestinal defects following X-ray irradiation (Xu H et al. 2010). Our 
zebrafish studies suggest that rad21 is essential for enteric neuron development: rad21a 
morphants recapitulate the CIPO phenotype, as they show a delayed transit along the gut and 
a significant depletion of enteric neurons. This latter finding is reminiscent of an enteric 
neuronal hypoganglionic phenotype observed in heterozygous retC620R/+ mice16 and shares 
similarities with the histopathology of some CIPO patients (Deglincerti A et al. 2007, Carniti 
C et al. 2006, Yin L et al. 2007). The similarity of the rad21 suppression phenotype in 
zebrafish to the neuronal defects of heterozygous retC620R/+ mice prompted us to test 
whether those two genes might interact genetically. We showed that RET and RAD21 interact 
epistatically during differentiation or maintenance of enteric neurons. However, the failure of 
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the two genes to rescue the gut innervation phenotype suggests that they activate different 
molecular pathways. 
Our previous studies identified Apolipoprotein B (Apob) as a target of RET signaling in 
Neuro2a cells, a murine model of enteric nervous system development. Moreover, in 
ret+/C620R mice that have an enteric neuronal hypoganglionic phenotype16 reminiscent of 
the histopathology observed in some CIPO patients, (Carniti C et al. 2006, Luo W et al 2007) 
Apob was markedly overexpressed. APOB is a major constituent of the plasma lipoprotein, 
and in mammals is synthesized in two different tissues, i.e. liver and intestine. Two different 
proteins derive from the APOB transcript by a RNA-editing enzyme, APOBEC1: the full-
lenght APOB100, a large protein of 512 kDa synthesized by the liver (which does not express 
APOBEC1), essential for triglyceride-rich VLDL formation; and the gut-specific isoform 
APOB48, formed via the RNA-editing process and co-linear with the N-terminal half of 
APOB100. APOB48 has a key role in chylomicron assembly and transport in the intestine 
(Black DD et al. 2007). 
APOB expression is regulated by a strong promoter in the proximal upstream region, 
containing several positive regulatory elements, including one within the noncoding exon 1, 
but also a negative regulatory element between bases −261 and −129.31 In this study we 
identified two RAD21-binding sites in APOB proximal promoter, i.e. one overlapping the 
negative element, and the other partially overlapping the exon 1 positive regulatory element. 
Only nuclear extracts from wild-type cells form a specific complex with either region, 
whereas no complex is observed in the presence of mutant RAD21. This suggests that RAD21 
may act as a repressor of APOB transcription, associating to its negative regulatory element 
and competing with the transcriptional activators that bind to positive regulatory element. 
Finally, we found that, compared to controls, gut-specific APOB48 levels were increased in 
the serum of the RAD21-mutated CIPO patient. Interestingly, sera from the sporadic CIPO 
patients, negative for RAD21 mutations, also showed consistently elevated APOB48 levels as 
compared to either IBS patients or healthy controls. We observed a variable expression of 
APOB100 in both controls and CIPO patients, in line with the fact that its regulation depends 
on different factors, including cholesterol and insulin levels (Watts GF et al. 2009). Notably, 
CIPO patients did not show evidence of altered lipid metabolism, i.e. total cholesterol and 
HDL levels were within the normal range. 
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APOB48 overexpression was further corroborated by the data on gut biopsies of CIPO 
patients: compared to controls, APOB48 immunoreactivity was significantly increased in 
cells (with morphological features of immunocytes) distributed throughout the lamina propria 
and in myenteric neurons of CIPO patients. Interestingly, a recent study identified a specific 
neuron-macrophage crosstalk in regulating gut motility (Muller PA et al. 2014). These data 
bear implications to the pathogenesis of functional bowel disorders, such as IBS. However, 
our study did not show any change in APOB expression in patients with IBS, suggesting that 
other molecular pathways can be also involved in patients with a more prominent gut 
dysfunction such as those with CIPO. 
Furthermore, we found a significant decrease in the mean number of myenteric neurons 
/ganglion in CIPO tissues exhibiting a high APOB immunoreactivity. This finding is 
reminiscent of severe hypoganglionosis14 in the patients who were found to carry the RAD21 
p.622Ala>Thr homozygous mutation in this study. 
Based on our data, APOB48 expression (at serum and tissue level) was homogeneously 
increased in sporadic and familial CIPO and therefore making a possible correlation between 
this marker and the degree of neuronal loss / symptom severity undetectable. Further studies 
are eagerly awaited to clarify whether the correlation between APOB expression levels and 
neuronal / clinical CIPO phenotype exists. 
It is currently unclear the pathophysiological significance of the generalized APOB 
overexpression observed in sporadic CIPO, where no mutation of RAD21 were identified. 
Our previous studies suggested a role for APOB in the molecular pathways required for 
enteric neuron development and survival (Evangelisti C et al. 2012). Therefore, APOB48 
increase may be activated as a compensatory effect to an abnormal / defective enteric nervous 
system occurring in CIPO. We still do not know the precise temporal origin of the defect that 
leads to CIPO in patients with RAD21 mutations. The observed transcriptional 
downregulation of runx1, which is likely relevant in early neuronal progenitors, possibly in 
the crest, argues for a migratory defect. At the same time, the observed loss of APOB 
suppression might be more relevant to neuronal progenitors in the gut itself (Figure 6). 
Further studies of patients and conditional mouse mutants will be required to understand the 
potential relative contribution of different sites to CIPO pathology. Likewise, further research 
will be required to elucidate the factors contributing to the specific APOB48 overexpression 
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and its clinical value in the management of CIPO patients. Nonetheless, our data inform the 
molecular aspects underlying the pathogenesis of CIPO and lead to the identification of a 
candidate biomarker, namely APOB48 overexpression, for this severe, disabling gut 
dysmotility disorder. 
69 
 
Figures: 
 
 
Figure 1. Identification of a novel homozygous mutation in RAD21 (A) Pedigree of the Turkish 
consanguineous family showing the segregation of the RAD21 mutation in the available members. For 
the homozygous patients, electropherograms are boxed in red. Grey boxes represent the haplotypes 
derived from microsatellite analysis. (B) RAD21 conservation across species surrounding the position 
p.622Ala (highlighted in red).(C) RUNX1 expression in controls and patient's LCLs (IV-9). 
70 
 
 
 
Figure 2. (A–D) RAD21 A622T affects runx1 expression in zebrafish embryos runx1 expression in 
the PLM in rad21a morpholino injected embryos rescued with wild type or mutants RAD21. 
Morpholino injected embryos were scored according to runx1 expression in the PLM as normal (A), 
partial (B), or absent (C). rad21a morphants could be rescued by wild type human RAD21 mRNA, 
while mutations previously reported in patients with “cohesinopathy” (P376A, C585R) and A622T 
can not rescue this phenotype. 
 
 
71 
 
 
 
Figure 3. Gut dysmotility is caused by enteric neuronal loss in zebrafish embryos To assess gut 
motility in zebrafish larvae, we injected fluorescent beads into the mouth and recorded the rate of gut 
motility versus time. (A) Lateral view of 5dpf zebrafish larvae. Representative images of injected 
larvae show (after eight hours post injection, hpi) fluorescent beads in different gut compartments 
(zone 1–4). (B) In control embryos, most of the fluorescent beads have exited the gut by 8hpi, while 
rad21 MO injected embryos have reduced gut motility. (C-D) Compared to control larvae, rad21 
morphants have a significant reduction of enteric HuC/D immunoreactive neurons at 4dpf (D; upper 
panel) and 5dpf (D; lower panel). (E) rad21 and ret interaction during the ENS development. 
Combination of suboptimal doses of rad21 and ret MOs causes a significant decrease in HuC/D enteric 
neurons, while embryos injected with suboptimal doses of rad21 MO or ret MO causes loss of HuC/D 
enteric neurons, not statistically significant (F). 
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Figure 4. RAD21 regulates APOB overexpression (A) EMSA on human APOB promoter containing 
two putative binding sites for RAD21:hAPOB_c1 (green), hAPOB_c2 (red). EMSA analysis for 
hAPOB_c1 and _c2 regions biotin-labelled probes: only the nuclear extracts from wild-type (control) 
LCL) show a specific gel-shift (black arrows). (B): RT-qPCR for APOB expression in HEK293 cells 
transfected either with empty, RAD21 wild-type, RAD21 mutant p.622 Thr vectors. Data represent the 
mean values of three independent transfection experiments. Bars represent the standard deviation; 
black asterisk indicates the significant p-value (see in text). (C) Western blotting analysis showing the 
expression of recombinant wild-type and mutant RAD21 inframe with DDK tag in transfected 
HEK293. 
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Figure 5. APOB overexpression is specific for CIPO patients (A)Western blotting analysis showing 
APOB48 expression in the patient carrying the homozygous RAD21 mutation (third lane), compared 
to control sera (upper panel); GAPDH was used as internal loading control (lower panel). (B) Western 
blotting analysis showing APOB overexpression in the sera of CIPO patients compared to controls 
(upper panel). (C) Western blotting analysis for APOB48 in IBS samples vs controls (in black) and 
CIPO patients (in red). Samples loaded in duplicates/triplicates are marked in bold (as index of 
reproducible blotting). IBS-C: constipation predominant irritable bowel syndrome; IBS-D: diarrhea 
predominant irritable bowel syndrome.(D) Immunohistochemistry and immunofluorescence staining 
for APOB in controls (D-i, iii,v), IBS cases (D-vii) and CIPO patients (D-ii, iv, vi). Representative 
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figures (D-i, ii) illustrate immunostaining of immunocyte-like cells distributed throughout the 
mucosa,including the lamina propria and the myenteric plexus (D-iii, iv). Note that the density 
ofAPOB immunoreactive immunocyte-like cells in the lamina propria was higher in CIPO patients (D-
vi) vs. controls or IBS cases. (E) Histogram showing the significant decrease in the number of neurons 
per ganglion in the myenteric plexus observed in CIPO, compared to control tissue biopsies. 
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Figure 6. Model of RAD21 functioning as cohesin complex (A) or as transcription factor (B) (A) 
RAD21 belongs to the cohesin complex regulating chromosomal replication. RAD21 p.622Thr does 
not alter SMC1A subunit-binding. (B) Wild-type RAD21 promotes RUNX1 and represses APOB 
expression. RAD21 p.622Thr downregulates RUNX1 expression, derepresses APOB expression and 
leads to ENS neuron loss with resultant hypoganglionosis. Alternative pathways, including RET 
abnormal activation (e.g. the p.620 Cys>Arg mutation [red asterisk] in heterozygous mice) can lead to 
APOB overexpression, which is phenotypically associated with hypoganglionosis. 
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Figure S1. RT-PCR analysis of knockdown efficiency for splicesite targeted rad21 Morpholino. 
(A) Schematic of zebrafish rad21. A splice blocking MO (red bar) was designed against the second 
exon-intron junction. PCR primers (blue bar) designed against exon 1 and exon 3 were used to test 
MO efficiency. (B) In control embryos, there is a single amplicon, while in rad21 MO, there are two 
amplicons, demonstrating the efficiency of the MO used. 
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Figure S2. Serial dilutions for APOB48 western blotting and negative controls for 
immunohistochemistry analysis: (A) serial dilutions of sera from CIPO patients and 
controls; images are representative of replica experiments; (B-C) images of negative controls, 
including primary antibody omission and blocking with the corresponding peptides for APOB 
(B) and RAD21 (C) are shown. 
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Figure S3. Functional studies of RAD21 mutation p.622Ala>Thr in vitro. (A) Screenshot 
of the parallel sequencing output for the mutation in RAD21 (genomic change). (B,C) RAD21 
expression is not altered in patient‟s blood (B) and lymphoblastoid cell lines (C). RAD21 
expression was evaluated by real-time qRTPCR; (D) RAD21 expression immunoprecipitation 
analysis for SMC1 and RAD21 from protein extracts of LCLs, showing that the binding is 
retained even in presence of the mutated protein (second lane in each panel). (E) RT-qPCR 
for RUNX1 expression in HEK293 cells transfected either with empty, RAD21 wild-type, 
RAD21 mutant p.622 Thr vectors. Data represent the mean values of three independent 
transfection experiments. Bars represent the standard deviation; black asterisk indicates the 
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significant p-value. (Representative western blotting analysis of recombinant RAD21 in frame 
with the DDK epitope in the transfected cells is reported in main Figure 4C). (F) EMSA 
analysis showing that LCL nuclear extracts containing either RAD21 wild-type or mutant 
protein retain the binding ability for the AC2 site on chromosome 11. Black arrows indicate 
the gel-shifts. 
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Figure S4. EMSA assays showing the RAD21-specific supershifts for the two regions in 
human APOB promoter. Black arrows indicate the shift, grey stars indicate the supershift 
observed only in lanes derived from control‟s nuclear extracts. For the c_1 region the 
complexes in the supershift were resolved only after a longer gel run, without keeping into the 
gel the free biotin-labelled probes. Images are representative of three independent 
experiments. 
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Figure S5. Western blotting for APOB on CIPO and IBS sera. (A) Western blotting 
analysis of APOB100 in sera of CIPO patient carrying RAD21 mutation, controls and CIPO 
patients; (B) Immunoblots showing the increased expression of APOB48 in sera of the CIPO 
patients included in RAD21 mutation screening, compared to controls; (C) Immunoblots for 
APOB48 in IBS vs CIPO patients and controls. Abbreviations are as shown in Figure 5. In 
bold are represented the samples loaded in different gels and analysed for APOB48 
expression. 
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Figure S6: RAD21 and APOBEC1 immunostaining. Figures (A-i to iv) show RAD21 
immunoreactivity in gut biopsies of controls (A-i, iii) and CIPO patients (A-ii, iv). The 
representative pictures indicate RAD21 immunolabeling in the nuclei of epithelial and lamina 
propria immunocyte-like cells (A-i, ii) as well as myenteric neurons (A-iii, iv). Figures (Bi-ii) 
illustrate APOBEC1 labeling with an overlapping immunoreactive pattern to that observed for 
RAD21, showing no changes in controls (B-i) and CIPO patients (B-ii). 
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Abstract  
Background: RAD21 is a double-strand-break repair protein and a component of the cohesin 
complex with key roles in several cellular functions. A RAD21 loss-of-function mutation was found 
in cases of chronic intestinal pseudo-obstruction (CIPO) with associated enteric neuronal loss. An 
analysis of RAD21 expression in the enteric nervous system is lacking, thus we aimed to identify 
and characterize RAD21 immunoreactivity (IR) in enteric ganglia. Methods: Double labeling 
immunofluorescence in mouse and human jejunum were used to determine co-localization of 
RAD21 with HuC/D, PGP9.5, neuronal nitric oxide synthase (nNOS), neuropeptide Y (NPY), 
choline acetyl transferase (ChAT), Kit, platelet-derived growth factor receptor-α (PDGFRα) and 
glial fibrillary acid protein (GFAP) IRs. Results: A subset of PGP9.5- and HuC/D-IR neuronal cell 
bodies and nerve fibers in the myenteric plexus of human and mouse small intestine also displayed 
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cytoplasmic RAD21-IR. This immunolabeling pattern was found in 42.5% of RAD21/HuC/D-
positive neurons/field in adult mouse small intestine and 43% of RAD21/HuC/D-IR neurons/field 
in young mice. RAD21-IR did not co-localize with nNOS. A subset of ChAT-positive neurons was 
RAD21-IR. Punctate RAD21-IR was restricted to the nucleus in most cell types consistent with 
labeling of the cohesin complex. RAD21-IR was not detected in interstitial cells of Cajal, fibroblast-
like cells or glia. Subsets of neurons in primary culture exhibited cytoplasmic RAD21-IR. RAD21 
signal was knocked-down in cultured neurons (shRNA). Conclusions: Our data showing 
cytoplasmic RAD21 expression in enteric neurons provide a basis towards understanding how 
mutations of this gene may contribute to altered neuronal function/survival thus leading to gut-
motor abnormalities. 
Keywords: chronic intestinal pseudo-obstruction; enteric neurons; immunofluorescence 
  
INTRODUCTION  
RAD21 is a transcription factor and a key central component of the multi-protein cohesin 
complex,1 which functions to protect chromosome separation during the metaphase–anaphase 
transition of mitosis.2 RAD21 is ubiquitously expressed3 and its critical role was indicated by the 
lethal early embryonic phenotype in RAD21 knockout mice.4 Studying a familial cluster of chronic 
intestinal pseudo-obstruction (CIPO), we have recently demonstrated a novel loss-of-function 
mutation in RAD21 which was associated with enteric neuropathy and severe gut dysmotility, in 
affected family members. The CIPO-causing RAD21 mutation was found to alter the expression of 
related genes, including RUNX1 and APOB. Indeed, APOB48, the gut-specific isoform of APOB, 
was overexpressed in sera of patients with CIPO carrying the RAD21 mutation.5 
CIPO is a rare and intractable chronic digestive disease in which clinical symptoms of intestinal 
obstruction appear without mechanical cause.6,7 CIPO can result from derangement affecting the 
integrity of a variety of regulatory cells/tissues, i.e. smooth muscle cells (effectors of contractility / 
relaxation), the interstitial cells of Cajal (ICC) (pace-makers of gut motility and regulators of 
neuronal input to smooth muscle cells), and neurons (both intrinsic and enteric nervous system).6 
Specifically, the RAD21 loss-of-function mutation was associated with a markedly reduced number 
of enteric neurons, thus implying a neurogenic origin of the gut dysmotility reported in the affected 
family.8,5 The clinical evidence that the small bowel is most affected in CIPO, provided the 
background to our set of experiments focusing on RAD21 expression in the small bowel. The 
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distribution of RAD21 in the enteric nervous system, the intrinsic neural network controlling 
gastrointestinal (GI) physiology and homeostasis,9,10 is unknown. The enteric nervous system 
contains different functionally distinct neuronal subclasses, e.g. motor neurons – either excitatory or 
inhibitory, interneurons and intrinsic primary afferent neurons, which can be identified according to 
their neurochemical coding.10 Inhibitory motor neurons are immunohistochemically identified by 
the presence of the neuronal isoform of the enzyme nitric oxide synthase (nNOS) leading to nitric 
oxide synthesis, whereas most excitatory motor neurons are immunohistochemically identified by 
choline acetyltransferase (ChAT) (the acetylcholine synthesizing enzyme) or via detection of 
peptides of the tachykinin family (e.g., substance P or neurokinin A). In addition to these two major 
subclasses of enteric neurons, a variety of secondary neurotransmitters or modulators, e.g. 
neuropeptide Y (NPY), can be co-synthesized, stored and released by other enteric neuronal 
subsets, depending on their localization throughout the GI tract and the mammalian species 
considered.11 The present study was designed to investigate whether RAD21 expressed in a subset 
of myenteric neurons in human and mouse small intestine. Furthermore, in order to establish 
whether RAD21 is influenced by age-dependent mechanisms, we compared the RAD21 expression 
in myenteric neurons of the small intestine from adult vs. young mice. Our findings clearly 
demonstrated enrichment of RAD21-IR in the cell bodies and nerve fibers of a subset of myenteric 
cholinergic, but not nitrergic, neurons in tissues and in primary culture using two different primary 
antibodies. Silencing (shRNA) of RAD21 expression confirmed specificity of RAD21-IR.  
MATERIALS AND METHODS 
All authors have access to the study data and have reviewed and approved the final manuscript. 
Immunohistochemistry 
Single and double labeling immunofluorescence for RAD21 was done using two specific, 
commercially available rabbit and goat polyclonal antibodies (Abcam, Cambridge MA and Santa 
Cruz, Dallas TX, respectively see Table 1 for details) directed to RAD21 protein according to 
previously validated protocols.12 Normal human small bowel (jejunum) was obtained from n=3 
(2F, age: 35-48 yrs) patients undergoing surgery for gastrointestinal cancers or having bariatric 
surgery at Mayo Clinic, MN, USA. The use of human tissue for research was approved by the 
Institutional Review Board of Mayo Clinic. Small bowel whole mount preparations from adult (n= 
4) and young (n= 3) BALB/c (Harlan Sprague-Dawley, IN, USA) mice were processed for RAD21 
immunolabeling (Abcam antibody at the same dilution used for human tissues, Table 1). Mice were 
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killed by CO2 inhalation and all experiments were approved by the Institutional Animal Care and 
Use Committee of the Mayo Clinic. Immersion-fixed (4% paraformaldehyde) human tissues (10 μm 
thick) and acetone-fixed mouse whole mounts were incubated over night at 4°C with rabbit RAD21 
primary antibody as well as with a number of antibodies to a variety of neuronal, neurochemical, 
glial, and interstitial cells of Cajal markers (for details see Table 1). After washing, sections and 
whole mounts were incubated with donkey fluorescein- and rhodamine-conjugated anti-rabbit 
secondary antibodies as well as secondary antibodies to the previously mentioned markers (Jackson 
ImmunoResearch West Grove PA, See Table 1 for details) for about 2 h at room temperature. 
Sections and whole mounts were thoroughly washed in 0.1 M phosphate buffered saline (PBS) and 
mounted in SlowFade® Gold Antifade Reagent with 4, 6-diamidino-phenylindole,dihydrochloride 
(DAPI) (Invitrogen, CA, USA), as a nuclear counterstain. Specificity tests to ensure that there was 
no cross reaction among secondary antibodies included omission and substitution of primary or 
secondary antibodies. Secondary antibodies directed against IgG from a different species were used 
to control for the specificity of secondary antibodies in doubly labeled tissues.  
Primary cultures from mouse jejunum 
Primary cultures were obtained by enzymatic dissociation of mouse jejunum from neonatal mice 
(post-natal day 3) based on a previously described protocol.13 Utilizing a collagenase-based 
dissociation cocktail, tissues were dissociated and then plated on a feeder layer of fibroblasts 
expressing the membrane bound m248 form of Kit ligand (steel factor). Cells were grown in M199 
media (Invitrogen) with 1% antibiotic/antimycotic mixture (Gibco). Primary cells were allowed to 
attach and recover for 24 hours before treatment. Living, single cells (150,000 each coverslip) were 
plated in a 12 -well plate with 1 ml of media M199 (Thermo Fisher, Waltham, MA, USA). Primary 
cultures were maintained at 37°C, 20% O2, 5% CO2 in M199 supplemented with glucose (4.5 g 
l−1, Sigma), antibiotic/antimycotic mixture (pencillin G sodium, 200 i.u. ml−1; streptomycin 
sulphate, 200 μg ml−1; amphotericin B, 0.5 μg ml−1; Thermo Fisher). Cultures were 
immunolabeled for RAD21, nNOS, ChAT HuC/D and PGP9.5 antibodies (see Table 1). Nuclei 
were counterstained with DAPI (Molecular Probes, Eugene, OR, USA). 
shRNA lentiviral particles transduction in primary cell cultures 
Primary cultures from 3 day old mice were exposed to shRNA lentiviral particles to knock down 
expression of RAD21 as follows: 50% of the culture medium was replaced with conditioned media 
and each experimental condition was run in duplicate. Cells were transduced for 24 h by adding to 
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the culture medium 2 µg/mL polybrene (Santa Cruz) and viral particles. Cultures were treated with 
non-targeting (NT) and shRNA RAD21 (n = 3) lentiviral transduction particles (Santa Cruz shRNA 
lentiviral transduction particles) with a multiplicity of infection (MOI) of 1 based on the confluence 
of the mixed cell culture being 50-70% at the time of treatment. For the next 5 days, cultures were 
washed and fresh culture medium was added daily. After day 1 and 5, cultures were used for 
RAD21 immunolabeling. 
Confocal microscopy 
Images of immunolabeling were collected using an Olympus FV1000 laser scanning confocal 
microscope. Confocal images were collected with ×60 1.2-NA or × 20 0.95-NA water objectives. 
Quantitative analysis counted the numbers of immunolabeled neurons using Olympus Fluoview 
Ver.2.1c viewer program. Neurons were counted from (635x635) µm2 fields per tissue. All images 
were prepared for individual figures using Adobe Photoshop CS. No 3D reconstructions, 
deconvolution, surface or volume rendering, or gamma adjustments were performed. 
Statistics 
Data are expressed as means ± SEM. Statistical significance was determined by GraphPad Prism 
using Student‟s t-test. P values of less than 0.05 were taken as statistically significant. The „N‟ 
value identifies the animal count.  
RESULTS 
Extranuclear RAD21 immunoreactivity in human myenteric neurons from the small intestine 
RAD21-IR was present in cell bodies and nerve fibers of a subset of human small intestinal enteric 
neurons identified by HuC/D-IR (Figure 1 A-C) and PGP9.5 (Figure 1 D-F) respectively. RAD21-
IR was not detected in nNOS-IR inhibitory neurons (Figure 1 G-I arrows). RAD21-IR colocalized 
with ChAT in some neurons (Figure 1 J-L arrowhead). To further characterize this labelling pattern, 
we used mouse small intestine.  
Extranuclear RAD21 immunoreactivity in mouse myenteric neurons from the small intestine 
The extra-nuclear labeling pattern of RAD21-IR was confirmed using two different primary 
antibodies raised against different epitopes in two different species. Rabbit (Figure 2A) and goat 
(Figure 2B) anti-RAD21 antibodies labeled the same structures (Figure 2C) in thin sections from 
mouse jejunum. Additional controls were performed to ensure specificity for RAD21 with regard to 
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each primary antibody. Pre-adsorption of antibody with specific blocking peptide abolished signal 
intensity suggesting specificity of antibody used (Figure 2D-F). Furthermore, no IR was observed 
when the tissue preparations were incubated with only secondary antibody, demonstrating that there 
was no non-specific labeling by the secondary antibody (data not shown). 
RAD21-IR is detected in the cytoplasm of a subset of HuC/D-positive myenteric neurons of 
adult and young mice 
Whole mount analyses were conducted in order to determine the mapping of RAD21 expression in 
adult and young mouse enteric nervous system. We performed RAD21 and HuC/D double labeling 
immunohistochemical analysis of adult BALB/C mice (n=4; age range: 4-8 weeks). In whole 
mounts of adult mouse small intestine, RAD21-IR was present in 42.5% of HuC/D positive 
myenteric neurons. Notably, RAD21-IR was detected in the cytoplasm of a subset of neurons 
(arrowheads in Figure 3A). Overall, there were 61.56±0.9 RAD21 and 144.7±4.1 HuC/D-positive 
neurons/field (6 fields per preparation; each field measured 635x635 µm2, n = 4 mice (P< 0.05, 
Figure 3B). 
To determine if RAD21 expression in the cytoplasm of enteric neurons is age dependent, we 
analyzed the expression of RAD21 in young mice (age range: 4 to 10 days old) (Figure 3C). Similar 
to adult mice, in young mice RAD21-IR was present in 43% of HuC/D positive myenteric neurons. 
Specifically, 79.56±4.5 RAD21 and 185.0±4.0 HuC/D-positive neurons/field (6 fields per 
preparation; each field measured 635x635 µm2) (n= 3, P< 0.05, t-test) (Figure 3D, P< 0.05 
compared to adult mice).  
Chemical coding of RAD21-IR neurons  
Co-labeling with several antibodies were used to clarify the neurotransmitters expressed in RAD21 
positive neurons (Table 1). RAD21-IR did not co-localize with nNOS (Figure 4A-C arrows). We 
also detected RAD21-IR cells that were positive for the neuronal peptide NPY in whole mount 
preparations (Figure 4D-F). RAD21-IR was present in a subset of neurons that expressed ChAT 
(Figures 4G-I arrows). Co-labeling of preparations with PGP9.5 demonstrated RAD21-IR in 
neuronal fibers (Figure 4J-L). 
RAD21 did not colocalize with Kit (ICC), PDGFRα or enteric glia (GFAP) in mice 
RAD21-IR was not detected outside the nucleus of Kit-IR interstitial cells of Cajal (ICC) (Figure 
5A-D) or PDGFRα-IR fibroblast-like cells (Figure 5E-H) in mouse whole mount preparations. 
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RAD21-IR also did not overlap with glial fibrillary acid protein (GFAP)-IR (Figure 5I-L) in mouse 
jejunal myenteric ganglia indicating that RAD21 is not expressed in the cell bodies of enteric glia. 
RAD21 expression in primary cultures from neonatal mouse jejunum 
Primary cultures from mouse small intestinal muscularis propria that contain myenteric neurons 
contained RAD21-IR similar to that observed in tissues. RAD21-IR was observed in the cell bodies 
and nerve fibers of a subset of enteric neurons that were identified by PGP9.5 (Figure 6A-D). 
RAD21-IR was also detected outside the nucleus of a subset of ChAT-IR neurons (Figure 6E-H), 
but not in nNOS-IR inhibitory neurons (Figure 6I-L).  We next used a shRNA lentiviral approach to 
knock down RAD21 in primary cultures. We first determined if we could maintain intact RAD21 
expression in 5-day-old primary cultures. We prepared primary cultures from mouse jejunum (4 
days old), grew these cultures for up to 5 days and performed an immunohistochemistry analysis for 
RAD21. We observed no significant changes in RAD21-IR when labelled after 5 days in primary 
culture (Figure 7E) compared to 1 day in primary culture (Figure 7B). We next optimized the knock 
down of RAD21 using Santa Cruz transduction shRNA-RAD21. A lack of RAD21-IR in shRNA 
treated cultures grown for up to 5 days confirmed the specificity of the RAD21 expression in a 
subset of enteric neurons (Figure 7H).  
 
DISCUSSION 
In the present study we demonstrated that RAD21-IR is expressed in cell bodies and processes of a 
subset of neurons of the adult human and mouse small intestine. High magnification revealed a 
predominantly cytoplasmic immunolabeling, although, as expected by its molecular nature (nuclear 
phospho-protein) and function (cohesin complex / transcription factor),15 RAD21-IR was also 
detectable in nuclei. No other cell types in the small intestinal muscularis propria displayed 
cytoplasmic RAD21-IR, including GFAP expressing glial cells, Kit+ ICC and PDGFRα-IR 
fibroblast-like cells. The specificity of the two anti-RAD21 antibodies was confirmed by a number 
experimental conditions and controls. First, both anti-RAD21 antibodies identified overlapping 
immunoreactive patterns, i.e. a selective subset of myenteric neurons (see below); secondly, 
omission of primary (or secondary) antibodies, substitution of the primary with secondary 
antibodies and preadsorption control did not yield any immunostaining; thirdly, experiments in 
which RAD21 was knocked-down by shRNA abolished RAD21-IR. Taken together these tests 
demonstrate the specificity of RAD21-IR and confirm neuronal expression. Based on this reliable 
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immunolabeling, we investigated the intrinsic innervation of the human and mouse small intestine 
and identified RAD21 expression in myenteric ChAT-IR neurons, likely belonging to motor 
neurons / ascending interneurons.16 By contrast, nNOS expressing myenteric neurons, mainly 
inhibitory motor neurons / descending interneurons, did not show RAD21-IR in either species. Our 
data provided the first analysis of RAD21 localization in the mammalian enteric nervous system 
and clearly showed that this cohesin complex protein is expressed outside the nucleus of cholinergic 
neurons in a subset of ChAT-IR neurons. RAD21 is known to exert a variety of regulatory functions 
critical to cellular homeostasis,17 thus our findings suggest a role for extra-nuclear RAD21 in 
maintenance and survival mechanisms of a subset of cholinergic neurons occurring in the healthy 
myenteric plexus.  
Expression of RAD21 in the cytoplasm of cells has been previously associated with the 
translocation of a 64 KDa C-terminal fragment of the RAD21 protein from the nucleus following 
cleavage by caspases.18 RAD21 contains a consensus caspase 3/7 cleavage site19 and it has been 
proposed that RAD21 translocation is an early indicator of activation of caspase dependent 
apoptosis.18 Both of the antibodies used in this study were directed against the C-terminal region of 
RAD21 and therefore would be expected to detect cleaved, cytoplasmic RAD21 if present. Recent 
studies in mice20 and our own unpublished observations in human tissues found that a surprisingly 
high proportion (10-20%) of myenteric neurons express cleaved, active caspase-3 leading to the 
controversial suggestion that there is extensive ongoing apoptosis in the enteric nervous system. 
The proportion of caspase-3 positive neurons is much lower than the proportion of myenteric 
neurons that express cytoplasmic RAD21-IR (approximately 40%), thus it is unlikely that the 
presence of RAD21 in the cytoplasm is a marker for imminent cell death. However, the present 
study does indicate that RAD21 cleavage and translocation occurs preferentially in ChAT-positive, 
but not nNOS-positive, myenteric neurons possibly suggesting transient activation of caspase-3 
activity in ChAT-positive neurons that does not always progress to cell death. In contrast, low 
caspase-3 activity or reduced RAD21 cleavage and translocation in nNOS-positive neurons could 
contribute to the sparing of these cells in healthy aging.12 The impact of the identified loss-of-
function mutation in RAD21, such as that reported to be associated with CIPO,5 may be related to 
altered sensitivity of RAD21 to cleavage and inappropriate translocation of the protein leading to 
loss of some or all subtypes of myenteric neurons. This mechanism may be responsible for altered 
motor function in CIPO patients. However, the actual effect of the RAD21 p.Ala622Thr mutation is 
still to be clarified in an appropriate mouse model. It is worth noting that rad21 homozygous null 
mice are embryonic lethal.14 In vivo studies in the rad21 morpholino zebrafish model showed a 
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delayed intestinal transit along with a significant reduction of enteric neurons, a finding indicative 
of an oligoneuronal hypoganglionosis reminiscent of the neuropathic CIPO phenotype.5 Our data 
indicate that RAD21 is not expressed by nitrergic inhibitory neurons, a functionally distinct 
subclass commonly targeted by damaging mechanisms taking place in experimental (nNOS-/- mice) 
and human enteric neuropathies, and detectable in early stages of achalasia or idiopathic 
gastroparesis.21 It has not been determined whether nitrergic neurons remain unaffected in 
pathological conditions such as patients with RAD21-related CIPO. 
Finally, in order to understand whether RAD21 distribution in myenteric neurons was altered during 
development, we investigated the distribution and relative abundance of RAD21-IR neurons in 
neonatal mice. RAD21-IR neurons were quantitatively comparable in neonatal and adult tissues, a 
finding implying that there is no major age-dependent cellular redistribution of RAD21-IR in the 
cytoplasm of neuronal subsets. 
 
In conclusion, our data showed that RAD21 is expressed in a distinct subset of myenteric, i.e. 
cholinergic, neurons supplying the human and mouse small intestine. These findings, combined 
with the knowledge that RAD21 mutations occur in distinct CIPO cases, imply that the cholinergic 
subset may be the primary target in some patients with this pathological condition. 
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Figure 1. RAD21-IR in human small intestine. RAD21-IR was distributed in the human similarly to 
the mouse small intestine. RAD21-IR was not found in nNOS-IR inhibitory neurons (A-C arrows). 
RAD21-IR also colocalized with ChAT in some neurons (D-F). RAD21 was observed in cell bodies 
and nerve fibers (arrows) of a subset of enteric neurons identified by HuC/D-IR (G-I) and PGP9.5 (J-
L). Scale bar 50 µm.
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Figure 2. Double labeling with two different RAD21 primary antibodies. Anti-rabbit (abcam 
ab992) (A) and anti-goat (Santa Cruz sc54323) (B) anti-RAD21 antibodies labeled the same structures 
in BALB/C jejunum preparations. Colocalization is shown in yellow (C). Pre-adsorption of antibody 
with specific blocking peptide abolished signal intensity suggesting specificity of antibody used in this 
study (D-F). Scale bar 50 μm. 
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Figure 3. HuC/D and RAD21 Immunolabeling in mouse jejunal whole mounts. (A). 
Immunolabeling of RAD21 in whole mounts of adult mice. Within the myenteric plexus this pattern 
was found in 61.56±0.9 and 144.7±4.1 neurons/field for RAD21 and HuC/D, respectively (n=4, P 
<0.05, t-test). (B) Graphs showing the number of neurons per field of RAD21 and HuC/D expression 
in whole mounts preparations of adult BALB/C mice (n=4, P< 0.05). Scale bar 10 μm (upper panel) 
and 50 μm (lower panel). (C) Immunolabeling of RAD21 in whole mounts of young (4 to 10 day old) 
BALB/C mice. Within the myenteric plexus this pattern was found in 79.56±4.5 and 185.0±4.0 
neurons/field for RAD21 and HuC/D, respectively (n=3 mice, P <0.05, t-test). (D) Graphs showing the 
number of neurons per field of RAD21 and HuC/D expression in whole mounts preparations of young 
BALB/C mice (n=3 mice, P <0.05). Scale bar 10 μm (upper panel) and 50 μm (lower panel). 
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Figure 4. Double labeling of RAD21 with different neuronal markers. RAD21-IR did not colocalize 
with neuronal nitric oxide synthase (nNOS) (A-C arrows). A subset of choline acetyl transferase 
(ChAT) positive neurons were RAD21-IR (D-F arrows). RAD21-IR was also present in neurons that 
were NPY positive (G-I). RAD21-IR was found in a subset of neuronal cell bodies and nerve fibers in 
the myenteric plexuses of mouse small intestine, labeled by PGP9.5 (J-L). Scale bar 50 μm.
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Figure 5. RAD21 did not colocalize with Kit (ICC), PDGFRα and GFAP. RAD21-IR was not 
detected in whole mounts preparations in the cytoplasm of interstitial cells of Cajal (ICC) with Kit (A-
C) and in fibroblast-like cells which were positive for PDGFRα (D-F). RAD21 was not detectable in 
glial cells identified by GFAP (G-I arrows). Scale bar 50 µm. 
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Figure 6. RAD21-IR in primary cultures from small intestine of BALB/C mice. RAD21-IR in primary 
cultures from mice small intestine showed a similar distribution to that found in tissues. RAD21-IR 
was observed in cell bodies and nerve fibers of a subset of enteric neurons identified by PGP9.5-IR 
(A-C). RAD21-IR also colocalized with ChAT in some neurons (D-F arrows), although none of the 
nNOS-IR neurons displayed RAD21 immunolabeling (G-I). Scale bar 50 µm. 
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Figure 7. Selective silencing of RAD21-IR. RAD21 knock down in 5 day old primary cultures. Note the 
absence of RAD21expression in 5 day old primary cultures from the mouse jejunum after shRNA lentiviral 
particles treatment (H). No difference in the density or distribution of RAD21-IR was seen in untreated 
controls (B, E) after 1 or 5 days seeded. Cells were immunolabelled for RAD21 at day 1 and 5 after seeded. 
Cells were treated with shRNA lentiviral particles at 24 hours after plating for 4 days. Photomicrographs in 
A, D and G illustrate DAPI for cell nuclei staining. Photomicrographs C, F and I show merged images. Scale 
bar 50 μm.
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Chapter VIII 
12. Protective Actions of Epithelial 5-Hydroxytryptamine 4 Receptors in Normal and 
Inflamed Colon 
 
Modified from  
―Protective Actions of Epithelial 5-Hydroxytryptamine 4 Receptors 
in Normal and Inflamed Colon‖ 
Stephanie N. Spohn, Francesca Bianco, Rachel B. Scott, Catherine M. Keenan, Alisha A. 
Linton, Conor H. O‟Neill, Elena Bonora, Michael Dicay, Brigitte Lavoie, Rebecca L. Wilcox, 
Wallace K. MacNaughton, Roberto De Giorgio, Keith A. Sharkey, and Gary M. Mawe. 
Gastroenterology 2016;151:933–944 
 
 
Abstract 
 
Background & Aims-The 5-hydroxytryptamine receptor 4 (5-HT4R or HTR4) is expressed 
in the colonic epithelium but little is known about its functions there. We examined whether 
activation of colonic epithelial 5-HT4R protects colons of mice from inflammation. 
 
Methods-The 5-HT4R agonist tegaserod (1 mg/kg), the 5-HT4R antagonist GR113808 (1 
mg/kg), or vehicle (control) were delivered by enema to wild-type or 5-HT4R knockout mice 
at the onset of, or during, active colitis, induced by administration of dextran sodium sulfate 
or trinitrobenzene sulfonic acid. Inflammation was measured using the colitis disease activity 
index and by histologic analysis of intestinal tissues. Epithelial proliferation, wound healing, 
and resistance to oxidative stress-induced apoptosis were assessed, as was colonic motility. 
 
Results-Rectal administration of tegaserod reduced the severity of colitis, compared to mice 
given vehicle, and accelerated recovery from active colitis. Rectal tegaserod did not improve 
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colitis in 5-HT4R knockout mice, and intraperitoneally administered tegaserod did not protect 
wild-type mice from colitis. Tegaserod increased proliferation of crypt epithelial cells. 
Stimulation of 5-HT4R increased Caco-2 cell migration and reduced oxidative stress-induced 
apoptosis; these actions were blocked by co-administration of the 5-HT4R antagonist 
GR113808. In non-inflamed colons of wild-type mice not receiving tegaserod, inhibition of 5-
HT4Rs resulted in signs of colitis within 3 days. In these mice, epithelial proliferation 
decreased and bacterial translocation to the liver and spleen was detected. Daily 
administration of tegaserod increased motility in inflamed colons of guinea pigs and mice, 
whereas administration of GR113808 disrupted motility in animals without colitis. 
 
Conclusions-5-HT4R activation maintains motility in healthy colons of mice and guinea pigs 
reduces inflammation in colons of mice with colitis. Agonists might be developed as 
treatments for patients with inflammatory bowel diseases. 
Keywords 
IBD; colonic motility; wound healing; mucosal drug action 
 
METHODS 
 
Animal Preparations 
All experimental protocols were approved by the Institutional Animal Care and Use 
Committees of the University of Vermont and the University of Calgary. Animals were 
euthanized by isoflurane overdose and exsanguination or cervical dislocation. The following 
animals were used for these studies: 7–8 week Male CD-1 IGS mice from Charles River, 
Canada; 7–8 week male and female 5-HT4R knockout mice and their litter mates on an 
SV129 background from Dr. Valérie Compan, Université Montpellier, via Dr. David Linden, 
Mayo Clinic; 250–300 g male Hartley guinea pigs, Charles River, Canada. 
 
Induction of Colitis 
Dextran sodium sulfate (DSS) colitis was induced in mice by administering DSS (w/v in 
water; 3% for SV129 mice and 4% for CD-1, MW: 36,000–50,000, MP Biomedicals, Solon, 
OH) for 5 days followed by a return to tap water for 2–10 days. 2,4,6-trinitrobenzene sulfonic 
acid (TNBS; Sigma-Aldrich, St. Louis, MO) colitis was induced by a single colonic enema 
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(mice: 7.5 mg/mL in 50% ethanol, 100 μL; guinea pigs: 25 mg/mL in 30% ethanol in 300 μL) 
delivered under anesthesia. 
 
Colitis Paradigms 
For the prevention experiments, mice received DSS for 5 days and were then switched to tap 
water for 2 days. Alternatively, mice and guinea pigs were given a single enema of TNBS. 
Enemas with either vehicle (1% dimethyl sulfoxide (DMSO) in 0.9% saline; 0.2 mL/mouse) 
or drug (tegaserod provided by John McRorie from Proctor and Gamble, GR113808 from 
Sigma-Aldrich; both delivered at 1 mg/Kg) were administered daily for 5–7 days starting 24 h 
after induction of colitis. These doses were chosen because they were effective in previous 
studies of the effects of luminal administration of these compounds on visceral sensitivity 
(Hoffman JM et al.2012). In a preliminary study, we found that enema treatment did not 
affect the histological damage score (HDS) (naïve, 0.6±0.25, n=5; vehicle enema, 1.1±0.3; 
p=0.13, n=7). In another preliminary study, involving enema administration of a vehicle 
solution containing 0.5% Evans Blue, we found that the solution delivered spread as far orally 
as the cecum after 10 minutes. Animals were euthanized on day 6 or 7 for TNBS or DSS 
studies, respectively. In the recovery paradigm drug treatment began on day 6 and lasted for 
10 days, with animals euthanized on day 15. The time courses were chosen to test the 
effectiveness of the treatments leading up to the peak of inflammation, or beginning once the 
peak had been reached. Transcript levels for the 5-HT4 receptor were not altered in DSS 
(p=0.56) or TNBS (p=0.9) colitis. 
 
Assessment of Inflammation 
Colitis severity was monitored using the disease activity index (DAI), which includes 
evaluation of weight loss, stool consistency, and presence of fecal blood.11 Fecal blood was 
assessed using Hemoccult Single Slide testing slides from Beckman Coulter (Brea, CA). After 
euthanasia, tissue was collected and fixed overnight in 4% paraformaldehyde for 
immunohistochemistry. 
Hematoxylin and eosin stained sections from paraffin embedded tissue were used for 
histological assessment of colitis. A scoring rubric based on histological features of human 
inflammatory bowel disease (IBD) was developed (Villanacci Vet al. 2013). This histological 
damage score (HDS) reflects epithelial damage, altered crypt architecture, infiltration of 
monocytes and polymorphonuclear cells into the lamina propria and epithelium, and evidence 
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of ulcers or erosions. Two slides for each experimental group were scored by an observer 
blinded to the treatment groups. 
 
Intestinal permeability 
On day 7 following enema treatment, mice were orally gavaged with FITC-dextran (150 
mg/mL, 60 mg/100 g body weight). Four hours following gavage, mice were anesthetized, the 
chest and abdomen cleaned with 70% ethanol and blood was drawn via cardiac puncture 
(Savidge TC et al 2007). Blood was allowed to clot, then spun at 2000 × g for 10 minutes, the 
supernatant was read on a spectrophotometer at 485/535 nm. 
 
Immunohistochemistry 
Immunohistochemical staining of sections from paraffin embedded tissue was performed as 
previously described (Hoffman JM et al. 2012). Immunostaining with a rat anti-mouse Ki-67 
primary antiserum (1:100; eBioscience, San Diego, CA) was visualized with a goat anti-rat 
Cy3 antibody (1:600; Jackson ImmunoResearch, West Grove, PA), in sections counterstained 
with DAPI (1:1,000; Sigma-Aldrich). The data are presented as proportion of Ki-67 positive 
cells relative to total epithelial cells per crypt (Joly F et al. 2009). Images were produced on 
an Olympus AX70 fluorescence microscope and captured using an Optronics MagnaFire 
digital camera and software. 
 
Motility 
Guinea pig distal colon motility was examined using a GastroIntestinal Motility Monitor 
(GIMM; Catamount Research and Development, St. Albans, VT), and prepared as previously 
described (Hoffman JM et al. 2010). The most distal 5–10 cm of colon was placed in the 
organ bath, and equilibrated for 30 minutes in circulating Kreb‟s solution (37°C). Five trials, 
spaced by 5 min rest periods, were performed for each colon. Murine colonic transit was 
assessed as previously described (Nasser Y et al. 2006). Mice were lightly anesthetized using 
3% isoflurane, and a small glass bead was inserted 2 cm into the distal colon. Time from the 
insertion of the bead to expulsion was recorded. This assay was performed before and after 
treatment with either vehicle, agonist or antagonist. For each time point, measurements were 
taken on two consecutive days and the two times averaged. For each mouse, bead expulsion 
time was normalized to the before treatment value. 
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Intracellular Recording 
Intracellular recordings from guinea pig colonic circular muscle were carried out in a Sylgard-
lined recording chamber with a circulating, aerated Kreb‟s solution (37°C) containing 
nifedipine (5 μM; Sigma-Aldrich) (Roberts JA et al. 2013; Strong DS et al. 2010). Cells were 
impaled with glass microelectrodes (70 to 120 MΩ, filled with 2M KCl) under visualization 
with an inverted microscope at 100X magnification. Junction potentials were evoked by 
transmural stimuli (0.5ms pulse duration, 0.5Hz, 50V). Voltage recordings were obtained with 
an Axoclamp-2A amplifier (Axon-instruments, Union City, CA, USA) and analyzed with 
PowerLab Chart (version 5.01; AD Instruments, Castle Hill, NSW, Australia). 
 
Cell lines culture and treatment for oxidative stress 
Human Caco-2 cells, a epithelial colorectal adenocarcinoma cell line (ATCC, UK), were 
maintained in a humidified atmosphere of 95% air and 5% CO2 at 37°C in Dulbecco‟s 
modified Eagle‟s medium (DMEM), supplemented with 10% (v/v) fetal bovine serum (FBS), 
100 U/mL penicillin and 100 Ag/mL streptomycin. To produce oxidative stress in Caco-2, 
cells were treated with 200 μM of H2O2 in phosphate-buffered saline (PBS) for 30 min 
(Clement MV et al. 1998; Strong DS et al. 2010). 24 h after the cells were seeded (Roberts JA 
et al. 2013).  
The sulforhodamine B (SRB) assay was used to determine cell density, as previously 
described and validated (Vichai V et al. 2006; Clement MV et al. 1998; Strong DS et al. 
2010). Cells grown in 24 well plates were treated for 1 hr with vehicle, agonist or agonist plus 
antagonist. Supernatant was aspirated from wells and cells were fixed with cold 
trichloroacetic acid solution (30% w/v) at 4°C for 1 h. Fixed cells were washed with H2O and 
dried, and SRB solution (0.057% w/v) was applied to stain the cellular protein contents. 
Using spectrophotometry, absorbance was measured at 540 nm with a reference wavelength 
of 630 nm. 
 
Scratch Assay 
Caco-2 cells (provided by Dr. J Turner, University of Chicago) were cultured in 6 well plates 
to ~90% confluence in DMEM high glucose supplemented with 10% FBS, 1% GlutaMAX, 
10 mM Hepes and 100 U/mL Penicillin-Streptomycin (ThermoFisher Grand Island, NY). 
Once ~90% confluence was reached, three wounds were created using a sterile 200 uL pipet 
tip dragged perpendicular to a black line drawn on the underside of the plate for reference. 
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Images were captured of each scratch at time points 0 h and 48 h with a Nikon D7100 camera 
on a Nikon Diaphot inverted microscope at 4X magnification. Only scratches whose edges 
could be captured in one frame at time point 0 h were included for final analysis. 
Measurements were taken from edge to edge at time 0 h and compared to measurements from 
48 h using ImageJ software (Schneider CA et al. 2012). The reported values are the difference 
between 0 h and 48 h, with higher values representing increased cellular migration. Three 
separate experiments were conducted with all three conditions.  
 
Bacterial Translocation 
After euthanasia, mice were wiped with alcohol, and the spleen and liver were removed. 
Samples were weighed and homogenized in 1 mL sterile PBS. Between samples the 
homogenizer was rinsed in sterile PBS, water, then 70% ethanol to prevent cross 
contamination. Homogenates (200 μL) were plated on Columbia and MacConkey agar plates 
(Dalynn Biologicals, Calgary, AB) and incubated at 37° C in 5% CO2.22 After 48 h, the 
number of positive plates was determined; contaminated plates were not counted. 
 
Data Analysis 
The data are presented as mean ± SEM for n of animals or preparations. Statistical analyses 
were performed using the GraphPad Prism software application (version 6.0c, GraphPad 
Software, La Jolla, CA). Data sets were examined prior to analysis to ensure the validity of 
test assumptions such as similar variability and n-values between groups. In cases in which 
assumptions were met, data sets were compared using unpaired student‟s t-test, 1-way 
ANOVA or 2-way ANOVA with Bonferroni‟s correction, or Fisher‟s exact test, when 
appropriate. The assumptions were not met in two of the experiments: a Welch‟s correction 
was used in the case of a t-test and a square root transformation was used to compress 
variance in the case of an ANOVA. These tests are indicated in the figure legends. Statistical 
significance was defined as one tailed p-values of less than 0.05. 
 
RESULTS 
 
Effects of Epithelial 5-HT4 Receptor Stimulation on Colitis 5-HT4 Receptor stimulation 
attenuates the development of colitis—In DSS-inflamed mice, treatment with tegaserod (1 
mg/Kg), beginning 24 hr after DSS was introduced, significantly reduced the clinical (DAI, 
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p<0.05) and the histological (HDS, p<0.001) damage of the colon compared to vehicle treated 
DSS inflamed animals (Fig 1A; Supplemental Fig 1). The protective effects of tegaserod were 
blocked by the 5-HT4 antagonist, GR113808 (Fig 1A; Supplemental Fig 1; DAI, p<0.05; 
HDS, p<0.0001). 
In TNBS colitis, treatment with tegaserod significantly reduced the DAI as compared to 
inflamed controls (Fig 1B; p<0.05); however, the HDS was not changed. The protective effect 
of tegaserod on the DAI was blocked by the 5-HT4 antagonist (Fig 1B; p<0.05). 
To further confirm that tegaserod was mediating its protective action via 5-HT4 receptor 
activation, experiments were conducted with 5-HT4 knockout mice and their wild type 
littermates with DSS colitis. Tegaserod failed to improve the DAI or HDS in mice lacking the 
5-HT4 receptor (Fig. 1C), but it significantly reduced inflammation in the wild type animals 
(DAI: vehicle, 7.7±0.5; agonist, 5.5±0.5; p=0.004; HDS: vehicle, 10.3±0.6; agonist, 8.2±0.3; 
p=0.017 by t-test; n=7–11 per group). 
 
5-HT4 receptor stimulation accelerates healing from established colitis—To test whether 
activation of epithelial 5-HT4 receptors in the distal colon affects the recovery from colonic 
inflammation, animals were treated with tegaserod after colitis was established (days 6–15; 
Fig. 2). 5-HT4 agonist treatment significantly accelerated the recovery from DSS colitis as 
compared to vehicle treated animals (Fig 2A; p<0.0001 at day 15). Furthermore, DSS-
inflamed mice treated with tegaserod showed significant improvement in HDS (Fig 2A; 
p<0.0001). These effects were blocked by the 5-HT4 antagonist (Fig 2A; DAI, p<0.001; 
HDS, p<0.001). 
5-HT4 agonist treatment in established TNBS colitis accelerated recovery of the DAI (Fig 2B; 
p<0.001 at day 15) and improved the HDS (p<0.01), and these actions were also inhibited by 
antagonist treatment (Fig 2B; DAI, p<0.001; HDS, p<0.05). 
 
Intraperitoneal administration of the 5-HT4 receptor agonist fails to affect colitis—To 
test whether the effects of enema-administered 5-HT4 agonist could involve 5-HT4 receptors 
at other sites in the GI tract or elsewhere, the agonist was delivered daily by intraperitoneal 
(IP) injection at the same dose (1 mg/Kg) beginning on day 1. In DSS-inflamed animals, IP 
administered agonist had no effect on the clinical or histological scores (DAI: vehicle, 
5.1±0.6; agonist, 4.5±0.5; p=0.4; HDS: vehicle, 10.0±0.9; agonist, 7.8±0.9; p=0.1 by t-test; 
n=7–8 per group). 
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5-HT4 receptor mediated protective mechanisms 
Epithelial 5-HT4 receptor activation could mediate the protective effects via a variety of 
mechanisms, including maintenance or reestablishment of the epithelial barrier through cell 
proliferation and migration, and also by increasing resistance to epithelial apoptosis induced 
by oxidative stress. We first assessed epithelial permeability by evaluating FITC-dextran in 
serum by spectroscopy (arbitrary fluorescence units; AFUs) following gastric gavage. Colitis 
was associated with a 3–4 fold increase in permeability (control, 3530 ± 125 AFUs, n=17; 
DSS, 15,690 ± 3222 AFUs, n=22, P<0.01). Despite the fact that the cecum and entire colon is 
affected in DSS colitis, a tegaserod enema in the distal colon demonstrated a tendency to 
reduce the permeability to FITC-dextran (9,372 ± 944 AFUs, n=16, P=0.07). Associated with 
the increase in epithelial permeability there is a degree of bacterial translocation associated 
with colitis (4/9 animals with colitis had bacterial translocation to the liver or spleen 
compared to 0/5 control animals). After tegaserod enema there was again a tendency for this 
to be reduced (1/8 animals with bacterial translocation). These actions prompted us to 
examine detailed mechanisms of action of 5-HT4 receptor activation in the epithelium. 
The effects of 5-HT4 receptor activation on proliferation were tested in the DSS recovery 
paradigm, as this condition yielded the most robust response. Effects of 5-HT4 receptor 
stimulation on migration and resistance to oxidative stress were evaluated in Caco-2 cells, 
which were found to express the 5-HT4 receptor by rtPCR and immunoblot (Supplemental 
Fig. 2). 
The nuclear protein, Ki-67, is an effective marker of post-mitotic cells (Joly F et al. 2009).  In 
the colons of DSS-inflamed animals that received daily agonist enemas beginning on day 6, 
there was a significant increase in the percentage of crypt epithelial cells that were Ki-67 
positive at day 15 (Fig. 3; p<0.05; Supplemental Fig 3), and this effect was blocked by the 5-
HT4 antagonist (Fig. 3; p<0.01; Supplemental Fig 3). The proportion of epithelial cells 
immunoreactive for Ki-67 was also significantly higher in colons from animals treated with 
DSS and agonist beginning on day 1 and euthanized on day 7 (vehicle, 0.5±0.04 vs 0.7±0.02; 
p<0.001; n=5 per group). 
An important mechanism of epithelial healing is enhanced epithelial cell migration (Heath JP 
et al. 1996). To assess this we performed a scratch wound healing assay (Denker SP et al. 
2002) and saw a significant increase in the rate of Caco-2 cell migration in cultures treated 
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with tegaserod (1 μM) (Fig. 4A,C; p<0.001), and this effect was inhibited in the presence of 
the antagonist (Fig. 4A,C; p<0.05). 
Oxidative stress is a feature of colitis (Shi XZ et al. 2011), and triggers epithelial apoptosis 
(Novak EA et al. 2015, Becker C et al. 2013). Therefore, Caco-2 cells were exposed to the 
free radical donor, H2O2 (200 μM), and cell survival in response to 5-HT4 receptor 
stimulation was determined using the SRB assay. H2O2 caused a significant reduction in cell 
survival compared to untreated cells (Fig. 4B; p<0.001), and cell survival in H2O2 treated 
cultures was significantly improved by tegaserod (10 μM) (Fig. 4B; p<0.001). This agonist-
mediated protection was blocked by the specific antagonist, GR113808 (10 nM) (p<0.001). 
 
Effects of 5-HT4 Receptor Activation on Propulsive Motility 
A central feature of IBD is altered GI motility (Reddy SN et al 1991, Brierley SM et al 2014). 
We have investigated dysmotility in guinea pig TNBS colitis (Roberts JA et al 2013; Strong 
DS et al. 2010; Linden DR et al. 2004; Hoffman JM et al. 2011), and have demonstrated that 
changes in enteric neuronal excitability (Hoffman JM et al. 2011) and purinergic inhibitory 
neuromuscular transmission (Roberts JA et al 2013) contribute to disrupted motility. We 
therefore treated TNBS-inflamed guinea pigs daily with tegaserod enemas (1 mg/Kg) for 6 
days beginning 24 h after TNBS instillation, and evaluated propulsive motility. 
Consistent with previous findings (Roberts JA et al 2013; Strong DS et al. 2010; Hoffman JM 
et al. 2011; Linden DR et al. 2003) the distal colons of TNBS-inflamed animals exhibited a 
significant reduction in the rate of propulsive motility (Fig. 5A; p<0.0001), and an increase in 
trials in which fecal pellets became obstructed (Fig. 5B; p<0.0004). Tegaserod significantly 
improved the rate of propulsive motility in TNBS inflamed colons (p<0.0001), and eliminated 
the obstructions (Fig. 5A,B). Antagonist treatment blocked the protective effects of tegaserod 
on the rate of propulsive motility (p<0.0001), and on the occurrence of obstructions 
(p<0.0001). It is worth noting that preparations from animals receiving antagonist treatment 
were more frequently obstructed than vehicle-treated TNBS inflamed preparations 
(p=0.0012). 
Since the disruption of propulsive motility in guinea pig TNBS colitis involves an attenuation 
of inhibitory junction potentials (IJPs), we measured IJP amplitudes in preparations from 
animals treated with tegaserod. Daily agonist treatment significantly improved the IJP in 
TNBS inflamed animals (naïve: −19.1 mV ± 1.3, TNBS with vehicle: −9.4 mV ± 0.9, TNBS 
with agonist: −18.1 mV ± 0.6; p<0.0001 by one-way ANOVA). 
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Colonic motility was also evaluated in vivo in mice in the 15 day recovery paradigm using the 
bead expulsion assay. As was detected in the TNBS inflamed guinea pig colon, mice with 
DSS colitis exhibited a slowing of colonic transit that was inhibited by tegaserod treatment 
(Fig. 5C). Furthermore, the effect of tegaserod (1mg/Kg) was blocked by the 5-HT4 
antagonist, GR113808 (1 mg/Kg).  
 
Epithelial 5-HT4 receptors play a protective physiological role in healthy animals 
The findings described above indicate that 5-HT4 receptor activation decreases the extent of 
colitis as it develops, and accelerates recovery from colitis once it has been established, 
raising the possibility that 5-HT4 receptors could serve as a novel therapeutic target for the 
treatment of colitis. These results also suggest that 5-HT4 receptors might play a role in 
maintaining the integrity of the epithelial layer under physiological conditions. 
To test whether 5-HT4 receptor activity influences epithelial integrity, normal mice were 
treated for 10 days with the 5-HT4 antagonist, GR113808 (1 mg/Kg), administered by enema. 
Daily treatment of mice with the 5-HT4 antagonist showed a significant increase in the DAI 
(p<0.0001; Fig. 6A) and HDS (p<0.0001; Fig. 6B, Supplemental Fig. 4). 
Consistent with the effect of pharmacologically inhibiting the receptor, 5-HT4 knockout mice 
exhibited a significantly higher HDS than wild type littermates (p<0.05; Fig. 6C) 
The results from colitis paradigms described above demonstrate that 5-HT4 receptor 
stimulation by agonist administration increases epithelial proliferation, as measured by Ki-67 
immunoreactive cells. Therefore, Ki-67 immunoreactivity was evaluated in normal animals 
treated with GR113808. In animals treated with the antagonist alone, there was a significant 
reduction in Ki-67 immunoreactivity compared to vehicle-treated controls (Fig. 7A; 
p<0.0001). 
Evaluation of bacterial translocation from the gut to either the spleen or the liver has been 
shown to be an effective assay to assess barrier permeability (MacEachern SJ et al. 2015; 
Deitch EA et al. 1992). Antagonist treatment in normal mice led to a significant increase in 
the proportion of cultures that were positive for bacterial translocation as compared to 
vehicle-treated animals (Fig. 7B; p<0.02). 
To test whether endogenous 5-HT4 receptor activation influences colonic function, propulsive 
motility was evaluated in distal colons from guinea pigs treated daily for 10 days with the 
antagonist alone. Treatment with the antagonist did not have a significant effect on the rate of 
propulsive motility; however, fecal pellet obstruction was observed in 25% of trials in colons 
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from animals receiving antagonist treatment, which was significantly different from the 
control patterns (Fig. 7C; p=0.0035). 
 
DISCUSSION 
This study tested the hypothesis that epithelial 5-HT4 receptor activation attenuates the 
development of colitis, and improves recovery from active colitis. Our findings support this 
hypothesis by demonstrating that epithelial 5-HT4 receptor stimulation reduced disease 
activity and histological damage in both DSS and TNBS colitis, supporting an anti-
inflammatory effect. The epithelial 5-HT4 receptor stimulation can exert its protective effects 
through several mechanisms, including increased epithelial proliferation, enhanced epithelial 
cell migration, and resistance to oxidative stress-induced apoptosis. Furthermore, treatment 
with the 5-HT4 agonist attenuated inflammation-induced changes in colonic motor function. 
Importantly, all of these effects were blocked by the 5-HT4 antagonist, GR113808, and 
protection was not detected in 5-HT4 KO mice. Our findings also indicate that epithelial 5-
HT4 receptors serve an important physiological role in maintaining mucosal integrity since 
inhibition of 5-HT4 receptor activity in normal animals leads to inflammation and disrupted 
motor function. Collectively, these studies contribute new knowledge regarding the protective 
actions of 5-HT4 receptor activation, and provide evidence for an anti-inflammatory role of 5-
HT4 in normal physiology. 
Prior to the current investigation, it had been established that 5-HT can exert a pro-
inflammatory influence in the GI tract (Gershon MD 2012). For example, colitis is reduced in 
mice lacking or deficient in mucosal 5-HT (Ghia JE et al. 2009), and it is worsened in SERT 
knockout mice, which have elevated mucosal 5-HT availability (Bischoff SC et al 2009). This 
effect is likely mediated by activation of 5-HT7 receptors on dendritic cells in the lamina 
propria (Bertrand PP et al. 2004). These previous studies examined the global effect of gut-
derived 5-HT on inflammation. The current study specifically examined the role of 5-HT4 
receptor activation in the context of inflammation and we found an anti-inflammatory role of 
5-HT signaling in the mucosa, supporting previous work from our labs suggested that 
activation of these receptors may be protective (Hoffman JM et al. 2012). It will be 
interesting, in future studies, to directly compare the relative pro- and anti-inflammatory 
effects of mucosal 5-HT signaling. Regardless, during colitis, the protective actions of 5-HT4 
stimulation by endogenous 5-HT are dominated by an over-riding influence of pro-
inflammatory mediators and mechanisms. On the other hand, this does not preclude the 
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possibility that stimulation of the 5-HT4 receptor pharmacologically could have a beneficial 
effect, as has been demonstrated in the current study. 
In addition to these protective, anti-inflammatory actions of epithelial 5-HT4 receptors, there 
is evidence that 5-HT4 receptors play a beneficial, neurogenic effect in the muscularis. 
Activation of 5-HT4 receptors in primary cultures of enteric neurons promotes neuronal 
growth and survival, and in vivo, agonist treatment promotes neurogenesis in adult mice (Liu 
MT et al. 2009). This neuro-protective action has been supported by in vivo studies 
demonstrating that recovery of the recto-anal reflex is significantly augmented, through 
neurogenesis and axon outgrowth, by 5-HT4 receptor treatment following rectal transection 
and anastomosis (Takaki M et al. 2014; Matsuyoshi H et al- 2010; Kawahara I et al 2012). 
Furthermore, 5-HT4 receptor-mediated enteric neurogenesis occurs in colitis (Belkind-Gerson 
J et al. 2015) a condition in which bioavailability of 5-HT is increased (Mawe GM et al. 
2013). Taken together with the results reported here, it is becoming increasingly clear that the 
5-HT4 receptor exerts protective actions in the inner and outer layers of the gut. 
Several mechanisms appear to contribute to the protective effects of epithelial 5-HT4 receptor 
stimulation, and these mechanisms are apparently effective for both Th1-(TNBS) and Th2-
predominant (DSS) inflammatory responses. One mechanism by which 5-HT4 receptor 
stimulation is acting is through enhanced wound healing processes. 5-HT4 receptor 
stimulation increased both cell proliferation and epithelial cell migration in a 5-HT4 
antagonist-sensitive manner. Epithelial erosions, ulcers and decreased epithelial barrier 
integrity are all common features of active colitis, and these conditions would likely be 
mitigated by enhanced epithelial proliferation and migration. 
The anti-inflammatory effects of 5-HT4 receptor activation may also involve resistance of the 
epithelium to the harmful effects of oxidative stress. Oxidative stress, and resultant epithelial 
apoptosis, is a key feature of inflammation and has been demonstrated in both DSS and TNBS 
colitis. Treatment with a 5-HT4 agonist protected CaCo-2 cells from apoptosis that was 
elicited by the free radical donor, H2O2, in a 5-HT4 antagonist-sensitive manner. 
Another unexplored mechanism that likely contributes to the protective effect of 5-HT4 
receptor stimulation is secretion of mucus from goblet cells. The mucus layer serves as a 
protective barrier, and disruption of this barrier with mucolytic agents or deletion of the mucin 
2 gene results in colitis (Van der Sluis Met al. 2006; Johansson ME et al. 2014). Goblet cells 
express the 5-HT4 receptor, and 5-HT4 receptor activation leads to degranulation (Hoffman 
JM et al. 2012). 
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The guinea pig distal colon ex vivo model of motility is probably the most extensively 
characterized animal model of propulsive motility (Hoffman JM et al. 2010; Costa M et al. 
1976; D‟Antona G et al 2001). We have previously used this assay to investigate changes in 
motility that are associated with TNBS colitis (Strong DS et al 2010; Linden DR et al. 2003), 
and we have linked disruptions in motility to inflammation-induced neuroplasticity, 
particularly intrinsic primary afferent neuron hyperexcitability (Hoffman JM et al. 2011) and 
attenuated purinergic neuromuscular transmission (Roberts JA et al. 2013). In the current 
study, treatment of TNBS-inflamed guinea pigs, and DSS-inflamed mice with the 5-HT4 
agonist improved propulsive motility and eliminated obstructive motility patterns. Consistent 
with our previous report linking disrupted motility to IJP attenuation (Roberts JA et al. 2013), 
the amplitude of the IJP is comparable to that of control animals following 5-HT4 agonist 
treatment in TNBS colitis animals. 
Data from studies reported here involving various models and paradigms of 5-HT4 receptor 
stimulation in colitis indicate that the 5-HT4 receptor plays a host defense role in 
inflammatory conditions through a number of actions that support the epithelial barrier and 
resistance to damage from oxidative stress. These novel findings, and the knowledge that 5-
HT released from enterochromaffin cells reaches the lumen (Bertrand PP et al 2004; Patel BA 
et al. 2007), led to the question of whether 5-HT4 receptor activity exerts a protective 
influence in the mucosal layer under physiological conditions. Treatment of normal mice with 
a 5-HT4 receptor antagonist led to increased DAI and HDS scores, bacterial translocation, and 
reduction in cell proliferation. Furthermore, inhibition of 5-HT4 receptors in the colonic 
epithelium of normal guinea pigs resulted in obstructed motility patterns, which is not a 
feature of the healthy colon. Also, antagonist treated mice exhibited slowed colonic transit. 
Consistent with these results, there were situations in our colitis paradigms in which 
antagonist treatment not only blocked the agonist, but led to a condition far worse than the 
vehicle treated inflamed group. This included the histological damage in the DSS mouse 
colitis prevention paradigm (Fig. 1) as well as the obstructed motility pattern in guinea pigs 
with TNBS colitis (Fig. 7). These findings suggest that endogenous 5-HT may be acting on 
epithelial 5-HT4 receptors to dampen physiological inflammation and maintain homeostasis. 
It is possible that treatment with the 5-HT4 antagonist mediates its effect by blocking 
stimulation of epithelial 5-HT4 receptors by 5-HT released from enterochromaffin cells. 
Another possibility is that the antagonist that was used, GR113808, decreased constitutive 
activity of the epithelial 5-HT4 receptors. Certain isoforms of the 5-HT4 receptor have low 
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levels of constitutive activity, which could lead to a steady state activation of the protective 
pathways stimulated by 5-HT4 receptor activation with an agonist (Claeysen S et al. 2001; 
Blondel O et al 1998; Claeysen S et al. 2000). The antagonist that was used in the current 
studies, GR113808, can suppress this constitutive activity by acting as an inverse agonist 
(Kamel R et al. 2005). 
 
Conclusion 
Here we report the discovery of a protective and healing action of epithelial 5-HT4 receptor 
stimulation in the colon. Translation of these observations could provide a new and safe 
treatment strategy for the treatment of colitis, and that expand our appreciation of the roles of 
5-HT receptor signaling in the GI tract. Treatment in two different models of colitis decreased 
the extent of inflammation as it was occurring, and accelerated the process of remission once 
colitis had been established. This beneficial effect likely involves several mechanisms that 
include enhanced wound healing, resistance to oxidative stress, and improved colonic motor 
function. Thus these findings demonstrate that luminally restricted, and therefore low risk, 
administration of 5-HT4 agonists could be beneficial in the treatment of IBD. The discovery 
that 5-HT4 receptors also contribute to the epithelial integrity in healthy animals reveals a 
newly identified role for 5-HT signaling in the mucosal layer, and one that physiologically 
opposes the previously identified pro-inflammatory actions of 5-HT in the colon. 
Collectively, these findings advance our understanding of colonic physiology and 
pathophysiology, and provide a new target for the treatment of colonic inflammation. 
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Figures 
 
 
Figure 1: Daily intraluminal treatment with the 5-HT4 agonist, tegaserod (1mg/Kg) reduced the extent 
of DSS and TNBS colitis. A. In DSS colitis, tegaserod caused an antagonist-sensitive reduction in the 
DAI and HDS (vehicle, n=9; agonist, n=10; agonist/antagonist, n=5; for HDS, 2 values were obtained 
from each animal). B. In TNBS colitis, agonist treatment significantly reduced the DAI, but did not 
affect the HDS (n=7 animals for all groups, with 2 values per animal for HDS). C. Tegaserod failed to 
improve DAI or HDS in DSS inflamed 5- HT4 knockout mice (n=8–9 animals per group, with 2 
values per animal for HDS). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 by one-way ANOVA. 
†p<0.05 by one-way ANOVA with square root transformation. 
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Figure 2: Daily intraluminal treatment with the 5-HT4 agonist, tegaserod (1mg/Kg) beginning on day 
6, after colitis had been established, accelerated recovery from DSS and TNBS colitis. A. In DSS 
colitis, the 5-HT4 receptor agonist significantly improved the DAI by day 12, and at the termination of 
the experiment on day 15, both the DAI and HDS were significantly improved as compared to the 
vehicle control and antagonist plus agonist treatment groups. (vehicle, n=21; agonist, n=23; antagonist, 
n=5 with 2 values per animal obtained for HDS). C. In TNBS colitis, significant improvement in the 
DAI was detected on Day 9, and at the day 15 time point, both the DAI and HDS were significantly 
improved (vehicle, n=13; agonist, n=14; antagonist, n=5 with 2 values per animal obtained for HDS). 
*p<0.05;**p<0.01; ***p<0.001; ****p<0.0001 by two-way ANOVA for DAI and one-way ANOVA 
for HDS. In the DAI graphs, comparisons were made between agonist treatment and the other groups. 
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Figure 3: Intraluminal treatment with tegaserod increased epithelial proliferation. Graph 
demonstrating the proportion of crypt epithelial cells immunoreactive for the proliferation marker, Ki-
67 (vehicle, n=10; agonist, n=9; antagonist, n=9). * p<0.05, **p<0.01 by oneway ANOVA. 
 
 
Figure 4: Treatment of Caco-2 cells with tegaserod increased the rate of cell migration, and caused 
protection from cell loss due to oxidative stress. A. Closure of scratches in Caco-2monolayer cultures 
after 48 h (1 well per treatment group, 3 scratches per well × 3 experiments). B. Survival data from 
cultures that were treated with normal medium (control) or 200 μM H2O2 (n=4 per group). C. 
Photomicrographs of Caco-2 cultures showing scratches at the 0 and 48 h time points. ** p<0.05, **** 
p<0.0001; one-way ANOVA.
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Figure 5: Daily intraluminal treatment with tegaserod (1 mg/Kg) improved distal colon propulsive 
motility in guinea pigs with TNBS colitis. A. Graph illustrating rate of pellet propulsion along the 
length of the colon (control, n=6; TNBS/vehicle, n=9; TNBS/agonist, n=6; TNBS/agonist plus 
antagonist, n=4; ****p<0.0001, one-way ANOVA). B. Graph showing the proportion of trials in 
which the fecal pellet cleared the colon or was obstructed, and did not clear the colon within 5 min (5–
6 trials per animal; ***p<0.001, ****p<0.0001, Fisher‟s Exact Test). C. Graphs demonstrating results 
of bead expulsion assays from mice with DSS colitis in the 15 day recovery paradigm that were 
treated in vivo by enema (DSS/vehicle, n=5; DSS/agonist, n=4; DSS/agonist plus antagonist, n=5; 
*p<0.05, paired t-test). 
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Figure 6:Pharmacological or molecular disruption of 5-HT4 signaling increased inflammatory scores 
in normal mice. Intraluminal administration of the 5-HT4 antagonist GR113808 (1 mg/Kg) induced 
colitis in mice. Antagonist treatment resulted in a significant increase in the DAI that was detected as 
early as day 3 (A), and an increase in the HDS (B). n=10/group. **p<0.01; ****p<0.0001 by two-way 
ANOVA; ††††p<0.0001 by t-test with Welch‟s correction. C. The HDS was significantly higher in 5-
HT4 knockout mice, as compared to wild type littermates (*p<0.05 by t-test; WT, n=4; 5-HT4 KO, 
n=8). 
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Figure 7:Daily intraluminal administration of the 5-HT4 antagonist GR113808 (1 mg/Kg) disrupted 
barrier function in normal mice, and motility in guinea pigs, as well as motility in mice. A. The 
proportion of crypt epithelial cells that were immunoreactive for the proliferation marker, Ki-67 was 
significantly decreased in animals treated with the antagonist (vehicle, n=8; antagonist, n=10; 
****p<0.001 by t-test). B. Proportion of mice in which bacteria were detected in the liver or spleen 
following 10 days of vehicle or antagonist treatment. Vehicle, n=5; antagonist, n=3; ****p<0.0001, 
Fisher‟s Exact Test. C. Proportion of trials in which pellet propulsion was obstructed for at least 5 min. 
(vehicle, n=31 trials from 4 colons; antagonist, n=30 trials from 5 colons; ****p<0.0001, Fisher‟s 
Exact Test). D. Time to bead expulsion at the onset and following daily antagonist treatment in normal 
CD-1 mice. Data for each mouse were normalized to data collected at onset of treatment (*p<0.05, 
paired ttest; n=5). 
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Chapter IX 
13. Prucalopride exerts neuroprotection in human enteric neurons 
 
Modified from 
―Prucalopride exerts neuroprotection in human enteric neurons‖ 
Francesca Bianco, Elena Bonora, Dipa Natarajan, Manuela Vargiolu, Nikhil 
Thapar,Francesco Torresan, Fiorella Giancola, Elisa Boschetti, Umberto Volta, Franco 
Bazzoli, Maurizio Mazzoni, Marco Seri, Paolo Clavenzani, Vincenzo Stanghellini, Catia 
Sternini and Roberto De Giorgio 
Am J Physiol Gastrointest Liver Physiol 310: G768–G775, 2016. 
Abstract 
Background: Serotonin (5-hydroxytryptamine, 5-HT) and its transporters and receptors are 
involved in a wide array of digestive functions. In particular, 5-HT4 receptors are known to 
mediate intestinal peristalsis and recent data in experimental animals have shown their role in 
neuronal  maintenance and neurogenesis. This study has been designed to test whether 
prucalopride, a well known full 5-HT4 agonist, exerts protective effects on neurons, including 
enteric neurons, exposed to oxidative stress challenge. 
Methods: SulfoRhodamine B (SRB) assay was used to determine the survival of SH-SY5Y 
cells, human enteric neurospheres and ex vivo submucosal neurons following H2O2 exposure 
in the presence or absence of prucalopride (1 nM). Specificity of 5-HT4 mediated 
neuroprotection was established by experiments performed in the presence of GR113808, a 5-
HT4 antagonist.  
Results: Prucalopride exhibited a significant neuroprotective effect. SH-SY5Y cells pre-
treated with prucalopride were protected from the injury elicited by H2O2 as shown by 
increased survival (73.5±0.1% of neuronal survival vs. 33.3±0.1%, respectively; P<0.0001) 
and a significant reduction of pro-apoptotic caspase-3 and caspase-9 activation in all neurons 
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tested. The protective effect of prucalopride was reversed by the specific 5-HT4 antagonist 
GR113808. 
Conclusions: Prucalopride promotes a significant neuroprotection against oxidative-mediated 
proapoptotic mechanisms. Our data pave the way for novel therapeutic implications of full 5-
HT4 agonists in gut dysmotility characterized by neuronal degeneration, which go beyond the 
well known enterokinetic effect. 
 
Methods 
Neuronal cell lines and neurospheres culture 
Murine Neuro2A as well as human SH-SY5Y, SK-N-BE, S-K-NSH, LAN-1 and HEK293  
(ATCC, UK) cells were cultured in 95% air and 5% CO2 at 37°C in Dulbecco‟s modified 
Eagle‟s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 100 U/mL 
penicillin and 100 μg/mL streptomycin. Primary human enteric neurospheres were generated 
from human ENS stem cells containing neurosphere-like bodies according to a previously 
modified method (Bondurand N et al. 2003). In order to produce oxidative stress, H2O2 was 
freshly prepared from 30% stock solution prior to each experiment. Cells were treated with 
200 μM H2O2 in phosphate-buffered saline (PBS) for 30 min as previously indicated (Clement 
MV et al. 1998).  
Western blotting 
Whole-cell lysates were obtained in IP buffer (Sigma-Aldrich, St. Louis, MO, USA), protease 
inhibitors cocktail (Roche Diagnostics, Indianapolis, IN, USA) and phosphatase inhibitors 
(Sigma-Aldrich) on ice for 15 min. Protein concentration was evaluated using the DC protein 
concentration assay kit (Biorad, Hercules, CA, USA). Fresh biopsies were sonicated on 
Bioruptor Pico Sonication System (V 1.1) (Diagenode, Liege, Belgium) in 100 μL of IP 
buffer and inhibitors cocktail (Sigma-Aldrich). Bands were visualized using the enhancer 
chemioluminescence method (GE Healthcare, Little Chalfont, UK). Primary antibodies used 
were: anti-5-HT4 (1:200; Abcam, Cambridge, UK) anti-HuC/D (1:200; Invitrogen, Carlsbad, 
CA, USA); anti-p75 (1:200; Thermo Fisher Scientific, Waltham, MA, USA); anti--tubulin 
and anti114 vinculin (1:10,000 and 1:50,000, respectively; Sigma-Aldrich); anti-caspase-3 
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and caspase-9 (both 1:200; Cell Signaling, Denver, CO, USA); anti-neuronal nitric oxide 
synthase (nNOS) (1:50; Santa Cruz, Dallas, TX, USA) and anti-peripheral choline acetyl 
transferase (pChAT) (1:100; Justus-Liebig University, Giessen, Germany). The experiments 
on neurospheres were performed on cells cultured for at least 14 days. 
Cytotoxicity assay 
Sulforhodamine B colorimetric (SRB) assay was used for cell density determination. The 
method has been optimized for the toxicity screening of compounds to adherent cells in a 24-
well plate (Vichai V et al. 2006). To determine the dose-response profiles of prucalopride, the 
SRB assay was performed by incubating cells for 0 (untreated), 30 and 60 min with 
prucalopride (Shire, Lexington, MA, USA) at the following final concentrations: 10mM, 
10μM, 10nM, 1nM and 10pM to establish a correct dose finding. Controls were exposed to 
0.05% (v/v) dimethyl sulfoxide in culture medium while wells containing only culture 
medium served as blank. The selective antagonist GR113808 (10nM) (1-[2-[(methylsulfonyl)-
amino]ethyl]-4- piperidinyl]methyl-1-methyl-1H-indole-3-carboxylate, Sigma-Aldrich), was 
applied 30 min before prucalopride administration (Figure 1A). Absorbance was measured at 
540 nm using spectrophotometry. 
Cell proliferation assay 
SH-SY5Y cells (3×105132 ) were plated in duplicate and incubated with 10μM BrdU 
(Millipore Corporation, Billerica, MA, USA) for 1-48 hrs. BrdU-labeled cells adhered to the 
plate by centrifugation (300xg for 10 min) and then dried to the plate at room temperature for 
1h. Anti mouse HRP-conjugated IgG antibody was used as secondary antibody. Absorbance 
measured at λ 450 nm was used to calculate the BrdU labeling index. 
Submucosal neuron whole-mount preparations from colonic biopsies 
A written informed consent (protocol: PaBio-2011) was obtained from enrolled subjects (n= 3 
female; age range: 30-55 yrs) undergoing routine screening colonoscopy with biopsy 
sampling (n=3 each subject from the descending colon). Subjects were recruited at the 
outpatient clinics of Internal Medicine and Gastroenterology Units of the Department of 
Medical and Surgical Sciences of University of Bologna. Biopsies were transferred to 
sylgard-coated Petri dish filled with ice-cold Hank's solution, pinned flat and the mucosa 
separated from the submucosa under a stereomicroscope (16). Fresh submucosal specimens 
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were treated with prucalopride (1nM) for 30 min in combination with H2O2 maintained in 
DMEM F12 medium. Biopsies were sonicated for cycles at 20-60 kHz. 
Immunofluorescence 
Immunofluorescence was performed on neurospheres fixed in 4% PFA, rinsed in PBS and 
treated with blocking solution for 30 min. Previously described primary antibodies, i.e. rabbit 
anti pChAT (1:100), mouse anti-nNOS (1:50), rabbit anti-5HT4 (1:200), HuC/D (1:200) were 
applied to neurospheres overnight at 4°C. Specificity experiments included primary antibody 
omission and pre-incubation with the respective homologous antigen. After washing with 
PBS, a donkey anti-rabbit Cy3, anti-rabbit Alexa488, anti-goat Alexa488 and anti-mouse 
Alexa488 (1:200, Thermo Fisher Scientific) secondary antibodies were applied for 30 min at 
room temperature. FluoroschieldTM 155 DAPI solution (Sigma Aldrich) was used as 
mounting solution and to counterstain nuclei. Image capturing was performed on a Nikon 
microscope using DS-5M digital camera (Nikon Instruments, Düsseldorf, Germany). 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software v.5.0 (San Diego, CA, 
USA). Statistical significance was defined as P<0.05 as evaluated by one-way analysis of 
variance (ANOVA) and Tukey's multiple comparison test. Statistical analysis of densitometry 
was performed using Image Lab™ Software (Bio-Rad, California, USA). 
 
Results 
Evaluation of the 5-HT4 expression in human enteric neurospheres and other neuronal 
cell lines 
The 5-HT4 protein expression was studied by western blot analysis using human 
neuroblastoma cell lines, SH-SY5Y, SK-N-BE, S-K-NSH, and LAN-1, the human embryonic 
kidney cell line HEK293, a mouse neural crest-derived cell line, Neuro2A (used as a negative 
control for antibody specificity) and human enteric neurospheres (Figures 1B and 1C). All the 
human cell lines analysed showed 5-HT4 expression, whereas no signals were detected in the 
murine Neuro2A cells since the antibody used was specific for the human 5-HT4 isoform. 
Western blot analysis of human enteric neurospheres and SH-SY5Y showed that these cells 
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also expressed the neuronal marker HuC/D and the progenitor/stem cell marker p75 ( Figure 
1D), thus indicating that these cells were suitable for studies on neuroprotection. 
The 5-HT4 agonist prucalopride protects SH-SY5Y cells from oxidative stress insult 
We tested different concentrations of the full 5-HT4 agonist prucalopride on SH-SY5Y cells 
exposed to the oxidative stress agent H2O2. The oxidative stress evoked by 200 μM of H2O2 
resulted in a significant reduction of cell survival (33.3±0.1%) compared to untreated cells 
(P<0.001). 
Prucalopride at 1 nM concentration showed the best protective effect, with a significantly 
higher cell survival compared to cells exposed to H2O2 (73.5±0.1% of neuronal survival vs. 
33.3±0.1%, respectively; P<0.0001) (Figure 2A). In order to verify the specificity of the 5-
HT4-mediated protective effect, cells were exposed to the selective antagonist GR113808 
(10nM) applied 30 minutes before prucalopride administration (18). Pre-treatment with 
GR113808 induced a significant reduction in cell survival, i.e. 23.3±0.1% vs. the 73.5±0.1% 
in the H2O2-treated cells exposed to prucalopride (P<0.0001). These data are comparable to 
those obtained in presence of H2O2 alone, indicating that the observed protection was elicited 
via 5-HT4 activation (Figure 2A). Untreated cells exposed to GR113808 at 10 nM 
concentration showed a survival rate of 81.3±0.1%, which was comparable to that of vehicle-
treated cells, indicating lack of toxicity of the 5-HT4 antagonist (Figure 2A, P<0.001). By 
contrast, prucalopride becomes toxic at high concentrations with the highest toxic effect 
observed with 10 mM prucalopride as indicated by reduced survival (32±1.2% and 29±1.2%, 
at 30 and 60 min, respectively) in cells unexposed to oxidative stress (cell survival being 
virtually 100%). Prucalopride at the lowest concentration tested (10pM) failed to rescue 
neuronal cells from damage induced by oxidative stress (survival being 41±0.8 vs. 32±1.2%, 
respectively) (Figure 2B). 
Evaluation of prucalopride in neurogenesis in vitro 
In order to determine whether prucalopride induces neurogenesis in vitro, we evaluated the 
bromodeoxyuridine (BrdU) incorporation 24 hours after the treatment with different 
concentrations of the 5-HT4 agonist. Prucalopride did not evoke a significantly different 
incorporation of BrdU compared to untreated SH-SY5Y or H2O2-treated cells (P=0.384) 
(Figure 2C). This suggests that the effect of prucalopride treatment of SH-SY5Y cells 
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exposed to oxidative stress is predominantly neuroprotective, and not due to 
neuroproliferation. 
 
Effect of prucalopride on caspase expression in neuronal cell lines and neurospheres 
To investigate the mechanisms underlying the neuroprotective effects mediated by 
prucalopride, we examined the expression of two apoptotic markers, i.e. caspase-3 and 
caspase-9, which are activated by oxidative stimuli. No changes in procaspases expression 
were found before and after treatments (Figures 2D, E and 3A, B), whereas a significant 
decrease of the active form of both oxidative stress-activated caspases-3 and caspase-9 was 
detected in SH-SY5Y cell lines (Figures 2F, G) and in human enteric neurospheres (Figures 
3C, D), treated with 1 nM prucalopride. 
Effect of prucalopride in different subgroups of neurons 
To determine whether the neuroprotective effect evoked by prucalopride occurred in selective 
subpopulations of enteric neurons, we investigated the effect of prucalopride following the 
oxidative stress injury on the expression of two major enteric neuron transmitters nNOS 
(neuronal nitric oxide synthase, the enzyme that produces nitric oxide) and pChAT (peripheral 
cholinacetyltransferase, the enzyene that catalyzes the synthesis of acetylcholine) in human 
enteric neurospheres. Both nNOS and pChAT expression was identified by 
immunofluorescence and western blot (Figures 3E-G). H2O2 treatment induced a quantitative 
reduction of both nNOS and pChAT proteins in neuropheres compared to the total protein. In 
contrast, prucalopride treatment prevented the oxidative-induced reduction of each subset of 
transmitters compared to H2O2 treatment without prucalopride (Figure 3H, I, P<0.05). 
Western blot analysis confirmed the expression of 5-HT4 in colonic biopsy-derived 
submucosae obtained during colonoscopy (Figure 4A). After treatment with prucalopride, 
submucosal whole mount preparations were exposed to H2O2 and the levels of activated 
caspases were measured. Procaspase expression did not vary with any treatment (Figures 4B, 
C). However, activated caspase-3 and caspase-9 were significantly reduced in prucalopride-
treated biopsies compared to H2O2 only (Figures 4D, E, P<0.001). 
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Discussion 
The results of this study provide strong evidence for a neuroprotective role of 5-HT4 
subtype,which is expressed in human neuronal cell lines, neurospheres and enteric neurons as 
confirmed by in vitro and ex vivo experiments. Stimulation of 5-HT4 with the specific, high-
affinity full agonist, prucalopride, induced significant protection against the oxidative stress 
injury elicited by H2O2. The protective effect of prucalopride on human neurons, including 
enteric neurons, was demonstrated by: 1) the increased survival of human neuronal cell lines 
exposed to oxidative stress; and 2) reduction of apoptosis in neuronal cell lines, human enteric 
neurospheres obtained from perinatal gut biopsies and whole mount preparation of 
submucosal neurons from adult colonic tissues, following oxidative stress challenge. The 
abolition of all of these effects by pretreatment with the 5-HT4 antagonist (GR113808) 
demonstrated that prucalopride-evoked protective effect was due to specific 5-HT4 activation. 
Taken together these results expand previous data showing that other 5-HT4 agonists (i.e. 
tegaserod and renzapride) protected primary cultures of mouse enteric neurons from apoptosis 
(Liu MT et al. 2009). Notably, our study indicated that the optimal neuroprotective effect was 
obtained with 1 nM prucalopride, which is at least 10 times lower compared to the doses used 
by Liu et al. with either tegaserod or renzapride (Liu MT et al. 2009). 
The difference in terms of concentrations and related neuroprotective effect can be the result 
of a diverse efficiency in 5-HT4 251 receptor activation exhibited by the different agonists 
used in our vs. Liu et al. study (Liu MT et al. 2009). The neural network supplying the 
digestive system, including the ENS, exerts a prominent regulatory role on several digestive 
functions (De Giorgio R et al. 2007). A tight association links gut dysfunction to ENS 
abnormalities characterized by neuronal damage and / or loss (Knowles CH et al 2013). In 
addition to the many effects elicited by serotoninergic pathways, 5-HT4 plays an important 
role in mediating 5-HT neuroprotective function as supported by the observation that mice 
lacking 5-HT4 displayed a markedly reduced number of submucosal and myenteric neurons 
in an age-dependent manner (Gershon MD et al 2007; Liu MT et al. 2009). Oxidative stress is 
well known to trigger neuronal loss and represents a key target for neuroprotection. A 
neuroprotective effect of 5-HT against oxidative stress-induced cell death has been supported 
by the results of a study showing that 5-HT treatment increased the activity of anti- oxidants 
enzyme and counteracted lipid peroxydation in the brain in a rat model of Parkinson disease 
(Anderson G et al. 2014). Our study extends the data reported in the brain, by showing that 
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prucalopride, a specific 5-HT4 receptor agonist protects peripheral neurons against oxidative 
stress-mediated proapoptotic insults induced by exposure to H2O2, as indicated by the 
significant reduction in caspase-3 and caspase-9 activation, both key regulators of apoptosis in 
a variety of cells including the ENS (Danial N et al. 2004; De Giorgio R et al. 2003). The 
prucalopride-mediated neuroprotection in SH-SY5Y cell lines, human neurospheres and ex-
vivo colonic submucosal neurons, indicates that 5-HT4 counteracts pro-apoptotic pathways by 
influencing the activation of both initiator and effector caspases. Notably, the finding that 
prucalopride rescued the neuronal expression of nNOS as well as pChAT that was reduced by 
oxidative stress challenge suggests that damage of functionally distinct neuronal populations, 
i.e. nitrergic (inhibitory) and cholinergic (excitatory) neurons (De Giorgio R et al. 2007; 
Furness JB 2012), can be prevented by 5-HT4 stimulation. The 5-HT4 activity is mediated by 
PKA / CREB signaling (. Liu MT et al 2009), a system crucial for neurogenesis and neuronal 
connectivity in the brain and pharmacological modulation of PKA has been proposed as a 
possible therapeutic target in neuronal degeneration, e.g. Alzheimer‟s and Parkinson‟s 
diseases (Irwin RW et al 2014; Park SY et al 2014). Ideally, 5-HT4-mediated PKA activation 
might be exploited to restore neuronal circuitry also in enteric neuropathies. Our results 
provide a pharmacological basis for prucalopride as a compound potentially useful in patients 
with enteric degeneration and loss of neurons, such as enteric neuropathies. These conditions 
are characterized by a severe abnormality of gastrointestinal motility and might represent the 
„tip of the ice-berg‟ of functional digestive disorders (Knowles CH et al 2013). Enteric 
neuropathies can be either primary (i.e. of unknown etiology) or secondary to a variety of 
diseases including central neurodegenerative disorders. Patients with enteric neuropathies 
manifest a broad spectrum of digestive symptoms resulting from the severe abnormalities of 
gut motility. Typical examples of such conditions, which markedly impair the patients‟ 
quality of life and can be life threatening, include gastroparesis, chronic intestinal pseudo-
obstruction and severe slow-transit constipation/colonic inertia. The treatment of these 
conditions is mainly supportive and so far lacking a targeted, e.g. receptor-mediated, approach 
(Furness JB 2012; . Knowles CH et al. 2013). Interestingly, a previous study reported that the 
5-HT4 partial agonist tegaserod increased the number of neurons and length of neurites of in 
vitro cultured neural crest-derived enteric neurons, indicating that activation of enteric neural 
5-HT4 receptors promotes neurogenesis (Gershon MD et al 2007; Liu MT et al. 2009; Takaki 
M et al. 2014). By contrast, our in vitro experiments did not show neurogenetic effects of 
prucalopride on human neuronal cell lines. This apparent discrepancy between our data and 
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the previously reported results may be ascribed to a shorter period of analysis used in our 
investigation (24 hours) compared to the Matsuyoshi et al. study where mosapride (another 
partial 5-HT4 agonist) was used for 15 days in animal models (Matsuyoshi H, et al. 2010). 
Whether a longer period of treatment with prucalopride can also induce an increase in cell 
proliferation and / or differentiation (i.e., neurite outgrowth) remains to be elucidated. 
In conclusion, the present data highlight for the first time that the specific 5-HT4 full agonist 
prucalopride evokes significant neuroprotective effects in neurons, including human enteric 
neurons, in vitro and ex vivo. Prucalopride is currently used for treatment of chronic 
constipation and has an excellent safety and tolerance profile. These findings widen the role 
of this compound beyond its well-defined enterokinetic property and support that 5-HT4 
activation can be a target for pharmacological intervention in neurodegenerative diseases of 
the gut. Ad hoc designed clinical trials are awaited to test the efficacy of 5-HT4 in stopping 
the progression of neuronal damage and loss in patients with severe gut dysmotility. 
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Figures 
 
Figure 1: A: experimental design used in the present study. Arm-A: serum starvation (medium only) 
was applied at time 0 in cell cultures. Prucalopride (1 nM) was applied 30 min after challenge with 
H2O2 (200 μM). Arm-B: the 5-HT4 antagonist GR113808 (10 nM) was applied 30 min before either 
prucalopride or H2O2. B: Western blot of total cell lysates with antibody to 5-HT4 protein and with 
anti-vinculin in SH-SY5Y (lane 1), SK-N-BE (lane 2), SK-N-SH (lane 3), LAN-1 (lane 4), Neuro2A 
(N2A, lane 5), and HEK293 (lane 6). Separate Western blot of total cell lysates with antibody to 5-
HT4 protein and with anti-vinculin in SH-SY5Y (lane 1) and human enteric neurospheres (lane 2). C: 
total cell lysates prepared from SH-SY5Y (a) and human enteric neurospheres (b) immunoblotted with 
anti-HuC/D, anti-p75, and anti-vinculin antibodies.
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Figure 2: A: percentage of SH-SY5Y survived after treatment with 1 nM prucalopride alone (C bar) 
or in combination with 200 μM H2O2 (prucalopride+ H2O2 vs. H2O2 **P < 0.0001) for 30 min (D bar) 
and GR113808 either alone [GR113808 vs. untreated (NT); ns] (F bar) or with 200 μM H2O2 
(prucalopride+ H2O2 vs. prucalopride+GR113808+ H2O2 ***P < 0.0001) (E bar). A bar, NT are 
considered as 100% cell survival; B bar, H2O2 alone. B: dose finding was established by treating SH-
SY5Y cells for 30 or 60 min with prucalopride at different concentrations (10 mM, 10 μM, 10 nM, 1 
nM, and 10 pM). Compared with 30 min, 10 nM prucalopride for 60 min resulted in a reduced 
neuroprotective effect (cell survival 80 vs. 60%, respectively, P < 0.0001). C: BrdU analysis in the 
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SH-SY5Y cell line. Percentage of SH-SY5Y proliferation after treatment with 1 nM prucalopride, 
alone (C bar) and in combination with 200 μM H2O2 for 30 min (D bar). A bar, NT; B bar, 200 μM 
H2O2 for 30 min. ANOVA and Tukey's multiple comparison tests did not reached statistical 
significance (P = 0.384). D and E: Western blotting of SH-SY5Y total lysates did not show differences 
in procaspase-3 and -9 expression; lane 1: NT; lane 2: 1 nM prucalopride (Pruca) and H2O2; lane 3: 
H2O2 alone. F and G: Western blotting of SH-SY5Y showing significant differences in active caspase-
3 and -9 expression (**P < 0.001 vs. NT); lane 1: NT; lane 2: 1 nM prucalopride and H2O2; lane 3: 
H2O2 alone. 
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Figure 3: A and B: Western blotting of human enteric neurospheres did not show differences in 
procaspase-3 and -9 expression; lane 1: NT; lane 2: 1 nM prucalopride and H2O2; lane 3: H2O2 alone. 
C and D: Western blotting showed significant differences in active caspase-3 and -9 expression (**P < 
0.001 vs. NT); lane 1: NT; lane 2: 1 nM prucalopride and H2O2; lane 3: H2O2 alone. E and F: note 
nitrergic (nNOS) (E) and cholinergic (pChAT) (F) immunoreactive neurons (scale bar 100 μm). G and 
H: Western blotting for nNOS and pChAT showed rescue of these 2 neuronal subsets after 
prucalopride treatment; lane 1: NT; lane 2: H2O2 alone; lane 3: H2O2+prucalopride (*P < 0.05 
pChAT/nNOS prucalopride+ H2O2 vs. H2O2). 
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Figure 4: A: Western blot showing 5-HT4 expression in submucosal neuron whole mounts (lane 1) 
compared with human SH-SY5Y (lane 2, positive control) and murine Neuro2A (lane 3, negative 
control). B and C: Western blotting did not show differences in procaspase-3 and -9 expression; lane 
1: NT; lane 2: 1 nM prucalopride+ H2O2; lane 3: H2O2 alone. D and E: Western blotting showed 
significant differences in active caspase-3 and -9 expression (**P < 0.001 vs. NT); lane 1: NT; lane 2: 
1 nM prucalopride+ H2O2; lane 3: H2O2 alone. 
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Chapter X 
14. Conclusions 
The ENS serves a vast array of regulatory functions through which the physiology of the GI 
tract occurs to preserve body homeostasis and ultimately life. Mounting evidence clearly 
indicates that the ENS is reminiscent of the CNS organization, not only for the neuro-
bioelectrical properties and function, but also for its neurochemical properties and receptor 
expression, which provides a number of possible targets of therapeutic intervention. In 
addition to neurons, the ENS possesses a prominent glial cell component, which is, in some 
extent, comparable to astrocytes for morphological and functional features. Thus, it should not 
be surprising that changes altering such a finely tuned and highly integrated system, such as 
the ENS, can lead to neuro-glia abnormalities and loss, thereby ensuing gut dysfunction. In 
this thesis, I tackled some aspects of enteric neuropathies particularly focusing on genetically-
driven molecular abnormalities. A clinical phenotype of enteric neuropathy is given by CIPO 
a severe dysmotility caharctaerized by a markedly compromised quality of life and poor 
prognosis for affected patients. Notably, there are no effective treatment for this condition and 
from a pathophysiological stand-point no established animal models for studying the various 
pathogenetic mechanisms contributing to neuropathy often underlying CIPO. My research 
work during this PhD program helped generating initial evidence that genetic mutations are at 
the base of ENS degeneration and loss. 
The first study focused on genetic aspects of a consanguineous family with syndromic CIPO 
(OMIM 611376). Whole exome sequencing analysis led ud to identified a novel homozygous 
mutation in the gene RAD21, mapping to the previously identified linkage interval on 
chromosome 8 (Deglincerti et al, 2007) and leading to the missense substitution A622T. The 
RAD21 protein is part of the cohesin complex involved in pairing and unpairing of sister 
chromatids during cell replication and regulates gene expression independently of cell 
replication (Horsfield et al, 2012). Heterozygous RAD21 mutations have been reported in the 
Cornelia de Lange syndrome (Deardorff et al, 2012), but none of RAD21 mutation carriers 
showed the clinical features of that syndrome. A few genes have been so far associated to 
CIPO and timely identification of genetic variants is essential to predict pathogenic 
mechanisms and guide appropriate management options for patients. 
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In this line, my second study was designed to investigate the localization of RAD21 in mouse 
and human ENS in order to understand how mutations of RAD21 may contribute to altered 
neuronal function/survival, thus leading to gut motor abnormalities. A thorough tissue 
analysis of RAD21 expression is lacking, thus we aimed to identify and characterize RAD21-
IR in enteric ganglia. Our data indicated that RAD21 was not expressed by nitrergic inhibitory 
neurons, a functionally distinct subclass commonly targeted by damaging mechanisms in 
experimental (nNOS
-/-
 mice) and human enteric neuropathies, e.g. in early stages of achalasia 
or idiopathic gastroparesis. It has not been determined whether nitrergic neurons remain 
unaffected in pathological conditions such as patients with RAD21-related CIPO. These 
findings, combined with the knowledge that RAD21 mutations occur in distinct CIPO cases, 
imply that those cholinergic subset may be the primary target in some patients with this 
pathological condition. In addition we are currently generate rad21
A626T
 conditional knock-in 
mouse for understanding the role of RAD21 in gut motility and creating a model for CIPO. 
This strategy will be relevant to increase our knowledge on ENS through the investigation of 
other mutations identified in idiopathic CIPO patients. 
These studies highlight neurodegeneration and related subsets of enteric neurons as 
pathogenetic features detectable in patients with CIPO. On the other hand, I posed the 
question as to how rescue or protect neurons from degenerative processes. Clearly, genetic 
factors cannot be modified as so far gene therapy did not yet emerge for the 
neurogastroenterological field. Therefore, I wanted to exlore the relatively less uncommon 
sporadic CIPO and establish whether neuroprotective mechanisms may be useable. In the 
attempt to establish whether 5-HT4 can be a possible target of reparative and protective effect, 
I have been involved in two main studies. The first demonstrated that 5-HT4 activation 
maintains motility in healthy colons of mice and guinea pigs and reduces inflammation in 
mice with colitis. The epithelial 5-HT4 receptor stimulation can exert its protective effects 
through several mechanisms, including increased epithelial proliferation, enhanced epithelial 
cell migration, and resistance to oxidative stress-induced apoptosis. Furthermore, treatment 
with the 5-HT4 agonist attenuated inflammation-induced changes in colonic motor function. 
Importantly, all of these effects were blocked by the 5-HT4 antagonist, GR113808, and 
protection was not detected in 5-HT4-/- mice. Translation of these observations could provide 
a new and safe treatment strategy for the treatment of colitis, and that expand our appreciation 
of the roles of 5-HT receptor signaling in the GI tract. Collectively, these findings advance 
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our understanding of colonic physiology and pathophysiology, and provide a new target for 
the treatment of colonic inflammation. 
In the second study, I tested whether prucalopride, a full 5-HT4 agonist used for the treatment 
of laxative resistant constipation, can evoke neuronal protection. The results demonstrated 
that prucalopride protect enteric neurons against oxidative (H2O2-induced) stress in vitro. 
These findings are important because many noxious factors converge to oxidative stress as 
ultimate mechanism promoting enteric neuron degeneration and loss (Brown et al. 2016; 
Gulbransen et al. 2012).  
As ancillary data during the PhD program I contributed to two other recently published 
studies by Giancola et al. One of these regarded the localization of 5-HT4 in the equine ENS. 
This model was investigated as a tool to detect the expression of 5-HT4, a largely known 
topic, which provides support to the physiological effect mediated by this enterokinetic 
serotonin receptor. Notably, the 5-HT4 expression occurs in both cholinergic and nitrergic 
motor neurons as well as in spinal ganglia of the horse. This latter finding open to 5-HT4 as a 
possible receptor pathway involved in sensory perception, an aspect so far poorly recognised 
and largely attribute to other serotoninergic receptors. 
The second study was designed to shed light on clinical, manometric and 
neurochemical/molecular findings in constipated Parkinson disease patients. In this study we 
showed a dowregulation of VIP and related receptors in non-PD and, with a slightly more 
pronounced compromission, PD constipated patients, which suggests an abnormal secretory 
function in ths latter group. Moreover, we recently submitted a study by Bonora et al. in 
which we detected 111 dysregulated genes in primary (idiopathic) achalasia. The 
identification of gene abnormalities (c-KIT downregulation and INPP4B upregulation) 
highlights novel signaling pathways involved in the neuro-interstitial cell of Cajal changes 
underlying achalasia.  
In conclusion, changes to the neuro-glial and epithelial aspects driven by genetic and 
environmental factors in the context of a severe dysmotility, i.e. CIPO, or animal models 
emerge as new important and fascinating topics fueling the interest of researchers in 
translational neurogastroenterology. The present thesis clearly manifests my willgness to 
continue to investigate pathophysiological mechanisms that impact on diseases affecting gut 
homeostasis. Over the years, I learned that perseverance and enthusiasm in research pave the 
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way to solving biological problems, which help clinicians in improving patients‟ management 
and treatment. 
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